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Abstract 
Chronic leg ulcers are a major health problem that affects 1-3% of adults over 
the age of 65 (Posnett & Franks, 2007). They are a financial burden on healthcare 
systems worldwide, particularly in countries with growing aging populations such as 
Australia and the United States. The annual cost of leg ulceration in Australia is 
estimated at $2.61 billion annually (AIHW, 2008), whilst in the United States this is 
estimated to be roughly $25 billion annually (Chandan K Sen et al., 2009). Chronic 
leg ulcers have a major impact on the quality of life of patients. The debilitating pain 
experienced by patients with chronic leg ulcer impacts on their ability to sleep, 
exercise and general mobility. Together, these symptoms can lead to social isolation 
and anxiety, and as a result lead to significant levels of depression (Flett et al., 1994; 
Persoon et al., 2004; Renner et al., 2014). Retrospective studies have revealed that 
approximately 50% of leg ulcers heal within six months, while many remain 
unhealed for years (L. P. Abbade & S. Lastoria, 2005; N. Cullum et al., 2000). 
Despite the negative impacts of these wounds, research into wounds remains 
underdeveloped in comparison to many diseases. There is limited understanding of 
the fundamental processes involved in the persistence of a chronic wound. This lack 
of knowledge impacts on the development of not only new treatment options, but 
also diagnostics which could identify at risk patients early and monitor responses to 
treatment.  
 
Initially the objective of this study was to undertake comprehensive 
metabolomic profiling of wound fluid samples collected from patients suffering from 
chronic leg ulcers. It was hypothesised that this profiling technique would lead to the 
discovery of biomarkers within the metabolome that indicated that the wound was 
transitioning to a healing state; thereby enabling identification of markers of healing 
and non-healing wounds. A metabolomic analysis pipeline was established; from 
sample processing through to detection using liquid chromatography – mass 
spectrometry and subsequent analysis using bioinformatics tools. In the course of this 
study, the data was found to contain several contaminants from various sources and 
ultimately was unable to be utilised for reliable analysis. Furthermore, it was clear 
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that metabolomics research is currently limited by the quality of data available from 
databases (Patti et al., 2012). These databases need further development to allow 
better biomarker discovery.  
 
As cytokines and growth factors are essential for normal wound closure and are 
involved in the key phases of the healing cascade I instead focused my attention on 
these factors. In particular I hypothesised that their levels would be different amongst 
healing and non-healing patients and thus diagnostic of wound healing. A 24 week 
study in which 20 patients received best practise treatment was conducted and 
allowed collection of sequential wound fluid samples and corresponding clinical 
data. Using a multiplex panel of human cytokines, I performed quantitation of 
relevant proteins in wound fluid samples collected from 10 patients which healed 
during the study period and 10 which remained unhealed. Statistical analysis using a 
linear mixed model demonstrated that there was a significant decrease in 
pro-inflammatory cytokines IL-6 and IFNγ over time in the healing patient cohort 
when compared to the non-healing cohort (p=0.006 and p=0.007 respectively). 
IL-12p70 and TNFα were also found to decrease over time in the healing cohort 
compared to the non-healing cohort, although these were not statistically significant 
(p=0.055 and p=0.071 respectively). Interestingly, the anti-inflammatory cytokines, 
IL-13, IL-10 and IL-1ra, did not change between the two cohorts over time. 
Consistent with the pro-inflammatory cytokine findings, the chemokine data also 
suggests a decrease in inflammation. MIP-1β and IL-8 were found to significantly 
decrease over time in the healing ulcers when compared to the non-healing ulcers 
(p=0.022 and p=0.002 respectively), whilst MCP-1 and MIP-1α also decreased over 
time but only trends towards statistical significance were found (p=0.058 and 
p=0.077 respectively). Overall, the pro-inflammatory cytokines and the chemokines, 
both key to sustaining inflammation, were found to decrease as wounds transitioned 
from a non-healing to a healing state. In the non-healing cohort this decrease was not 
observed, suggesting that chronic leg ulcers are an inflammatory disorder in which 
the resolution of inflammation is lacking.  
 
These observations are verified by the demonstration for the first time that the 
inflammasome is activated in chronic leg ulcer wounds. The inflammasome was only 
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recently discovered and has received considerable attention as an inflammatory 
mechanism which primarily functions to activate inflammatory cytokines IL-1β and 
IL-18 (Schroder et al., 2010). My analysis of clinical samples was able to confirm 
this inflammasome-mediated activation by measuring the active levels of IL-1β in 
wound fluid samples collected from chronic leg ulcers. Western blot analysis of 
wound fluid collected from chronic leg ulcers confirmed the presence and 
localisation of ASC, a key protein which is required for inflammasome assembly. 
Together with HMGB1, which is also secreted following inflammasome activation, 
the identification of ASC is persuasive evidence that this new inflammation pathway 
may play a critical role in prolonging the inflammatory state, such as that which is 
evident in chronic wounds. These novel findings reveal novel therapeutic targets; 
targeting these pathways therefore holds potential to provide therapeutic benefits for 
individuals suffering with chronic wounds. 
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Chapter 1: Background and Literature 
Review 
1.1 ACUTE WOUND HEALING 
Skin in humans, as with all other animals, acts as a natural barrier which is 
responsible for protection against pathogens, the external environment and for 
retaining water required for homeostasis. Insult or injury to the skin results in the 
activation of a complex biological process that is identical across almost all tissue 
types in the human body. This complex process of repair remains the same 
irrespective of the cause of the injury, whether it be a burn, gunshot, heart attack or 
incisional wound inflicted by a surgeon. The process is sequential yet continuous and 
is usually described and broken down into three overlapping phases: (1) haemostasis 
and inflammation (2); migration / proliferation and; (3) remodelling. During acute 
wound healing haemostasis and the inflammatory phase begins immediately after an 
injury has occurred and is followed by the proliferative phase, which begins between 
2-10 days post injury. Finally, the remodelling phase begins 2-3 weeks later and 
continues to occur for up to a year after injury. The cells involved and the specific 
events that occur during these phases are summarised in Table 1.1 and discussed 
below. 
 
1.1.1 INFLAMMATORY HAEMOSTASIS  
Tissue injury causes the disruption of blood vessels and leakage of blood 
constituents. In effect this facilitates the increase of blood flow around the injured 
site, which brings in blood-borne products, such as antibacterial proteins and white 
blood cells, as the first line of defence (C. K. Sen & Roy, 2008). Activation of the 
coagulation cascade triggers the adhesion and aggregation of platelets at the injury 
site. Also, Factor X cleaves prothrombin to thrombin, which is required for the 
conversion of fibrinogen to fibrin polymers (Camerer et al., 1996). The cross-linking 
transglutaminase Factor XIII forms covalent bonds between lysine and glutamine 
residues in fibrin, thereby stabilising the fibrin plug (Devine & Bishop, 1996). This 
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results in the formation of a haemostatic clot consisting of platelets embedded in a 
mesh of cross-linked fibrin fibres, together with extracellular matrix proteins (ECM) 
such as plasma fibronectin, vitronectin and thrombospondin. This provides a scaffold 
structure for subsequent cell attachment, proliferation and migration of inflammatory 
(neutrophils and monocytes) and non-inflammatory cells (fibroblasts and endothelial 
cells) (P. Martin, 1997). The clot prevents any further blood loss from the site of 
injury and reduces the risk of local and systemic infection. 
 
Throughout the coagulation process platelets release a wide range of growth 
factors, including platelet derived growth factor (PDGF), epidermal growth factor 
(EGF) and transforming growth factor beta (TGF-β) (S. Barrientos et al., 2008). The 
fibrin clot serves as a reservoir for these growth factors, which act as chemotactic 
cues recruiting inflammatory cells and later play a role in ECM formation (Kondo & 
Ishida, 2010; P. Martin, 1997; Witte & Barbul, 1997). Changes in the expression of 
selectins and adhesions molecules on the surface of endothelial cells lining the 
capillaries at the wound site also occur; these act as cognate receptors for the binding 
of circulating neutrophils and monocytes from the blood, recruiting them to sites of 
injury and inflammation. Subsequently, this process leads to diapedesis, whereby the 
activated leukocytes migrate between or through the endothelial cells into the 
extravascular space (Springer, 1994). The fibrin clot acts as a provisional matrix 
allowing neutrophils to infiltrate and cleanse the wound area of bacteria and cell 
debris. 
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Table 1.1: The major events and cell types involved in the overlapping phases of 
wound healing following an injury. Adapted from Falanga et al (2005).
Time Process Main cell types Specific events 
 
 
 
 
 
 
 
   
 
 
Platelets 
 
 
 
 
Hours 
 
 
  
Neutrophils, 
Monocytes 
 
 
 
 
 
 
 
 
 
 
  
 
Macrophages 
 
 
 
Days 
 
 
 
  
 
 
 
Keratinocytes 
 
 
 
 
 
 
 
 Fibroblasts 
Endothelial cells 
 
 
 
 
 
 
 
Weeks - Months 
 
 
 Myofibroblasts 
 
 
 
 
 
  
Coagulation 
Fibrin plug formation, 
Release of growth 
factors, cytokines, 
hypoxia 
Inflammation 
Cell recruitment, 
chemotaxis & wound 
debridement 
Migration/proliferation 
Epidermal resurfacing, 
fibroplasia, 
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Neutrophils are a source of pro-inflammatory cytokines and, like many 
immune cells, express pattern recognition receptors (PRR) such as Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs) and nucleotide-binding oligomerisation 
domain (NOD)-like receptors (NLRs) on their cell surface (Hubner et al., 1996; 
Thomas & Schroder, 2013). These PRRs serve as detection mechanisms for 
structural motifs on pathogens and also on endogenous stress signals released as a 
result of host injury. Ligand binding to these receptors leads to the secretion of 
cytokines that in turn recruit more immune cells and regulate inflammation in the 
wound. Neutrophils are not necessary for wound closure and their loss in sterile 
wounds leads to significantly faster closure rates in a neutrophil-depleted mouse 
wound model (Dovi et al., 2003). The loss of neutrophils leads to a reduction in 
proteases and reactive oxygen species (ROS), which can damage the surrounding 
tissue and ECM and also reduce recruitment of macrophages to the wound, thus 
reducing the overall inflammatory response. However, in a non-sterile environment 
the depletion of neutrophils might result in an infected wound and delayed healing. 
After the neutrophils have performed their role, typically by day 2 in an acute 
wound, they apoptose and are either extruded with the eschar or phagocytosed by 
macrophages (Robert F Diegelmann & Melissa C Evans, 2004). 
 
Next, monocytes from the circulating blood infiltrate the wound approximately 
two days following injury and differentiate into macrophages through the stimulation 
of environmental cues in the wound. Macrophages in the wound can have distinct 
phenotypes; they can be divided into M1 and M2 phenotypes and then further 
sub-divided based on how they are activated. M1 (or classically activated) 
macrophages are activated through the binding of bacterial agents to TLRs or 
through cytokines such as interferon gamma (IFNγ) (Rodero & Khosrotehrani, 
2010). These M1 macrophages produce what is known as a Th1 response that results 
in the production and secretion of pro-inflammatory cytokines, such as tumor 
necrosis factor (TNF) and interleukin (IL)-6. They also have a robust microbicidal 
activity, releasing high levels of reactive oxygen species, such as superoxide anions, 
oxygen and nitrogen radicals, to reduce and prevent infection. In a cutaneous wound 
mouse model it was demonstrated that it is the early wound macrophages that are 
expressing the majority of VEGF which is critical for vascularisation (Willenborg et 
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al., 2012). M2 macrophages on the other hand are thought to be more reparative. 
They secrete anti-inflammatory cytokines, such as IL-10, that downregulate 
inflammation and release growth factors, such as TGFβ and PDGF, to promote 
angiogenesis, recruit fibroblasts and stimulate myofibroblast differentiation. The M2 
macrophage phenotype is sub-divided into M2a, which are activated by IL-4 and 
IL-13, and M2b, which are activated by IL-1R ligands and TLRs. The final subtype 
is M2c which are IL-10 activated and more related to the suppression of the immune 
response, whilst M2a and M2b induce a Th2 response (Mantovani et al., 2004). It is 
thought that the M1 and M2 phenotypes are much more complex than this and they 
often co-exist. The phenotypic mix is dependent on activatory and inhibitory factors 
in the local environment. 
 
Activated macrophages phagocytose micro-organisms and fragments of the 
cells and extracellular matrix which may have been damaged during the injury (C. K. 
Sen & Roy, 2008). Their adherence to the extracellular matrix also induces the 
expression of monocyte colony-stimulating factor 1 (MCSF1), a cytokine that 
supports monocyte and macrophage survival at the wound site (C. K. Sen & Roy, 
2008). Accumulation of macrophages continues through the recruitment of 
monocytes from the blood stream. Interestingly, the absence of macrophages and 
neutrophils in PU1 null mice has demonstrated that perhaps the inflammatory 
response is not necessary for acute wound healing, as both controls and PU1 null 
mice healed at the same time (Paul Martin et al., 2003). The PU1 null mice exhibited 
lower levels of growth factors such as TGFβ, and almost absent levels of the 
pro-inflammatory cytokine IL-6. More recently a transgenic mouse was generated 
with monocytes expressing the diphtheria toxin receptor. These cells can be 
selectively ablated using diphtheria toxin and have revealed differing roles for 
macrophages at distinct time points (Goren et al., 2009). Depletion of macrophages 
throughout the wound healing process resulted in delayed re-epithelialisation, 
reduced collagen deposition, impaired angiogenesis and overall decreased cell 
proliferation in the wound bed. Further studies dissecting the role of these 
macrophages show that the loss of early macrophages (days 0-5) leads to slower 
re-epithelialisation and reduced collagen deposition, suggesting they are responsible 
for scar formation. Once the diphtheria toxin was stopped (day 4) and new 
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macrophages entered the wound, re-epithelialisation increased and was similar to 
control mice by day 14. Loss of macrophages in the mid-stage of the inflammatory 
phase led to severe haemorrhage in the wound, loss of maturation and failure to 
re-epithelialise. Loss of macrophages after the mid-stage of the inflammatory phase, 
however, has no effect on wound healing outcomes. These data suggest that 
macrophages play differing roles depending on the timing and further, these roles 
might be related to whether they have a M1 or M2 phenotype (Lucas et al., 2010).  
 
1.1.2 MIGRATION, PROLIFERATION AND REMODELLING OF THE WOUND 
The next stage of wound repair occurs approximately 2-10 days after injury 
depending on the duration of the inflammatory phase. During this phase a new 
functional barrier (re-epithelialisation) is formed, the blood supply is re-established 
(angiogenesis), and the injured dermal tissue is reinforced (fibroplasia) (Li et al., 
2007). This phase is characterised mainly by cellular proliferation and migration of 
specific cell types to the site of injury (Gurtner et al., 2008). 
 
Re-epithelialisation is initiated by the migration of keratinocytes along the 
injured dermis. A number of key changes have to occur to enable keratinocyte 
migration. Phenotypically the keratinocytes undergo changes in integrin (cell 
adhesion receptors) expression to enable migration. Disassembly of 
hemidesmosomes, which normally keep the basal keratinocyte anchored to the 
basement membrane, occurs. This disassembly and keratinocyte migration requires 
cross-talk between the integrins, growth factors, structural proteins, matrix 
metalloproteinases (MMPs) and other enzymes that cleave ECM proteins to allow 
cell migration through the wound (V. Falanga, 2005). Integrins on the cell surface 
bind the ECM, enabling the formation of lamellipodia, which aid motility of the 
keratinocytes into the wound site. In order to migrate into the fibrin clot these cells 
need to up-regulate the expression of tissue plasminogen activator (tPA) and 
urokinase plasminogen activator (uPA). These enzymes act on the zymogen 
plasminogen to produce activated plasmin, which in turn creates a path for the 
migrating cell (V. Falanga, 2005). MMPs, such as MMP-9 which cleaves denatured 
collagen (gelatin), fibronectin and laminin, also contribute to creating a path for 
infiltrating immune cells. MMP-9 is also up-regulated by wound edge keratinocytes 
 Chapter 1: Background and Literature Review 25 
and requires plasmin for activation (P. Martin, 1997; Ramos-DeSimone et al., 1999). 
In larger wounds where the migration of cells is not sufficient to close the wound, 
keratinocytes undergo a proliferative burst in response to EGF and TGF-α amongst 
other signals (Li et al., 2007). Keratinocytes behind the leading edge also undergo 
proliferation, mature and migrate to restore the function of the epithelium. 
 
In an acute wound the formation of the granulation tissue by fibroblasts, a 
collagen-rich matrix containing proteoglycans and elastin, occurs between 3-5 days 
post injury (Woodley et al., 1985). It is rich in proliferating fibroblasts and newly 
formed loops of capillaries housed in a loose matrix (Enoch & Leaper, 2005). This 
granulation tissue provides support for the proliferative phase as it forms a matrix for 
cell migration and is the first step towards neovascularisation (Enoch & Leaper, 
2005). Fibroblast migration into the wound and their proliferation, stimulated by the 
acidic, low oxygen levels in the centre of the wound, leads to the production of new 
collagen and other matrix proteins, which also contribute to the formation of 
granulation tissue (Li et al., 2007). Fibroblast proliferation diminishes with the onset 
of angiogenesis due to the formation of new blood vessels (Li et al., 2007).  
 
New blood vessels enhance re-epithelialisation by providing oxygen and 
nutrients and a means of transporting inflammatory cells to the site of injury (Li et 
al., 2007). Angiogenesis is regulated by vascular endothelial growth factor (VEGF) 
produced by macrophages and keratinocytes in the wound environment. The sprouts 
of capillaries, together with fibroblasts and macrophages, replace the fibrin matrix 
with granulation tissue and this in turn forms a new matrix for keratinocyte 
migration. This new matrix is important for the latter stages of the repair process 
(Gurtner et al., 2008). Once the granulation tissue has filled the wound, angiogenesis 
ceases and many of the new blood vessels break down as a result of apoptosis (Ilan et 
al., 1998). Fibroblasts also undergo apoptosis once matrix has been deposited in the 
wound / granulation tissue; dysregulation of these processes can result in fibrotic 
disorders such as hypertrophic scarring (Desmouliere et al., 1995). Fibroblasts also 
play a critical role in healing by second intention in which they differentiate into 
myofibroblasts and assist wound closure through contraction of the ECM (Enoch & 
Leaper, 2005). Once closure is achieved the apoptosis of blood vessels and 
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fibroblasts marks the end of the proliferation and migration phase and the transition 
into the remodelling phase. 
 
The last stage of wound repair is the remodelling phase, which begins roughly 
2-3 weeks following an injury and can continue for 6-12 months. In this stage the 
acellular matrix is actively remodelled from a mainly type III collagen backbone to 
one predominantly composed of type I collagen, which is stronger and organised into 
parallel bundles (Gurtner et al., 2008). These bundles are organised along tension 
lines and induce contraction to decrease the wound area. This process is carried out 
by matrix metalloproteinases secreted by fibroblasts and macrophages to strengthen 
the repaired tissue (Mignatti et al., 1996). Most wounds heal without difficulty; 
however, abnormal healing is observed under certain pathological conditions. 
 
1.2 ABNORMAL WOUND HEALING RESPONSE 
In acute / normal wounds, the healing cascade is observed as an orderly 
sequence of events as described in the previous section. However, wounds can be 
pathologically trapped in a specific phase or can exhibit a pathological response upon 
injury. Problems can occur as a result of a wound undergoing excessive healing, as 
seen in fibrosis, or delayed healing, as seen in chronic ulcers. Fibrosis in wound 
healing can result in hypertrophic or keloid scars at the site of injury as a result of 
over deposition of collagen. During scar formation high levels of transforming 
factor β (TGFβ) act on fibroblast cells to synthesise more collagen (Shah et al., 
1995). The collagen that is deposited has an altered and disorganised structure, which 
does not stretch as well or have the same tensile strength as normal tissue, and if it 
occurs near joints can lead to a loss of function (Van Zuijlen et al., 2002). 
 
Inflammation involving mast cells and macrophages has also been implicated 
in scar formation. Mast cell numbers are increased in fibrotic skin compared to 
normal skin and they have up-regulated production of enzymes that are required for 
the processing of pro-collagen into collagen (Gruber, 2003). The role of mast cells on 
scar formation is unclear with some studies showing a role, while others indicate no 
role. For macrophages the story is much clearer. The absence of macrophages during 
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healing in mice has demonstrated reduced collagen deposition (R. Mirza et al., 2009) 
and mammalian embryos heal scar free with significantly lower numbers of less 
differentiated inflammatory cells (Ferguson & O'Kane, 2004). Studies with 
transgenic mice that have macrophages ablated in the early stages of inflammation, 
reveal that it is these cells that are responsible for regulating scar formation (R. Mirza 
et al., 2009). 
 
On the other end of the spectrum are wounds that have delayed healing that are 
commonly referred to as chronic wounds or ulcers. The pathology of chronic leg 
ulcers is complex, multifactorial and poorly understood. However, as with fibrosis, 
the inflammatory phase is also heavily implicated in chronic wounds. Chronic ulcers 
are described as being stalled in the inflammatory phase and are not progressing to 
the proliferative phase of healing (Loots et al., 1998). Of these chronic wounds, leg 
ulcers are the most common, and by definition begin as a breach in the epithelial 
integrity of the skin below the knee and remain unhealed over a period of more than 
4 weeks (Fletcher, 2008). Chronic leg ulcers are difficult to heal and treatment is 
often complicated, lengthy and expensive. Currently, no drug treatments have been 
shown to be effective at assisting in the closure of these wounds. Chronic leg ulcers 
can be subdivided into several aetiologies. Venous ulcers as a result of venous 
disease are the most prevalent (approximately 70%), followed by arterial ulcers and 
mixed arterial / venous (approximately 20%), and with diabetes and pressure ulcers 
amongst others making up the rest (Manj S Gohel & Poskitt, 2010). New treatment 
strategies are likely to arise through a better understanding of the processes involved 
in delayed wound healing. 
 
1.2.1 PREVALENCE OF CHRONIC LEG ULCERS 
Chronic leg ulceration effects 1-3% of the population aged over 65 (N. Cullum 
et al., 2000) and this incidence further increases with age (Stephen R Baker & 
Michael C Stacey, 1994; Margolisa et al., 2002). According to the Australian Bureau 
of Statistics the over 65 year age group will be growing at 3.5% per year until 2022, 
at which stage there will be over 4 million people within this cohort. This has the 
potential to dramatically increase the number of people with chronic wounds in the 
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Australian population. Moreover, the predicted increase in obesity and diabetes and 
the high rates of cardiovascular and peripheral arterial disease will most certainly 
lead to increased rates of chronic leg ulcers. Indeed, increased prevalence of leg 
ulceration has already been observed in Finland over the last 20 years (Hjerppe et al., 
2006). Interestingly, the duration of ulcers has also been reported in this 20 year 
period and it has been hypothesised that this is due to ulcers being more complex, 
with multiple factors contributing to the development of these wounds (Hjerppe et 
al., 2006). These factors are not only localised to the ulcer area but include systemic 
problems such as diabetes, as well as lifestyle choices such as poor nutrition and 
smoking. Additionally, factors local to the wound, such as arterial disease and 
venous insufficiency, also impact on wound healing and these are used by clinicians 
to define the ulcer aetiology. These factors are summarised in Table 1.2. It is 
estimated that around 30% to 40% of adults aged over 60 years suffer with peripheral 
arterial disease (Hopf et al., 2008) and 50% of adults have peripheral venous disease 
presenting as chronic venous insufficiency (L. P. F. Abbade & S. Lastoria, 2005). 
These two conditions are the primary underlying disease factors contributing to 
chronic leg ulcers and can work synergistically to delay wound healing. It is quite 
clear that the complexity and prevalence of chronic leg ulcers will continue to be an 
ongoing / long term issue, highlighting the need for further research into chronic leg 
ulceration, especially for countries like Australia with a rapidly aging population.  
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Table 1.2. The local, systemic and regional factors influencing wound healing. 
Adapted from Hunt et al. (2000). 
 
Factors influencing wound healing 
Local Factors ↓Growth factors 
 Platelet-derived growth factor  
↑Pro-Inflammatory Cytokines 
 Tumor necrosis factor alpha 
 Interleukin 6 
Oedema and ischemia 
Infection 
Low oxygen tension 
Systemic Factors Inadequate perfusion 
Diabetes mellitus 
Regional Factors Arterial insufficiency 
Venous insufficiency 
Neuropathy 
Miscellaneous Factors Smoking 
Nutrition 
Pre-existing illness 
Radiotherapy treatment 
 
  
 30 Chapter 1: Background and Literature Review 
1.2.2 AETIOLOGY OF CHRONIC LEG ULCERATION 
A number of systemic factors can play a role in chronic wound formation. 
Chronic venous insufficiency is a disruption of the valvular function of the lower 
limbs resulting in hypertension in the leg veins due to failed venous return. The loss 
of valvular function can be the result of a genetic disposition, episodes of deep vein 
thrombosis or trauma. Typically venous ulcers occur on the medial gaiter area of the 
leg, but on rare occasions can occur on the lateral leg or foot. The majority of 
patients with chronic leg ulcers suffer from venous disease as a comorbidity, with a 
reported prevalence between 60-80% (S. R. Baker & M. C. Stacey, 1994; O. Nelzen 
et al., 1991). Unfortunately for patients with venous leg ulcers, recurrence of ulcer 
formation is especially prevalent. It has been reported that between 60-70% of ulcers 
will reoccur in the 12 months following wound closure (Abbade et al., 2005; Barwell 
et al., 2004). Of the 20-40% of patients that do not achieve wound closure, it is 
estimated that they take up to 33-44% more nursing time and therefore incur higher 
costs through both staffing needs and products. (Harding et al., 2013; Tennvall & 
Hjelmgren, 2005).  
 
Arterial ulceration occurs through multilevel arterial stenosis or occlusions, 
which results in ischemia leading to tissue damage. Typically arterial ulcers occur on 
the foot but they can arise more proximally. Mixed ulcers are a combination of 
venous and arterial disease and it is often difficult to identify which is the major 
contributor in the hard-to-heal wound. The identification of the underlying disease 
state is necessary in regards to the treatment provided by the clinician. For example, 
a mixed ulcer with a higher degree of arterial disease treated with compression will 
result in a worse healing outcome. Mixed aetiology venous / arterial and those with 
pure arterial origin are the second highest in regards to prevalence. Mixed ulcers are 
reported in 10-25% of patients (Callam, Harper, et al., 1987; O Nelzen et al., 1996; 
Valencia et al., 2001), whilst pure arterial ulcers are usually reported in 5-20% of 
patients (Callam, Ruckley, et al., 1987; Manj S Gohel & Poskitt, 2010). The less 
reported aetiologies of chronic leg ulceration make up the remainder and these 
include trauma / pressure ulcers, diabetic ulcers, vasculitis and ulcers due to 
rheumatoid arthritis (Manj S Gohel & Poskitt, 2010). Although diabetic ulcers are 
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becoming more prevalent they are often reported in the mixed ulcer population 
(Hjerppe et al., 2006). 
 
It should, however, be noted that the majority of epidemiological data in the 
current literature are based on older studies, and from various geographical locations. 
As a result, it is not uncommon for recent studies to report a patient demographic 
which does not fall into the above figures. Heinen et al. (2007) reported a patient 
cohort consisting of 70% mixed ulcer aetiology. A recent study of 31,619 patients in 
Germany suffering from chronic leg ulcers attributed only 47% to venous leg 
ulceration (Körber et al., 2011). It is likely that new epidemiology studies would 
confirm a trend of more ulcers being of mixed aetiology considering the increase in 
prevalence in diseases such as diabetes and arterial diseases seen in our aging 
population. These studies might give researchers more direction into areas that have 
not been given much attention, such as mixed ulcers, and those with several 
attributions that add complexity to healing the ulcer. 
 
1.2.3 IMPACT ON PATIENTS 
An aspect that is often overlooked and understated in regards to chronic leg 
ulcers is the patient’s quality of life (QoL). Leg ulcers are associated with significant 
levels of pain (Gonçalves et al., 2004) with 17-65% of patients reporting severe or 
continuous pain. Persistent pain results in poor patient compliance in regards to 
wearing of compression stockings, and also limits the amount of exercise undertaken, 
which in turn impacts on the reduction of oedema in the wound area through calf 
muscle pump activation. Excessive wound fluid formation is another problem for 
patients with venous leg ulcers, and can also occur in other ulcer types. Excessive 
drainage and wet bandages cause patient discomfort (L. M. Edwards, 2003). This can 
lead to a foul odour, feelings of disgust, self-loathing and low self-esteem (Jones et 
al., 2008). A review by Persoon et al. (2004) collating 37 studies identified that 
chronic leg ulcers contribute to significant levels of depression, anxiety and social 
isolation. They can also impair patient mobility, leading to isolation and perpetuating 
the negative emotional impact. Together the lack of mobility, pain, worries about 
health, isolation and lower self-esteem all contribute to the overall reduced QoL for 
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patients with a chronic leg ulcer (Flett et al., 1994). Not surprisingly, QoL scores 
improve significantly following wound closure (Franks et al., 2003). 
 
1.2.4 CURRENT TREATMENT 
The current treatments for chronic leg ulcers vary depending on the type of 
ulcer, but are predominantly ‘mechanical’ in nature. Treatment of venous leg ulcers 
involves measures to reduce the oedema through compression stockings/bandages. 
This has been shown to be most effective in promoting venous return when patients 
are compliant. For example, multilayered compression therapy has a reported healing 
success rate between 60-80% following 12 to 24 weeks of treatment (N Cullum et 
al., 2001; O'Meara et al., 2012). Other treatment measures include elevation of the 
legs above the heart, as well as activation of the calf muscle pump, since simple calf 
muscle exercise (e.g. heel raises) reduces oedema in the area through induced venous 
return (O'brien et al., 2013).  
 
Whilst pressure stockings / bandages work well for promoting venous return, 
their application to a mixed ulcer with a predominantly arterial component will result 
in more damage to the affected area. Arterial disease reduces blood flow to the area 
and compression would exacerbate this negative effect (Callam, Harper, et al., 1987). 
In regards to treatment of mixed ulcers, some success has been reported with a 
reduced number of layers in multilayer compression therapy systems; this approach 
applies reduced pressure compared to that used for pure venous leg ulcers. This 
modified compression bandaging approach was shown to be effective for patients 
with a predominantly venous component and moderate arterial disease. Healing rates 
of 68% were observed, whilst of those with severe arterial disease, only 53% healed 
(Humphreys et al., 2007). For ulcers with a predominantly arterial aetiology, 
treatment is very limited and typically involves surgical intervention through either 
angioplasty or revascularisation. Other measures include lifestyle changes in order to 
prevent further arterial damage, such as ceasing smoking, monitoring and better 
management of diabetes, and increasing walking to promote blood flow to the lower 
limbs.  
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1.2.5 NEW TECHNOLOGIES 
There have been a limited number of new technologies on the market in 
regards to the treatment of chronic leg ulcers. Negative pressure wound therapy 
(NPWT) is a technique which involves sealing an acute or chronic wound with a 
dressing and applying a negative pressure to the area under the dressing through the 
use of a vacuum pump to remove fluid from the affected area. It has emerged as a 
new treatment option over the span of the last decade but with mixed results reported 
in the literature regarding its efficacy. Meta-analysis of randomised and 
non-randomised clinical trials showed there is no data to suggest that NPWT 
provides additional clinical benefit in wound closure (Gregor et al., 2008). Treatment 
with NPWT did not reduce oedema or bacterial clearance, mechanisms that were 
previously attributed to NPWT (Moues et al., 2004) and there is no difference in 
granulation tissue formation (Braakenburg et al., 2006). A more recent study has 
suggested that treatment with NPWT had favourable impact on wound healing, 
however, the study was not randomised (Téot et al., 2014). Further, the treatment 
cost associated with NPWT were relatively high compared to best practice, with the 
cost for pressure ulcers being 4.1 times higher and diabetic wounds 5.7 times higher. 
Venous, arterial and mixed ulcers were combined in the study and together were 3.1 
times more expensive to treat with NPWT compared to non-NPWT (Téot et al., 
2014). Clearly better designed RCT studies are required as there is mixed evidence in 
the literature as to the efficacy of NPWT. In addition, different NPWT devices need 
to be compared and a cost-benefit analysis performed.  
 
Apart from the mechanical mechanisms developed to assist wound closure a 
number of topical agents have been developed based on our knowledge of wound 
healing. They typically deliver growth factors, aim to neutralise enzymes or are 
involved in replacing ECM components in the wound. Regranex® is a growth 
factor-based treatment available on the market; it is based on the delivery of 
platelet-derived growth factor (PDGF) to the wound to stimulate fibroblast 
proliferation and differentiation (Chan et al., 2006). Unfortunately, the treatment of 
chronic wounds with growth factors is prohibitively expensive and has yielded 
contradictory results in the literature and for PDGF, use of 3 tubes or more, is linked 
to an increase in death due to cancer (Stephan Barrientos et al., 2014). Chronic 
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wounds have high levels of enzymes that break down the new ECM that would 
normally provide the scaffold for new cells to migrate into the wound. 
PROMOGRAN® (Systagenix), a collagen and cellulose based matrix product, has 
been designed to target MMPs in the wound. Again results from clinical trials are 
inconsistent, with some demonstrated an improvement in healing time, while others 
demonstrated no difference (Fan et al., 2011). This may be due to the study designs; 
for example, no statistical difference was seen when compared to the use of a 
moistened gauze, but when compared to ‘good wound care’ there was a statistical 
difference. It may simply be that dressings that can mop up wound fluid might be 
beneficial. Two treatments have been developed to provide new ECM, rather than 
block its degradation. OASIS® (Mostow et al., 2005), a matrix derived from porcine 
small intestinal submucosa, is already on the market and the limited number of 
clinical trials suggest it may be beneficial. VitroGro® ECM, is another recombinant 
protein that acts as an ECM component to stimulate wound repair (Harding et al., 
2014; Shooter et al., 2013) and is currently progressing through regulatory approval.  
 
While several of these products are already on the market, they are relatively 
new and post market surveillance in broader real world conditions are yet to be 
performed to demonstrate their benefit. Thus, there is still an unmet clinical need for 
effective, low cost therapeutics. This has led to recent thinking that perhaps in order 
to decrease the time required to heal a wound, which will in turn improve 
compliance, more than one therapy might be applied that complement and work 
synergistically with another. Given the complex nature of chronic leg ulcers this may 
be especially relevant. To date the most chronic wound treatments are based on 
mechanical removal of oedema from the lower leg and as yet there are no topical 
drugs that are widely used in the clinics. Currently, the only study which applied 
anti-inflammatory antibodies (anti-TNFα) demonstrated successful wound reduction 
(7 out of 8 patients) in hard-to-heal ulcers which did not respond to any previous 
treatments (Streit et al., 2006). Even with low patient numbers this study 
demonstrates the potential of perhaps targeting the inflammatory phase for treatment 
options. Since chronic wounds are halted in the inflammatory stage (see section 
1.2.6) more treatments targeting this aspect of the healing cascade may yield greater 
healing success for patients with chronic leg ulcers. 
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1.2.6 PATHOGENESIS AND BIOCHEMISTRY OF CHRONIC LEG ULCERS 
The exact mechanism responsible for chronic leg ulceration is poorly 
understood but several theories have been developed by researchers in an attempt to 
explain the cause. One of the first theories was proposed after observation of 
increased amounts of peri-capillary fibrin cuffs was made (Burnand et al., 1982). 
This accumulation of fibrin was proposed to reduce gas exchange in the local area 
and could result in reduced metabolic function and therefore delayed wound healing. 
A follow on theory proposed that the ulceration is a result of immune cells becoming 
trapped and activated in the legs where the blood is pooled (P. C. Smith et al., 1988). 
These activated immune cells then release toxic oxygen metabolites and proteolytic 
enzymes which in turn cause an inflammatory response and lead to tissue damage. 
Another theory was that growth factors are trapped by larger molecules such as fibrin 
and are not available for normal repair processes (Vincent Falanga & Eaglstein, 
1993). Since these hypotheses were published there have been a number of studies 
comparing acute and chronic wounds that have increased our understanding of the 
biochemistry of the pathology (T. J. James et al., 2000; Loots et al., 1998; Mast & 
Schultz, 1996; Tarnuzzer & Schultz, 1996; Trengove et al., 1999). Our current 
knowledge of the pathology of chronic leg ulcers illustrates that although the theories 
themselves did not hold entirely true, the data that supported them has added to our 
understanding of the complexity of wounds. The key feature of these findings is an 
increase in the number of immune cells and inflammation in the wound impacts on 
the local environment (Figure 1.1). This includes increased levels of proteases, 
degraded extracellular matrix, increased oxidative stress, altered secretion and 
degradation of growth factors, in some cases infection, and the main feature, 
increased inflammation. These attributes of chronic wounds are described in further 
detail below. 
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Figure 1.1 Biochemical and cellular mechanisms identified to contribute to the non-healing environment in chronic leg ulcers. Research 
has demonstrated that chronic leg ulcers have increased proteases, such as the MMPs, and decreased protease inhibitors, such as TIMPs. The 
presence of high levels of cytokines, reactive oxygen species (ROS) and inflammatory cells in chronic leg ulcers also contributes to wounds 
being stuck in a pro-inflammatory state. Adapted from Eming et al. (2007)  
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Proteases and Extracellular Matrix Degradation 
Studies have shown that the degradation of key ECM components may be one 
of the crucial factors that keep wounds in their chronic state. Degradation of 
fibronectin in the wound environment has been demonstrated (Grinnell et al., 1992; 
Schmidtchen, 2000; Wysocki & Grinnell, 1990). Similarly, vitronectin is another 
ECM protein that has been shown to be critical for wound healing (Jang et al., 2000), 
but is degraded in chronic ulcers (Grinnell et al., 1992). Hyaluronan, a 
glycosaminoglycan, can act as a signalling molecule by interacting with cell surface 
receptors regulating cell proliferation, migration and differentiation. This ECM 
component has been shown to be in low abundance in pressure ulcers compared to 
acute wounds (Dechert et al., 2006). The combined effect of all the above-mentioned 
disruptions to the ECM will negatively impact on wound closure since the ECM acts 
as a scaffold for cells to migrate across the wound bed.  
 
While proteases play an important beneficial role in clearing damaged ECM 
and facilitating cell migration in the normal wound healing process, a significant 
body of research has shown that the chronic wound environment is highly 
proteolytic. Proteases cause excessive degradation of the ECM, as mentioned above, 
thus preventing cell migration across the wound bed. High levels also inhibit 
proliferation as they degrade growth factors, which along with the loss of ECM, can 
lead to delayed healing. MMPs, zinc-dependent endopeptidases, are found at higher 
concentrations in chronic wound fluid compared to acute wound fluid acquired from 
patients undergoing a mastectomy (Wysocki et al., 1993). The study found 5-10 fold 
higher levels of MMP-2 and MMP-9 in both active and pro-enzyme forms in chronic 
wounds. This excessive MMP-2 and MMP-9 activity has been further confirmed by 
other studies (Weckroth et al., 1996; D. R. Yager et al., 1996) with increased levels 
found to correlate with wound chronicity (Rayment et al., 2008). Moreover, research 
has demonstrated that not only are there increased levels of MMPs, but also low 
levels of their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). The 
ratio of MMP-9 compared to its inhibitor, TIMP-1, is increased (Ladwig et al., 
2002), as is the ratio of MMP-2 compared to TIMP-2 in non-healing ulcers compared 
to those that are healing (Mwaura et al., 2006).  
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The upregulation of proteases, in particular MMP-2 and MMP-9, results in the 
degradation of ECM proteins such as gelatin, fibronectin and laminin (Nagase & 
Woessner, 1999). As a result, it is no surprise that degradation of the ECM and 
associated growth factors in this highly proteolytic wound environment would 
contribute to wound chronicity. Consequently, several adjunct therapies have been 
developed to provide cells with a provisional scaffold to allow cell migration across 
the wound bed and promote closure (see section 1.2.5). Furthermore, it has been 
proposed that the comparative levels of degradation fragments of fibronectin and 
vitronectin in wound fluids may be indicative of healing and could therefore be 
considered for development as future biomarkers (R. Moseley, Stewart, et al., 2004). 
This has yet to be validated. 
 
Oxidative stress 
Oxidative stress is defined as a microenvironment that experiences an 
imbalance in favour of pro-oxidants versus antioxidants. Oxidative stress is mediated 
by reactive oxygen species (ROS), such as superoxide (O
2-
), hydrogen peroxide 
(H2O2), hydroxyl radical (
•
OH) and hypochlorous acid (HOCl). Low concentrations 
of these free radicals are instrumental in early angiogenic and mitogenic signalling 
during dermal wound healing (Roy et al., 2006). However, excessive amounts of 
these free radicals can damage lipids, DNA and proteins and disrupt normal cellular 
functions such as proliferation, migration and ECM synthesis during wound healing 
(Ryan Moseley et al., 2002). For example, keratinocyte migration is impaired in vitro 
in the presence of high levels of H2O2 and loss of migration would negatively impact 
on the re-epithelialisation of a wound (O'Toole et al., 1996). 
 
With regards to chronic wounds, protein carbonyl groups generated by free 
radical-induced oxidation in chronic and acute wound fluid have been measured as 
an indicator of oxidative stress (R. Moseley, Hilton, et al., 2004). However, two 
methods were used to quantify the protein carbonyl groups that produced 
contradictory results. The first method, a biochemical based technique, showed no 
difference between the two groups, whilst the second method, western blot detection 
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for carbonyl groups, demonstrated a higher concentration in acute wound fluid 
compared to chronic wound fluid. The complexity of the biochemical process and the 
highly volatile nature of free radicals have been blamed for the limited and mixed 
information about oxidative stress and chronic leg ulceration (Wlaschek & 
Scharffetter-Kochanek, 2005). As a result, it is clear that further research is required 
into oxidative stress and its role in perpetuating wound chronicity. 
 
Bacteria involvement in reduced wound healing 
The skin hosts native microflora bacterium, sometimes referred to as normal 
flora (Evans et al., 1950), and loss of this protective barrier can allow their entry. 
This normal skin flora is the primary bacterium that colonise chronic wounds (D. R. 
Yager et al., 2007), with Staphylococcus and Pseudomonas being the most 
commonly identified species of bacteria in wounds (Davies et al., 2004; Gjødsbøl et 
al., 2006). Analysis of tissue biopsies demonstrates that they have different 
localisation in the wound, with Pseudomonas aeruginosa found significantly further 
from the wound surface compared to Staphylococcus aureus (Fazli et al., 2009). It 
has been suggested the deeper imbedded bacteria stimulate a stronger inflammatory 
response (Fazli et al., 2009). 
The research conducted to date has also focused on quantifying the amount of 
bacteria present in wound tissue. Human skin that is intact consists of normal flora at 
10
5 
colony forming units per gram of tissue (Noble, 1999). Interestingly, this same 
quantity of bacteria within a wound is the golden standard that determines that a 
wound is “infected” (Robson & Heggers, 1970). Moreover, previous studies have 
found no difference between microbial load and healing outcome using this 
quantitation method (Moues et al., 2004). Studies have also used wound fluid 
collected from healing and non-healing patients to quantitate bacterial load and 
similarly found no significant difference between the two groups (Trengove et al., 
2000). However, it has been argued that these conventional culture techniques do not 
reveal significant differences between healing and non-healing wounds because only 
2% of microorganisms can be cultured using these methods (Tuttle et al., 2011). 
Next-generation sequencing, a more recently developed technology, allows 
quantitation and identification of microbial specific species without the requirement 
to culture the sample. Such methods have been used to examine combat wounds, but 
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no correlation between bioburden and healing outcome was found (Nicholas et al., 
2014). There has been no published data utilising this technology to quantitate and 
speciate microbes in chronic leg ulcer wound fluid.  
 
Bacterial colonisation on moist surfaces involves species which interact / 
coexist as communities that are aggregated, rather than free-living planktonic 
organisms (R. Edwards & Harding, 2004). This phenomenon has been termed a 
biofilm, wherein the bacteria are embedded in a self-secreted extracellular 
polysaccharide matrix. In regards to wounds, several animal models have 
demonstrated that biofilms can significantly delay wound healing (Schierle et al., 
2009; G. Zhao et al., 2010). Research in this area is still very limited and the role that 
biofilms play in wound healing needs further investigation (G. A. James et al., 2008; 
Percival et al., 2012; Thomson, 2011). 
 
Growth Factors 
Growth factors are important at various stages of the wound healing process 
(see section 1.1.2) and as such there has been a huge focus on the impact of growth 
factors on chronic leg ulcer healing. It has been proposed that growth factors are 
trapped in the dermis by macromolecules such as fibrin, and are therefore 
unavailable for tissue repair in chronic wounds (Vincent Falanga & Eaglstein, 1993). 
Early studies suggest that there are decreased levels of growth factors in non-healing 
ulcers (Mast & Schultz, 1996). Insight as to what could be happening with the 
growth factors in the wound environment were found when growth factors were 
incubated in wound fluid collected from either chronic leg ulcers or chronic wounds 
(Trengove et al., 1999; D. Yager et al., 1997). The studies demonstrated degradation 
of growth factors supplemented in the wound fluid of chronic leg ulcers. This could 
then be inhibited through the addition of a broad-spectrum serine proteinase 
inhibitor, as well as by a neutrophil elastase inhibitor, thereby confirming the 
involvement of proteases in growth factor degradation (D. Yager et al., 1997).  
Many growth factors have been trialled as topical therapeutics for chronic 
wounds but these have not been successful and this may be due to the proteolytic 
nature of the wound environment (Hunt et al., 2000). Interestingly, in later studies no 
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significant differences were observed in the levels of PDGF, FGF, EGF and TGF-β 
in wound fluid obtained from healing and non-healing ulcers (Trengove et al., 2000). 
This data was in direct contradiction to the hypotheses that predicted ‘trapped’ or low 
abundances of growth factors in chronic wounds. It was therefore hypothesised that 
resolution of chronic ulcers may be impaired by inflammatory mediators, rather than 
inhibited by a deficiency of growth factors in these chronic wounds (Trengove et al., 
2000). 
 
Inflammation in Chronic Wounds 
Chronic wounds are described as being stalled in a state of pathologic 
inflammation (Loots et al., 1998) since increased and sustained inflammation is a 
characteristic feature of these wounds, even in the absence of infection (R. F. 
Diegelmann & M. C. Evans, 2004). In particular, a strong inflammatory response 
results in delayed or static healing and does not allow the wound to progress through 
the normal stages of wound healing which results in poor anatomical and functional 
outcomes for the patient (Lazarus et al., 1994). Sustained inflammation has been 
described as a cause of tissue breakdown and can even result in the formation of 
ulcers if left unresolved (Chen & Rogers, 2007).  
 
The inflammatory response is a reaction triggered by infection, mediated 
through pathogen-associated molecular pattern molecules (PAMPs), or tissue injury 
mediated through damage-associated molecular pattern molecules (DAMPs), and 
involves blood-derived immune cells (Medzhitov, 2008). The DAMPs and PAMPs 
activate receptors, such as the toll-like receptors (TLRs), leading to the production of 
pro-inflammatory cytokines. Bacteria colonising the wound could therefore 
contribute to the perpetual inflammatory response in chronic ulcers. PAMPs, such as 
the bacterial cell wall component lipopolysaccharides (LPS) which binds to TLR4 
(Takeuchi et al., 1999), and Flagellin, a principal component of bacterial flagella 
recognised by TLR5, mediate the production of cytokines that regulate inflammation 
(Hayashi et al., 2001). Further evidence indicating that bacteria play a role in the 
sustained inflammatory response in chronic wounds stems from the discovery of an 
antibacterial protein, Lipocalin-2 (Lcn-2). Increased expression of Lcn-2 is an innate 
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response to minimise microbial invasion and Pukstad et al. (2010) have demonstrated 
a reduction of Lcn-2 during wound healing progression. 
 
DAMPs also play a critical role in the inflammatory response and the same 
TLRs that recognise PAMPs also recognise DAMPs, indicating that similarities exist 
between pathogen-induced and non-infection induced inflammatory responses (Adib-
Conquy & Cavaillon, 2007). DAMPs are typically either intracellular proteins that 
are normally hidden from immune cells by being present within cells and are 
released upon damage, or they can be cleaved extracellular components. For 
example, cleaved or damaged extracellular matrix components, such as heparin 
sulphate and hyaluronan, trigger an inflammatory response (Scheibner et al., 2006). 
Similarly, high-mobility group box 1 (HMGB1), a DNA binding protein found in the 
nucleus and released upon injury, triggers an inflammatory response (Scaffidi et al., 
2002). Another intracellular component, this time cytosolic, is the metabolite uric 
acid, which can trigger inflammation. Metabolites are small molecules (below 
3000 Da) that are the end products of metabolism. Injured cells rapidly degrade their 
DNA and RNA and liberate more purines, which are then sequentially metabolised to 
produce more uric acid. Uric acid is thought to be one of the major DAMPs 
triggering inflammation. High levels of uric acid have been identified in chronic 
wound fluid and its levels have been correlated with wound chronicity (Melissa L. 
Fernandez et al., 2012). The study suggests that chronic wounds are characterised by 
prolonged inflammation and that this metabolite may play an important role in 
perpetuating the inflammatory response.  
 
In addition to the TLRs, some DAMPs and PAMPs also bind intracellular 
NOD-like receptors (NLR). The NLR family is comprised of 22 genes and several of 
these NLRs have been reported to assemble into multiprotein complexes which have 
been termed inflammasomes, namely, NLRP1, NLRP3, IPAF and AIM2 (Schroder 
& Tschopp, 2010). These multiprotein oligomers (hexamers / heptamers) form and 
trigger the caspase-1 auto-activation critical for the processing of the 
pro-inflammatory cytokines pro-IL-18 and pro-IL-1β into their active forms; these 
are then secreted into the extracellular space (Figure 1.2) (Martinon et al., 2002). 
The unoligomerised inflammasome complexes are still poorly understood, however, 
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some proteins / domains are common amongst several of the four inflammasomes 
and form scaffolds which promote the assembly of other proteins required in the 
structure. The leucine-rich repeat (LRR) domain has been described as the ligand 
sensing and auto-regulation portion of the complex, although the mechanism of how 
this is achieved is unknown (Martinon et al., 2009). The nucleotide-binding and 
oligomerisation domain (NACHT) is central to all NLRs, whilst the pyrin domain 
(PYD) recruits apoptosis-associated speck-like protein containing caspase 
recruitment domain (ASC). The ASC N-terminal contains a PYD domain, whilst the 
C-terminal has a caspase recruitment domain (CARD), which is the key component 
for the formation of the inflammasome (the complex is summarised in Figure 1.2) 
(Mariathasan et al., 2004). The pro-caspase-1 binds to the CARD domain and 
activates upon stimulation. Pro-inflammatory cytokines induce the production of 
pro-IL-1β and pro-IL-18 which is then cleaved by activated caspase-1 following 
inflammasome activation. PAMP activators of the inflammasome include LPS, 
flagellin, microbial nucleic acids (Franchi et al., 2009), Candida albicans, 
Saccharomyces cerevisiae (Gross et al., 2009) and Staphylococcus aureus 
(Mariathasan et al., 2006). DAMP activators include uric acid (Martinon et al., 
2006), extracellular ATP (Mariathasan et al., 2006) and glucose (Zhou et al., 2010). 
The PAMP and DAMP inflammasome activators listed above can be found in 
chronic leg ulcers and may well be responsible for increased pro-inflammatory 
cytokine stimulation.  
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Figure 1.2 NLPR3 Inflammasome Activation and Assembly. Damage associated 
molecular patterns (DAMPs) or pathogens associated molecular patterns (PAMPs) 
trigger the assembly of the inflammasome, NLPR3. The leucine-rich repeat (LRR) 
domain is the sensing portion of the complex. The nucleotide binding and 
oligomerisation domain (NACHT) is central to all NLRs which are bound to the 
pyrin domain (PYD), which in turn recruits the ASC portion and binds to the critical 
caspase recruitment domain (CARD). Finally the pro-caspase 1 is activated and can 
cleave pro-IL-1β and pro-IL-18 prior to their secretion out of the cell to induce a 
pro-inflammatory response. Adapted from Schroder et al (2010). 
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Both PAMPs and DAMPs induce the production and secretion of cytokines 
that regulate the inflammatory response. In acute wound healing the levels of 
pro-inflammatory cytokines are high in the early stages and decrease at 
commencement of the proliferative stage. TNFα is one of the first pro-inflammatory 
cytokines produced and is implicated in the exacerbated inflammatory response in 
chronic wounds. Significantly higher concentrations of TNFα are found in chronic 
ulcer wound fluid compared to acute wound fluid (Tarnuzzer & Schultz, 1996). 
Importantly, the levels of TNFα were found to be significantly higher in wound fluid 
samples from non-healing wounds compared to healing wounds, suggesting a 
continual stimulation of the immune system (Trengove et al., 2000). TNFα is a 
pro-inflammatory cytokine and so high levels would contribute to the perpetual 
inflammation that plays a role in the chronicity of these wounds. Mouse studies using 
antibodies to neutralise TNFα have shown that reduction in its levels can improve 
wound healing (Goren et al., 2007). Indeed, a topical antibody against TNFα led to 
improvement in healing rates for chronic venous leg ulcer patients not responding to 
conventional treatment, albeit there were only 8 patients in this study and they were 
not compared to patients receiving a placebo (Streit et al., 2006). Additional trials are 
required to determine whether neutralising TNFα is a feasible strategy to improve 
healing of chronic ulcers.  
 
Protein expression and secretion, including that of cytokines, can dramatically 
change in response to intrinsic and extrinsic stimuli, hence highlighting the need for 
multiple assessment points during the course of healing. While cytokines have been 
identified as key modulators of the sustained inflammatory response and are involved 
in delaying healing, they have not been used diagnostically. One might expect the 
level of pro-inflammatory cytokines to decrease as wound healing progresses and / or 
the level of anti-inflammatory cytokines to increase. Many studies investigating 
cytokine levels in wounds use pooled chronic wound samples, which will not give a 
clear picture of the wound inflammatory state. Longitudinal assessment of cytokines 
from individual patients is required to provide a greater understanding into 
inflammation in a chronic wound and how inflammation correlates to wound healing. 
Data from this kind of study could be used in the future to monitor the stage of ulcer 
healing, as well give insights into new treatment options. Recent advancements in 
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analytical technologies has resulted in the development of several new high 
throughput quantitation and identification methods, which can be employed to 
investigate cytokine expression in the wound environment. Of importance, many of 
these approaches only require relatively small volumes of sample; hence will be 
applicable to the analysis of wound fluid, given that often only small volumes can be 
collected. 
 
1.3 BIOMARKER DISCOVERY  
The importance of identifying biomarkers during wound healing was 
recognised early in chronic wound research (Mani, 1999; Tarlton et al., 1999). It has 
been proposed that future wound management might be based, as with many other 
diseases, on individualised treatment. This would ideally be guided by a biomarker(s) 
indicating healing / non-healing status which can be used diagnostically in the clinic. 
These biomarkers might be used to track the response of a particular treatment or aid 
in the identification of a pathogenic process. They could also identify hard-to-heal 
wounds, allowing the clinician to alter treatment options accordingly to maximise the 
possibility of wound closure. Wounds are very complex with many factors affecting 
healing outcome (Mani, 1999; Trengove et al., 1996). Biomarkers could be anything 
from a specific DNA sequence to altered expression of a protein or metabolite, either 
in wound fluid or in the damaged tissue itself. To date no such biomarker has been 
identified for use in the clinic that can consistently predict or identify non-healing 
wounds. 
 
Wound fluid is reflective of the extracellular environment and the state of the 
wound (Mani, 1999; Trengove et al., 1996). As it is localised to the site of injury, it 
contains a variety of constituents that might be indicative of the state of healing and, 
in the case of factors such as TNF, may also contribute to the healing or non-healing 
state of the ulcer (S. L. Drinkwater et al., 2002 2000; Staiano-Coico et al., 2000). 
Characterising wound fluid from healing and non-healing wounds could therefore 
give an indication of what might be happening in the wound over time and 
potentially lead to the detection of biomarkers that may correlate with healing 
outcome.  
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The composition of wound fluid has for a long time been of interest to 
researchers and early data demonstrated a difference between acute and chronic 
wound fluid through in vitro experiments. Fluid from acute wounds has been found 
to increase proliferation of vascular endothelial cells, fibroblasts and endothelial cells 
(Greenburg & Hunt, 1978; Katz et al., 1991), while chronic wound fluid had the 
opposite effect and inhibited proliferation in vitro (Bucalo et al., 1993; T. Phillips et 
al., 1998). Data such as this, together with the ease of accessibility of samples and 
new technology, has led to analysis of wound fluid in recent years.  
 
Biomarker identification is achieved by analysis of sequential samples in order 
to observe patterns or trends. The complexity of wound fluid and the associated 
technologies employed made it difficult in early chronic leg ulcer research studies to 
simultaneously detect the vast array of proteins. Generally single target antibody 
based techniques, such as mainly enzyme-linked immunosorbent assay (ELISA) and 
immunoblotting, have been used. These processes are not only time consuming, but 
also the volume of wound fluid limits the number of proteins analysed by these 
methods. Newer technologies such as multiplexing ELISAs, where multiple protein 
targets can be quantified at once, and Mass Spectrometry (MS), allow greater 
potential to discover biomarkers. Increasingly with biomarker discovery, untargeted 
MS is used in metabolomics and proteomic studies (Bogdanov et al., 2008; Indovina 
et al., 2013). This method involves sample components being separated based on 
affinity to a selected high-performance-liquid-chromatography (HPLC) column. The 
sample is then ionised prior to entering the mass spectrometer and the 
mass-to-charge ratio (m/z) is identified using a detector. Multiplexing on the other 
hand is a targeted method, where several antibodies to proteins of interest are 
conjugated onto separate beads allowing the identification and quantification of 
proteins of interest simultaneously in the one assay. For this type of analysis you 
must know what to target, such as known inflammatory cytokines. MS on the other 
hand, as an untargeted approach, allows for the identification of hundreds of peaks 
which can later be identified if found to be of interest. Both methods require very 
little wound fluid but can yield large volumes of data. 
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1.3.1 WOUND FLUID COLLECTION  
Wound biopsies have been used to investigate protein expression and cell 
localisation (Beidler et al., 2009; Berry et al., 1998). However, creating a second 
wound within the ulcer is not an ideal situation and is not a common procedure, 
especially in a wound that is already having difficulties healing. Thus, collecting 
wound fluid is probably the most common and ideal sample source for biomarkers. 
To identify biomarkers in wound fluid a reliable collection method is required. Over 
the last decade, various collection techniques have been used to sample fluid from 
the wound site. Ideally, any collection method used should be non-invasive and 
require minimal time. Collection methods have included the extraction of wound 
fluid absorbed onto a wound dressing placed on top of the ulcer (Fivenson et al., 
1997). Absorption onto membranes or dressings, however, leads to some loss of 
sample on these materials, leading to lower sample volume and protein 
concentrations in comparison to a direct aspiration method (R. Moseley, Stewart, et 
al., 2004). Absorption methods that have been published include the use of foam 
dressing to absorb the exudate and then the exudate was subsequently extracted by 
squeezing the foam through a syringe with a 20 gauge needle (Seah et al., 2005). 
Porous, inert hydrophilic dextranomer beads have also been used to collect wound 
fluid with the bound protein released through incubation of the beads for 12 hours at 
4°C in phosphate buffered saline (PBS); this, however, dilutes the samples (Cooper 
et al., 1994). Importantly, the collection of wound fluid samples using a material will 
influence the analysis of biochemical components, especially proteins, as they will 
differentially adhere to the selected material depending on their chemical properties, 
such as hydrophobicity and charge. Secondary steps involving the extraction of the 
exudate out of various materials have been used, but biochemical analysis of the 
exudate, such as determination of pH and redox, is not possible due to the use of 
various extraction buffers. This ultimately means that the collection method has the 
potential to influence the composition of the exudate (Trengove et al., 1996). 
Further, these materials will not capture small molecules, such as metabolites and 
small peptides, which may themselves be key markers of healing.  
Microdialysis, involving insertion of tubing to passively collect protein in the 
fluid local to the leg ulcer, has also been used to collect samples for biomarkers 
analysis (Clough & Noble, 2003). This technique is invasive and not surprisingly, 
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has very low patient consent. A less invasive collection technique is through 
collection of fluid directly from a NPWT device during treatment (Stechmiller et al., 
2006). Using this method no significant differences were found in key cytokines and 
proteases, such as IL-1β and MMP-2 and MMP-3. Nevertheless, it was concluded 
that perhaps the device draws too much intestinal fluid, thereby diluting the true 
wound fluid sample (Stechmiller et al., 2006; D. R. Yager et al., 2007). 
 
The most common technique for collecting wound fluid is direct aspiration of 
wound fluid that has accumulated beneath an occlusive dressing (Broadbent et al., 
2010; Tarlton et al., 1999; Trengove et al., 1996; D. R. Yager et al., 2007; D. R. 
Yager et al., 1996). Although the collection technique is very similar across many of 
these studies, variations have been described during wound fluid collection that 
could lead to differences, such as patients fasting for eight hours, minimisation of 
hydration differences through standardised intake of water, and duration of 
application of the occlusive dressing. Ideally, all research should only use one 
method to allow comparison of data but to date there has been no agreement on a 
standardised method. The Wound Management Innovation CRC, which facilitated 
the project described within this thesis and a number of other related projects, have 
collected samples by directly aspirating wound fluid from the ulcer using a Pasteur 
pipette as described in section 2.1.4. This approach allows the analysis of metabolites 
and other small molecules as they are not lost during wound fluid collection. 
Additionally, quantitation of proteins, such as cytokines, will not be altered through 
the collection technique via preferential binding or dilution.  
 
1.3.2 HIGH THROUGH-PUT BIOMARKER DISCOVERY 
The emergence of MS, microarray technology and multiplexing has opened a 
new door in the hope of identifying biomarkers to aid chronic leg ulcer treatment. 
These new technologies have moved away from the traditional detection of single 
targets as discussed earlier in this section and has instead allowed the identification 
of several targets simultaneously using multiplexing or hundreds of targets using 
MS. MS boasts high throughput sample analysis on systems that continually have 
greater sensitivity, thus allowing discovery of potential biomarkers that may have 
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been elusive due to their low abundance. These technologies have created the 
research fields, which are now termed ‘omics’ which encompasses the study of 
transcriptomics, proteomics and metabolomics as depicted in Figure 1.3. The 
combination of data from several of these ‘omics’ fields is now coined ‘systems 
biology’. Genes encode proteins and the transcription of the genes through mRNA is 
the study of transcriptomics. Proteomics is the qualitative and quantitative study of 
the altered protein expression by the genome, while metabolomics is the study of 
metabolites. Summarised below are the ‘omics’ techniques that have been used in the 
context of wounds, as well as the application of multiplexing in chronic wound 
research. 
 
 
Figure 1.3 The ‘omics’ cascade. Metabolomics can provide the endpoint biological 
information about a pathophysiological process as metabolites are the result of gene 
and protein function. Unlike its upstream counter parts, metabolomics cannot detect 
false positives as there are no regulators such as epigenetics or post-translational 
modification, such as those seen in genomics and proteomics, respectively. 
 
Transcriptomics  
Transcriptomics largely uses microarray technology to quantitate the 
messenger RNA (mRNA) levels and also micro RNA (miRNA) that regulate the 
translation of the mRNA. Microarray chips can quantitate the level of hundreds of 
targets and are typically used to examine the mRNA or miRNA response to a drug, 
the environment, or for comparison of disease versus control states. Using this 
technology miRNA extracted from tissue samples were recently found to be 
differentially expressed in patients with chronic venous insufficiency compared to 
control tissue (Cui et al., 2012). All of the eight up-regulated and five 
down-regulated miRNAs identified have functions in vascular biology and vessel 
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remodelling through either ECM or metalloproteinases. Interpreting the miRNA 
results is complicated, however, by the fact that a single miRNA can have up to a 
100 different targets and multiple miRNAs can have the same target (Hendrickson et 
al., 2009). This is further amplified by the discovery of proteins that bind the target 
mRNA and competing endogenous RNA (ceRNA), which negate the blocking effect 
of miRNA (Pasquinelli, 2012). Further, mRNA can be spliced or degraded prior to 
translation (Feder & Walser, 2005) and levels correlate poorly to protein expression 
(Anderson & Seilhamer, 1997; Maier et al., 2009), suggesting that for a biomarker, 
proteins or metabolites are preferable. 
 
Proteomics 
For the reasons stated above proteomics has emerged as the preferred method 
for chronic wound biomarker discovery. Proteomics is generally defined as the 
identification and quantification of proteins in a particular point in time or 
physiological state using high-throughput technologies. The first publication to 
identify a large number of proteins in wound fluid from patients suffering from 
venous leg ulcers was achieved with mass spectrometry (M. L. Fernandez et al., 
2008). It demonstrated that the majority of the proteomic profile of wound fluid was 
due to high abundant proteins; in light of this a method to deplete wound fluid of 
these proteins was developed to allow detection of less abundant species (M. L. 
Fernandez et al., 2008).  
 
By comparing acute wound fluid collected from surgical wounds to wound 
fluid collected from patients suffering from venous leg ulcers 149 proteins have been 
identified in fluid, 23 that were unique to healing and 29 unique to non-healing 
wounds (Sabine A. Eming et al., 2010). Of interest, wound fluid from non-healing 
wounds contained significantly increased levels of annexin-A1, lactotransferrin and 
S100A9, all which were validated using either immunoblotting or ELISA. In the 
context of wound healing, annexin-A1 and S100A9 are both involved in 
inflammation and lactotransferrin is secreted by immune cells and has strong 
antibacterial activity. Other proteins found exclusively in non-healing, samples but 
which were not further validated, included proteases such as neutrophil elastase, 
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matrix metalloproteinase 9 (MMP9), which has previously been identified as 
increased in non-healing wounds, and Lipocalin, an anti-microbial protein. Edsberg 
et al. (2012) recruited patients suffering from pressure ulcers and collected 
longitudinal samples looking at healing and non-healing wounds and also at the 
interior and peripheral of a wound. In total the study identified 21 proteins that could 
distinguish healing from non-healing pressure ulcers and 19 proteins that were 
differentially expressed between the interior and periphery region of the wound. 
Proteins that were significantly higher in chronic wound samples were mostly pro-
inflammatory in nature, such as IFNγ, IL-11, IL-12p40, IL-1a, IL-8 and IL-15. The 
proteins that were significantly higher in the healing cohort were Eotaxin-2, a 
chemotactic protein for eosinophils and neutrophils, and MIP-1d, another 
chemoattractant for neutrophils, as well as for monocytes and lymphocytes. The 
remaining significantly upregulated proteins in the healing cohort were, surprisingly, 
the ECM degrading MMPs -3, -10 and -13.  
 
The high-throughput nature of proteomics allows identification of novel 
proteins. However, it is important to note that protein identification is based on 
trypsin digested peptides, rather than whole proteins. This method will therefore not 
differentiate between whether these tryptic fragments come from whole proteins or 
cleaved protein products in the wound fluid. Given the nature of the wound 
environment and its high levels of proteases, it is entirely possible that many might 
be degradation products and thus most likely are not able to perform their original 
function. Hence, it is essential that with proteins identified through high-throughput 
mass spectrometry techniques that they are further validated through other 
biochemical methods such as immunoblotting and ELISA. While studies are starting 
to identify proteins of interest in regards to healing and non-healing wounds, no 
research to date has produced a biomarker that is used diagnostically in clinical 
settings. Nonetheless, it is interesting to note that many of the markers identified to 
date have a role in inflammation. 
Metabolomics 
The metabolome represents a complement of all low molecular weight 
molecules below 3000 Da, and as occurs in the other “omics” fields, the metabolome 
is identified via high-throughput technologies, mainly nuclear magnetic resonance 
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(NMR) or MS. Metabolomics is the endpoint of the “omics” cascade (Figure 1.3) as 
metabolites are the breakdown products of metabolic reactions and are the most 
predictive of phenotype (Fiehn, 2002). They provide an insight into how an organism 
responds to genetic alteration, disease and / or environmental influences. Metabolites 
in other disease states include markers of oxidative stress, such as 
8-hydroxy-2-deoxyguanosine (8-OHdG), which is a major product of DNA 
oxidation, and glutathione that can be measured in its oxidative or reduced state to 
provide information on the oxidative stress present. Other metabolites include uric 
acid, which, as mentioned before is indicative of cell damage and purine catabolism. 
Uric acid can be broken down to allantoin, a metabolite that indicates a highly 
oxidative environment since uric acid is not broken down enzymatically in 
mammals.  
 
Metabolomics has lagged in comparison to its “omics” counterparts due to the 
lack of electronic databases such as GenBank and UniProt (Wishart, 2007). It was 
not until 2005 and 2007 that the METLIN metabolite database and the Human 
Metabolome Database, respectively, were established (C. A. Smith et al., 2005; 
Wishart et al., 2007). Since then, several groups have completed global metabolomic 
profiling of several non-wound bio-fluids to expand the current database libraries 
(Lawton et al., 2008; Psychogios et al., 2011; Wishart et al., 2008). Whilst a 
metabolomic approach has not been used to investigate chronic leg ulcers, other 
methods have identified several metabolites in wound fluid, but even these findings 
have been limited. Comparing wound fluid and the matching patient serum sample 
has shown that lactate levels are higher in wound fluid, whilst glucose and uric acid 
were lower Trengove et al. (1996). These lower uric acid levels are in line with a 
study which investigated the ratio between uric acid and allantoin to predict 
oxidative stress in patients with chronic venous ulcers (Tim J James et al., 2003). 
The Trengove et al. (1996) study also reported no significant differences in uric acid 
levels between healing and non-healing cohorts, albeit the study had a limited 
number of patients (n=4, n=5, respectively). More recently a study using a much 
more sensitive and targeted metabolomic technique found very high levels of uric 
acid in wound fluid and found that these levels correlate with wound chronicity 
(Melissa L. Fernandez et al., 2012). The authors suggest that high levels of uric acid 
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in the wound environment might intensify inflammation, as is observed in gout. This 
is the only study to date that has investigated metabolites in the wound environment. 
Again, the biomarker is linked to inflammation in chronic wounds. 
 
Cytokinomics 
Cytokinomics uses various methods and technologies to ultimately quantitate 
the levels of secreted cytokines in fluid as markers of inflammation, typically 
between a disease state versus control. Multiplexing is the most common approach 
currently used for mass cytokine quantitation. The technology is based on the same 
principles as ELISAs in that the quantification of the protein of interest is based on 
antibodies binding to the target and is therefore very specific. In multiplexing assays 
the antibodies are immobilised on a surface and the experiment is designed according 
to a capture sandwich ELISA format. The high specificity of the antibodies, together 
with the capture format of the assay, allows the detection of multiple protein targets 
simultaneously in the same assay. As a result, very little sample volume is required 
to quantitate a large number of cytokines in the same experiment, thereby making it 
ideal for research areas with low sample volumes.  
 
Multiplexing has been successfully applied for broad cytokine screens of 
patient samples to identify specific biomarkers in other diseases (Fujita et al., 2013; 
Yamada et al., 2014). Large multiplex panels with 27 targets, including 
anti-inflammatory cytokines, pro-inflammatory cytokines and growth factors, have 
been used. For example, increased IL-17 levels have been found in patients with 
sporadic Creutzfeldt-Jakob disease compared to controls (Fujita et al., 2013), whilst 
higher levels of granulocyte macrophage colony-stimulating factor (GM-CSF) were 
found in patients with metastatic renal cell carcinoma responding well to tyrosine 
kinase inhibitor treatment versus those not responding (Yamada et al., 2014). These 
studies reemphasise the power of biomarkers. They can be indicators of disease, or 
they can be used as tools to monitor treatment. 
 
Multiplexed cytokine assays have been used in several wound studies (Beidler 
et al., 2009; Edsberg et al., 2012). The results are often contradictory but this may be 
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as a result of differences in the wound sample collection techniques, wound type and 
/ or the quantitation method used. For example, using two separate techniques, planar 
antibody arrays and liquid bead suspension, to quantitate 58 separate targets in 
wound fluid collected from patients suffering from pressure ulcers, IL-15 and 
IL-12p70 were found to be increased significantly (p value of 0.00) in non-healing 
ulcers compared to healing ulcers (Edsberg et al., 2012). Another study comparing 
30 tissue biopsies from both venous ulcers and adjacent healthy tissue showed IL-15 
and IL-12p70 had either undetectable tissue measurements, or no statistical 
significance, when comparing healthy and ulcer tissue before and after compression 
therapy (Beidler et al., 2009). This same study showed that levels of the 
pro-inflammatory cytokines IL-6, IL-1β, TNFα and IFNγ all significantly decreased 
in wound tissue following therapy. While these studies investigated different ulcer 
types and used different collections techniques, they demonstrate that multiplexing 
can successfully be applied to chronic ulcer research. All the same these studies do 
not present individual patient cytokine levels, or group them in the analysis stage into 
either non-healing / chronic versus healing / healed. We contend that longitudinal 
assessment of cytokine levels in individual patient samples might improve the 
possibility of identifying a protein or cytokine which could be used as a biomarker. 
Grouping all patients in terms of weeks following treatment could skew data and 
may overlook key indicators because not everyone responds to treatment at the same 
rate, and further, patients attending clinics all have different ulcer durations at 
presentation. 
 
1.4 SIGNIFICANCE OF RESEARCH  
Chronic leg ulcers are a financial burden on healthcare systems worldwide, 
particularly in countries with an increasing ageing population such as Australia. 
Moreover, poor lifestyle choices have resulted in an increase in obesity, 
cardiovascular disease and peripheral arterial disease. The higher rates of these 
co-morbidities will in turn lead to an increase in chronic leg ulcers, wound 
complexity and poor healing outcomes in the future. Chronic wounds are painful, 
debilitating and promote negative self-image, social isolation and depression, 
significantly reducing the quality of life of sufferers. Despite these negative impacts 
on both the patient and the wider community, and the significant cost of wound care, 
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wound research remains underdeveloped. Currently, there is a limited understanding 
of the fundamental processes involved in persistent wound chronicity but 
inflammation appears to be consistently disrupted. This lack of knowledge has a 
significant impact on the diagnosis, treatment and monitoring of chronic wounds. It 
is clear that improved approaches to accelerate wound repair are urgently required 
and this project is focused on addressing this problem. 
 
Disruptions in the normal healing process results in the modification of many 
biochemical factors and biochemical pathways that might lead to wound chronicity. 
Wound fluid is composed of a complex mixture of proteins, peptides and metabolites 
that are dynamic over the healing process. We hypothesise that sampling exudate 
directly from the wound and then subjecting this to current state of the art 
biochemical analysis technologies will allow the identification of biomarkers that are 
indicative of both healing and non-healing wounds. For the most part, prior studies 
have compared wound fluid from chronic wounds with that obtained from surgical / 
acute wounds. This has resulted in the identification of several key factors that are 
different between the two wound types. However, there is little data looking at 
healing and non-healing wounds, or studies examining non-pooled samples and 
distinct time points from healing. To date no reliable indicators of healing or 
non-healing wound trajectory have emerged. 
 
The research described herein examines wound fluid from chronic leg ulcers 
with various aetiologies for potential biomarkers. Since metabolites are predictive of 
phenotype, a metabolomic approach was first adopted for this project. This included 
profiling wound fluid samples from both healing and non-healing wounds using a 
LC-MS approach. In a second approach, biochemical changes in inflammatory 
mediators were identified using antibody-based multiplex techniques. The overall 
goal of the project was to further our understanding of biochemical alterations in the 
chronic wound environment and to enable the development of diagnostic indicators 
to predict healing outcome. This could also facilitate the development of improved 
and individualised wound therapies for patients and in turn enhance wound healing 
outcomes. 
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1.5 SPECIFIC AIMS AND HYPOTHESIS 
We hypothesise that attaining wound fluid samples directly from the site of the 
ulcer will allow the identification of biomarkers that are indicative of non-healing 
wounds and will also provide new knowledge in wound inflammation through 
biochemical analysis. The specific aims of this project were therefore to: 
1. Establish, validate and identify biomarkers using a metabolomic approach 
to profile wound fluid samples from patients with chronic leg ulcers;  
2. Determine pro-inflammatory cytokine profiles in longitudinal wound fluid 
samples obtained from healing and non-healing chronic leg ulcers; and; 
3. Investigate inflammasome activation in patients suffering from chronic 
leg ulcers. 
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Chapter 2: Materials and Methods 
2.1 GENERAL METHODS 
2.1.1 PATIENT RECRUITMENT AND STANDARD PROCEDURE 
Ethical approval was obtained from the Queensland University of 
Technology’s (QUT) Human Research Ethics Committee for the collection of patient 
clinical data, wound fluid samples and swab samples (approval number 
1000001255). Patients were recruited to the study through the Wound Healing 
Community Outreach Service located at QUT’s Health Clinics based at Kelvin 
Grove, Queensland, by research nurses working at the clinic. Patients that presented 
to the QUT Health Clinics were considered to have hard to heal wounds. The 
majority of these patients were referred to the clinic by their General Practitioner as 
they had failed to respond to ongoing treatment. All patients that met the inclusion 
and exclusion criteria were eligible to participate in the study.  
The inclusion criteria were: 
 Patients with a chronic wound of longer than four weeks duration. 
The exclusion criteria were: 
 Patients with cognitive impairment; 
 Presence of clinical signs of infection on admission; or 
 Patients with diabetic foot ulcers. 
Patients with more than one ulcer were allowed to participate and each ulcer 
was documented separately. Patients attending the clinic underwent a clinical 
assessment to ensure they fitted the study inclusion and exclusion criteria. All 
patients presenting with a chronic wound that fitted the inclusion and exclusion 
criteria were invited to participate in the study. Patient treatments were not 
standardised as patients with ulcers of several aetiologies, including pressure ulcers, 
arterial ulcers, venous ulcers, and mixed aetiology ulcers, were recruited. Instead 
each patient ulcer was individually assessed and treated by the Nurse Practitioner 
according to evidence based best practise. Compression therapy was used for venous 
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leg ulcers, while reduced compression was used for mixed ulcers, depending on the 
arterial component of the wound. Wounds that became infected following admission 
into the study were treated by best practice as deemed by the treating clinician. The 
treatment was documented and the patient was allowed to continue in the study.  
 
2.1.2 DATA COLLECTION 
Once recruited into the study, the patient’s relevant medical data was recorded. 
This included comorbidities, previous episodes of deep vein thrombosis and 
medications currently used. Additionally, baseline clinical data, such as ulcer 
aetiology, duration of ulcer, size of the ulcer and wound samples were collected by 
the appointed Research Assistant at the clinic. Patient data and wound samples were 
collected at each visit for 24 weeks or until the wound completely healed. 
Additionally, patients were provided questionnaires to complete at the beginning of 
the study and at, week 12, week 24 or when healing was achieved. Ulcer aetiology 
was determined using clinical assessment and the Ankle Brachial Pressure Index 
(ABPI). This measurement utilises the systolic blood pressure ratio between the arm 
and ankle of the affected leg. An ABPI of 0.9 and 1.2 was classified as an ulcer with 
venous hypertension. An ABPI <0.9 was considered as either mixed aetiology or 
arterial in origin and the classification was determined by the clinician. Qualitative 
patient data, including but not limited to, age, gender, living arrangements, financial 
situation, height, weight and requirement of a walking aid was also documented. The 
patient’s quality of life was measured using the Spitzer’s Quality of Life Scale 
(Spitzer et al., 1981), whilst pain was measured using the Rand Medical Outcomes 
Study Pain Measures (Sherbourne, 1992). The Philadelphia Geriatric Centre Morale 
Scale (Lawton, 1972) was used to quantify motivation and the Geriatric Depression 
Scale (Yesavage et al., 1982) was used to assess if the patient was suffering from 
depression, a condition which is common amongst sufferers.  
 
Information on variables related to the healing outcome of the ulcer was 
recorded at each patient visit. The strategies used to measure these are outlined 
below. 
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 Ulcer area: The ulcer wound area was calculated using Visitrak 
TM
, a 
wound tracing device developed by Smith & Nephew. This involved a 
standardised approach of tracing the edge of the ulcer onto an acetate grid 
to determine the wound area by planimetry. This standardised method 
provides accurate and reproducible data and allows calculation of wound 
area reduction, percentage reduction and total healing rates. Additionally, 
each ulcer was photographed at each visit.  
 PUSH tool: The Pressure Ulcer Score of Healing (PUSH) tool was used to 
track healing (Scott et al. 2001). This measure of healing incorporates 
wound area, exudate and the type of tissue (i.e. epithelial, granulating, 
slough or necrotic).  
 Other clinical data relevant to the area around the ulcer, such as oedema, 
eczema and inflammation, were also recorded.  
2.1.3 PATIENT SAMPLE COLLECTION 
A standard wound fluid collection technique has been established and is 
routinely used within our research group. Briefly, the ulcers were washed with sterile 
water prior to collecting the wound fluid, followed by the application of an occlusive 
film over the wound. Wound fluid that accumulated under the film after 30 to 60 
minutes was subsequently aspirated with a sterile Pasteur pipette. In previous studies 
conducted within our research group (Melissa L. Fernandez et al., 2012), the ulcer 
was washed with 1 mL of saline to recover the wound fluid. However, this method 
was modified to exclude the use of saline as it was found to dilute potential 
biomarkers and also requires normalisation of data to account for volumetric 
variation across samples. Moreover, concentration of these samples led to 
accumulation of salts which can interfere with subsequent biochemical analysis 
techniques. Other wound fluid collection methods, including absorption of wound 
fluid on to a porous, hydrophilic wound dressing were previously examined. It was 
found that direct aspiration using a Pasteur pipette was the most suitable approach 
compared to those involving the absorption due to loss of sample on the material.  
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Following the collection of wound fluid, one more clinical sample was 
obtained from the patients in the form of a microbial swab. The microbial swab 
collection technique involved a broad Z stroke technique to isolate microbial species 
at the wound site. The patients were then treated with evidence-based best practice 
depending on the type of wound they had.  
2.1.4 WOUND SAMPLE PROCESSING 
The wound fluid samples were processed using a standard protocol established 
in our laboratory. The wound fluid samples were centrifuged at 14,000 x g for 10 
min to clarify the sample and remove any cellular debris. The supernatant was 
aliquoted and an equal volume of 0.5 M sodium citrate pH 4.7 was added to stabilise 
the sample prior to storage at -80°C. Previous studies have shown that 0.5 M sodium 
citrate, pH 4.7, is capable of stabilising small metabolites and inhibiting the oxidation 
of free thiols (Williams et al., 2001). The microbial swabs, along with all processed 
samples, were stored at -80°C until further analysis.  
 
2.1.5 PROTEIN QUANTIFICATION 
Protein quantitation of the wound fluid samples and the swab extract was 
determined using a modified Bradford method, the Coomassie Plus protein assay kit 
(Thermo Scientific, Waltham, MA, USA). As per the manufacturer’s instructions, a 
BSA standard ranging in concentrations from 0.03 – 1 mg/mL was prepared. Wound 
fluid and extracted wound swab samples were diluted in phosphate buffered saline 
(PBS). Subsequently, 10 µL of the diluted samples or the standards was added to 
each well. Then, 300 μL of Coomassie Plus reagent was added to each well and 
incubated on a plate shaker at room temperature for 10 mins. All samples, including 
those in the standard curve, were performed in triplicate. Finally, all samples and 
standards were measured at 595 nm in a Bio-Rad UV-Visible Benchmarkplus 
microplate spectrophotometer (Bio-Rad, Hercules, CA, USA). The protein 
concentration of each unknown sample was determined based on the standard curve 
generated.  
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2.2 METABOLOMIC METHODOLOGY 
2.2.1 MATERIALS 
All buffers for liquid chromatography (LC) and sample processing were 
prepared using analytical grade reagents. Nanosep® centrifugation cut-off filter 
(3 kDa) devices used for metabolite enrichment were purchased from PALL 
(Pensacola, FL, USA). Pre-cast gels (gradient 4-12%) and reagents for sodium 
dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) were purchased 
from Invitrogen (Carlsbad, CA, USA). Metabolite separation for MS detection was 
achieved using a C18 column obtained from Agilent (Santa Clara, CA, USA). 
 
2.2.2 WOUND FLUID COLLECTION  
Wound fluid samples and clinical data were collected from consenting patients 
as described in section 2.1.3. Wound fluid was diluted 1:1 with 0.5 M sodium citrate 
pH 4.7 and further processed as described below. 
 
2.2.3 METABOLITE ENRICHMENT OPTIMISATION 
A centrifugation cut-off ultrafiltration method was used to separate and enrich 
metabolites present in wound fluid samples. Briefly, 3 kDa cut-off filtration devices 
(PALL) were equilibrated with equilibration buffer A (25 mM ammonium acetate 
20 % Acetonitrile (ACN) buffer). The buffer was centrifuged at 10,000 x g for 5 min 
at room temperature. The filtrate was discarded and the procedure was repeated to 
remove any impurities bound to the filter. Five microlitres of wound fluid was 
diluted in 295 µL of the equilibration buffer A and added to the top chamber. The 
diluted wound fluid was centrifuged at various speeds (6000 – 14000 x g) for 15 min 
in order to examine optimal metabolite separation. After centrifugation, the filtrate 
was dried using a rotary vacuum concentrator (Labconco, Kansas, MI, USA) at 
ambient temperature. The concentrated sample was then resuspended in loading dye 
containing a reducing agent (Invitrogen) and applied to a NuPAGE Novex 4-12% 
Bis-Tris gel (Invitrogen). The samples were electrophoresed at 200 V for 35 min at 
4°C.  
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The SDS-PAGE gels were silver stained using the Pierce Silver SNAP II 
staining kit purchased from Thermo Scientific (Waltham, MA, USA) according to 
the manufacturer’s instructions. Briefly, following electrophoresis, the gels were 
washed twice in ultrapure water and the immobilised proteins were fixed in 30% 
ethanol, 10% acetic acid for 30 min. Subsequently, the gels were washed in 10% 
ethanol and then distilled water to remove any residual fixative prior to sensitising. 
The gels were stained in a silver solution for 30 min at room temperature on a plate 
shaker. Finally, developer solution was added and the bands were visualised within 
30 sec. Once the desired band intensity was achieved, the reaction was stopped using 
a solution of 5% acetic acid.  
 
2.2.4 SAMPLE PREPARATION AND METABOLITE DETECTION 
Wound fluid was processed as described in section 2.2.3 and required further 
preparation for MS. The metabolite fraction (100 μL) was concentrated using a 
Labconco concentrator (Labconco, Kansas, MI, USA) at room temperature until the 
sample was completely dried. The dried samples were then resuspended in 20 μL of 
0.1% formic acid and 2% ACN. The solution was then transferred into vials for 
Direct Injection (DI) -MS or LC-MS analysis. 
 
Direct Injection Mass Spectrometry  
The untargeted metabolomic fingerprinting was achieved using a direct 
injection approach and was conducted using an Agilent Q-TOF 6510 (Santa Clara, 
CA, USA). As no column is required for metabolite separation using this approach, 
5 µL of sample was directly injected via the auto-sampling LC component which 
was pumping 80% ACN and 0.1% formic acid. Data was acquired by the instrument 
for 2 min following each sample injection. 
 
Liquid Chromatography –Mass Spectrometry 
The untargeted metabolomic global profiling was performed on the AB SCIEX 
Triple TOF™ 5600 system (AB SCIEX, Farmingham, MA, USA) located at the 
proteomics facility within the Institute for Molecular Bioscience (IMB), University 
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of Queensland. The metabolite fraction was first separated using a reverse phase C18 
column (Agilent) with a 2.1 mm internal diameter and 100 mm length. The LC 
component of the mass spectrometer was a Shimadzu Ultra Performance Liquid 
Chromatography (UPLC) (Shimadzu, Japan). The mobile phase consisted of buffer 
A that contained 0.1% formic acid and 2% ACN, while buffer B consisted of 80% 
ACN. The metabolites were separated using a gradient from 0% to 100% buffer B 
over 7 minutes. This was followed by a wash with 100% buffer B for 1 minute and 
finally the column was equilibrated with buffer A for 3 minutes. The temperature 
was kept constant at 45°C throughout the LC run. The total length of the run was 11 
minutes with a flow rate of 0.5 mL/min. 
 
The LC-MS instrument was run in positive mode with the source temperature 
set at 450°C and VCAP at 4500V where the metabolites are ionised. The curtain gas 
was maintained at 50 psi and only MS1 spectra were acquired for each sample. 
Metabolites between m/z values of 200 to 1200 were recorded and visualised on 
Analyst QS 2.0. All samples were analysed in triplicate and sample acquisition was 
performed as three separate batches. All UPLC-MS runs included negative controls 
and wound fluid pool sample controls. 
 
2.2.5 ANALYSIS OF LC-MS METABOLITE DATA 
Two separate software packages were used for the analysis of the metabolite 
profiling data. The first was a licenced software package developed by AB-SCIEX, 
MarkerView (software version 1.2.1). The MarkerView software uses principal 
component analysis, both supervised and unsupervised (PCA and PCA-DA 
respectively), for biomarker discovery. The second package was XCMS, an online 
pipeline developed by the Scripps Research Institute (La Jolla, California). The 
parameters used are described in detail below. Subsequently, two online databases 
were used for the identification of metabolites, namely METLIN (Scripps, 
California) and human metabolome database (HMDB) developed by the University 
of Alberta (Canada). 
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MarkerView Parameters 
The MarkerView peak search options were set as follows: the subtraction 
offset was set at 10 scans and the subtraction multiplication factor was set to 1.3. The 
minimum spectral peak width was 0.01 Da, the minimum retention time peak width 
was 2 scans and the noise threshold was 100 cps. The peak alignment options were 
set as follows: retention time tolerance at 0.5 min and a mass tolerance of 0.01 Da. 
Metabolite peaks that were detected in less than 10% of the samples were eliminated 
from further analysis. The dataset was transformed logarithmically and Pareto-scaled 
before unsupervised and supervised statistical models (PCA, PCA-DA) were applied. 
 
XCMS Parameters 
The XCMS parameters were selected through the online user interface. The 
following were the parameters selected: maximum tolerated m/z deviation in 
consecutive scans was 15 ppm. The minimum peak width was set at 5 sec and the 
maximum peak width was 20 sec. Peak alignment was based on width of overlapping 
0.015 m/z slices that were used to create peak density chromatograms and grouping 
peaks across samples. The retention time tolerance was set at 10 sec and peaks that 
were present in less than 5% of the samples were not considered for further analysis. 
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2.3 CYTOKINE PROFILING MATERIALS AND METHODS 
2.3.1 MATERIALS 
All buffers for multiplexing cytokine quantitation were purchased as part of a 
BioPlex Pro Human Cytokine 27 Plex assay (M50-0KCAF0Y; Bio-Rad, Hercules, 
CA, USA). The 27 cytokines including in the panel were IL-1β, IL-1 receptor 
antagonist (ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, 
IL-17, eotaxin, basic FGF, granulocyte colony-stimulating factor (G-CSF), 
granulocyte macrophage colony-stimulating factor (GM-CSF), IFNγ, interferon-
inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), 
macrophage inflammatory protein (MIP)-1α, platelet-derived growth factor 
(PDGF-BB), MIP-1β, regulated on activation, normal T cell expressed and secreted 
(RANTES), TNFα, and VEGF. 
2.3.2 METHOD 
The multiplex assay was performed according to the manufacturer's 
instructions for cytokine detection in plasma (Bio-Rad Precision Pro Manual). 
Briefly, 2 µL of each wound fluid sample was diluted in 48 μL of sample diluent 
buffer and incubated with multiplexed microbeads labelled with specific antibodies 
to the cytokines for 60 min at room temperature (RT), shaking at 300 revolutions per 
minute (RPM) and covered from light. Following 3 washes with the supplied wash 
buffer, the beads were incubated with the detection antibody cocktail, with each 
antibody specific to a single cytokine, for 30 min at RT, shaking at 300 RPM and 
covered from light. After a further 3 washes, the beads were incubated with 
streptavidin-phycoerythrin for 10 min at RT, washed again 3 times and finally 
resuspended in 125 μL of supplied assay buffer. The concentration of each cytokine 
was determined using the Bio-Plex 200 array reader (Bio-Rad, Hercules, CA, USA). 
The wound fluid samples were tested in triplicate on a 96-well plate alongside the 
standard curve. The Bio-Rad supplied standards of each cytokine are serially diluted 
to construct a plot of intensity versus concentration. The unknown concentrations 
were then calculated from the standard curve generated in the software package. The 
software parameters were set to a bead map of 100 and 50 beads per region for 
quantitation. The injection volume of sample was 50 μL.  
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2.3.3 WOUND FLUID COLLECTION AND SAMPLE PREPARATION 
Wound fluid samples and clinical data were collected from consenting patients 
as described in section 2.1.3. Wound fluid was diluted 1:1 with 0.5 M sodium citrate 
pH 4.7 following collection. 
 
2.3.4 LINEARITY AND OPTIMISATION  
Serial dilutions (1, 2, 3 and 4 μL) of a generated wound fluid pool from healing 
and non-healing patient samples were added to each Bio-Plex panel as a control. This 
allowed the assessment of linearity of the analytes quantitated. Poor linearity of the 
quantitated serial dilution was used as an indicator of interference of quantitation 
within the assay.  
 
2.3.5 ANALYSIS OF CYTOKINES AND GROWTH FACTORS  
Bio-Rad acquisition software reports cytokine concentrations in picograms of 
analyte per millilitre of sample. For the analysis and illustration of the Bio-Plex data, 
the concentrations were normalised to total protein (picograms of analyte per 
milligram of total protein). Statistical analysis was then performed using a linear 
mixed model (LMM) to compare the two cohorts. All LMM analyses were 
performed using the Statistical Package for Social Sciences (SPSS software version 
21). LMM can analyse datasets with repeated measures, unbalanced longitudinal data 
and allows for missing values. Graphs were produced in GraphPad Prism (version 6) 
and error bars display the standard error of the mean.  
 
2.4 INFLAMMASOME DETECTION METHODOLOGY 
2.4.1 MATERIALS  
HEK Blue IL-1β (293) cells were purchased for quantification of active IL-1β 
(InvivoGen, San Diego, CA, USA). Pre-cast gels (gradient 4-12%) and reagents for 
SDS-PAGE were purchased from Invitrogen (Carlsbad, CA, USA). Detection of the 
ASC protein was achieved through detection via antibody (AL-177) purchased from 
AdipoGen (San Diego, CA, USA). The HMGB1 antibody (ab18256) was acquired 
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from Abcam (Cambridge, UK). All lytic enzymes required for DNA extraction from 
swab samples were purchased from Sigma Aldrich (St. Louis, MO, USA). A mix of 
three enzymes was used, lysostaphin, lysozyme and mutanolysin. Additionally, bead 
beating tubes (2.8 mm) were purchased from Gene Works to aid lysis (Adelaide, 
Australia). A QIAamp DNA mini kit was used for DNA purification (QIAGEN, 
Hilden, Germany). The quantitation was performed using SYBR Green from Life 
Technologies (Carlsberg, CA, USA) on a Rotor Gene 6000 RT-PCR (software 
version 1.7.61) from Corbett Life Science (QIAGEN, Hilden, Germany). 
 
2.4.2 IL-1β ACTIVITY ASSAY 
The HEK-Blue IL-1β cell activity assay was performed according to the 
manufacturer’s recommendations. In brief, the cells were grown and the experiment 
was performed at normal cell culture conditions, 37°C and 5% CO2. The cells were 
maintained in 10% FCS (heat inactivated) in DMEM (4.5 g/L glucose) with the 
addition of selection drugs, Zeocin (100 μg/mL) and HygroGold (200 μg/mL), and 
antibiotics Normacin (100 μg/mL), Penicillin (50 U/mL) and Streptomyocin 
(50 μg/mL). As advised, TNFα was used as a negative control. To match the 
Bio-Plex experiment the same wound fluid volume was used (2 μL) but required 
dilution in 50 μL of DMEM for the experiment. The bioactive IL-1β was monitored 
through an altered NF-κB pathway with a secreted embryonic alkaline phosphatase 
reporter. The QUANTI-Blue reagent was subsequently used to detect and quantitate 
SEAP. The data was normalised to a blank control and the quantitation was based on 
a standard curve of active IL-1β. Data was imported into GraphPad Prism (version 6) 
for analysis.  
 
2.4.3 DETECTION OF PROTEINS USING WESTERN BLOT 
Firstly, the wound fluid samples were loaded on 15-well SDS-PAGE gels 
(process and reagents described in section 2.2.3) and separated by size. Following 
separation the SDS-PAGE gels were then transferred to PVDF membranes (PALL) 
in Tris-Glycine buffer (250 mM Tris, 400 mM Glycine, 10% methanol) at 200 mA 
for 1-1.5 hrs. The membranes were then blocked with 7.5% (w/v) BSA in Tris 
Buffered Saline buffer with Tween-20 (TBST) (10 mM Tris-HCl, 0.5 M NaCl, 0.1% 
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Tween-20, pH 7.5) for a minimum of one hour at room temperature with agitation. 
The primary antibodies were diluted in 1% BSA and the membranes incubated for 1 
hour at room temperature with agitation. Following primary antibody incubation, the 
membranes were washed three times for five minutes with TBST buffer prior to 
incubation with the secondary antibody. The secondary antibody was also in 1% 
BSA in TBST and incubated at room temperature for half an hour with agitation. 
Following secondary antibody incubation, the membranes are washed six times for 
five minutes each time with TBST. Subsequent to the final TBST wash, the 
membranes were blotted dry and incubated in ECL Plus, a chemiluminescent 
substrate (GE Healthcare, Buckinghamshire, UK), for five minutes. The signal was 
detected by exposing the membranes to Fuji X-ray film (FujiFilm Corporation, 
Tokyo, Japan) over various time points and then developing these in an automated 
film developer (AGFA CP 1000, Mortsel, Belgium). 
 
2.4.4 MICROBIAL LOAD QUANTITATION 
Microbial swabs were collected alongside wound fluid and used to quantitate 
microbial DNA as an indicator of the microbial load at the wound site. The approach 
was adapted from previously published work (Price et al., 2009) and involved both 
physical and enzymatic cell lysis and the method quantitated microbial 16S rRNA. In 
brief, -80°C stored swabs were thawed at room temperature and then the swab tips 
were suspended in 300 μL of ultra-pure DNAse and RNAse free water (Roche, 
Penzeberg, Germany) and 50 μL of lytic enzyme mix. The lytic enzyme mix 
consisted of 40 μL/mL of Lysostaphin (Sigma-Aldrich, catalogue number L7386), 
20 mg/mL Lysozyme (Sigma-Aldrich, catalogue number L6876) and Mutanolysin 
100 U/mL (Sigma-Aldrich, catalogue number M4782). These tubes were then 
incubated for 30 min at 37°C in a dry heating block. Following a centrifugation step 
at 1500 rcf for 1 min, the solutions were transferred to bead beating tubes (MoBio, 
Carlsbad, CA) which were vortexed for 1 min in a bead beating vortex (Mini-
Beadbeater-24, Biospec Products, Bartleesville, OK). The samples were once more 
briefly centrifuged, 1200 rcf for 1 min, and the solution was transferred to QIAGEN 
spin columns where the manufacturer’s instructions for a QIAamp DNA mini kit 
were followed to purify DNA. The purified DNA (50 μL) was stored at -80°C until it 
was required.  
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Prior to Real-Time PCR the extracted genomic DNA quality and quantity was 
measured using the NanoDrop spectrophotometer (ND-1000, Biolab, Australia). A 
ratio between 1.8–2.0 in 260/280 absorbance was deemed as acceptable for DNA 
purity, which all samples met. Each RT-PCR reaction contained 1.25 μL of forward 
and reverse primers (Table 2.1) with 10 μL of SybrGreen mastermix (Life 
Technology, Carlsberg, CA, USA), 5.5 μL of DNAse/RNAse free water and 2 μL of 
extracted DNA. The 16S amplification protocol contained a three step Real-Time 
PCR cycling procedure including a 50°C hold for 2 minutes, followed by 95°C for a 
further 2 minutes, and then 58 cycles of, 95°C hold for 10 seconds, followed by 58°C 
for 20 seconds and finally 72°C for 30 seconds. After the 58 cycles, the DNA 
amplicons were subjected to a hold at 72°C for 5 minutes and followed a melt step 
ramping from 50°C to 99°C rising by 1°C and waiting for 90 seconds for pre-melt 
conditioning on the first step only, followed by a 5 second wait for each step 
thereafter. The data was compared to a standard curve of known concentration from 
Staphylococcus aureus (N315).  
 
Table 2.1 The sequence for 16S rRNA primers for bacterial load determination 
in microbial swab samples collected from chronic wounds. 
Forward 
16S-U8F : 
5’-CCTCTCTATGGGCAGTCGGTGATAGAGTTTGATCCTGGCTC
AG-3’ 
Reverse 
16S-U338R : 
5’-CCTCTCTATGGGCAGTCGGTGATTGCTGCCTCCCGTAGGAG
T-3’ 
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Chapter 3: Metabolic Profiling of Wound 
Fluid from Chronic Leg Ulcers 
3.1 INTRODUCTION 
Metabolites are the breakdown products of metabolic reactions and provide an 
insight into metabolic changes due to disease or environment. Unlike proteomics and 
transcriptomics, where the functions of proteins and genes are regulated via 
epigenetic and post-translational regulation, respectively, metabolomics measures 
metabolites, the endpoints of biochemical activity. Differential expression of 
metabolites can be used to monitor disease prognosis or disease progression as 
changes in gene expression and enzyme activity will alter levels of metabolites in 
particular disease states. In the case of chronic wounds they have the potential to 
indicate what metabolic processes might occur or be altered as the wound heals (S. 
L. Drinkwater et al., 2002; Trengove et al., 1996; D. R. Yager et al., 2007).  
 
Metabolomics is the global quantitative assessment of all endogenous 
molecules with a MW < 3000 Da within a biological system, in our case wound 
fluid. It involves the use of high-throughput instruments such as mass spectrometers 
for the identification and quantification of metabolites. MS has the ability to monitor 
changes in a wide variety of compounds, as well as having good sensitivity and 
reproducibility, and requires only limited sample volume, which is crucial for studies 
with wound fluid (Theodoridis et al., 2008). The first step in a metabolomics study 
requires proper separation of molecules to improve the detection of metabolites. 
Separation techniques such as gas chromatography (GC) and liquid chromatography 
(LC) have been used in combination with MS, and in fact, GC-MS was the gold 
standard in early metabolomics studies (Harrigan & Goodacre, 2003). However, GC-
MS is predominantly used for volatile compounds and is unable to detect molecules 
that cannot be readily volatilised (Montuschi et al., 2010). LC-MS is a more robust 
and is often used to map a wide range of metabolites in untargeted approaches (Dunn 
& Ellis, 2005). No single method can capture all metabolites in a given sample. 
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However, MS provides the greatest number of metabolite identifications (IDs) due to 
its superior sensitivity, as long as appropriate sample preparation and sample 
separation techniques are applied. As a result, MS was chosen as the method for our 
metabolite profiling as increased metabolite identifications (IDs) provides more 
opportunities to identify potential biomarkers.  
  
Using MS the metabolome can be studied using an untargeted or targeted 
approach as illustrated in Figure 3.1. Untargeted metabolomics involves 
simultaneous fingerprinting, or profiling, of as many metabolites in a biological 
sample as possible. Targeted metabolomics refers to a method where one or more 
specific metabolites are quantified in a given sample. It involves the use of a triple 
quadrupole MS (QqQ), and a technique known as selective reaction monitoring, to 
quantitate the known metabolite via fragmentation patterns using LC-MS/MS. 
Untargeted metabolomic fingerprinting is usually achieved through direct injection 
(DI) MS (DI-MS), whilst profiling is accomplished through LC-MS. LC-MS enables 
the detection of thousands of metabolites from biological samples and has been the 
method of choice for global metabolite profiling. Since metabolomic approaches 
have not previously been used to study chronic leg ulcers, an untargeted approach, 
both DI and LC-MS based, was undertaken in this study to firstly identify 
metabolites present in wound fluid from chronic wounds. The objective of the study 
reported in this chapter was to therefore establish and validate a metabolomic method 
to profile wound fluid samples from patients with chronic leg ulcers. 
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Figure 3.1 Comparison of targeted and untargeted metabolomics profiling workflows. A| In targeted metabolomics, metabolites of 
interest are already known and a standard fragmentation pattern is established using LC-MS/MS. The metabolite standard is serially diluted 
to establish a standard curve to allow quantitation of a known metabolite in samples. B| The untargeted workflow is designed for global 
metabolomic profiling. The sample extraction and subsequent acquisition process require optimisation. Using software algorithms the 
chromatograms are aligned, metabolites are extracted and analysis performed on unknown peaks. The peaks are then identified using online 
databases, thus identification is confirmed using LC-MS/MS fragmentation patterns in comparison to an obtained standard.  
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3.2 RESULTS 
3.2.1 WOUND FLUID COLLECTION AND PATIENT DEMOGRAPHICS 
A total of 176 wound fluid samples from 28 chronic leg ulcers were collected 
by direct aspiration and analysed using mass spectrometry. The wound fluid samples 
were obtained from 24 patients, 15 female and 9 male, ranging from 39 to 98 years 
of age with a median age of 76. The majority (46%) of ulcers were classified as 
mixed venous / arterial aetiology, 28% were pure venous and 21% were pure arterial. 
Of these, 82% of patients had a previous history of ulcers. The duration of ulcers 
ranged from 2 to 1040 weeks prior to the commencement of the study, with ulcer 
size ranging from 0.5 to 71.0 cm
2
 with an average ulcer size of 10.5 cm
2
. The 
average PUSH score for the healing ulcer cohort was 10 on entry to the study ranging 
between 6-16. The average PUSH score for the non-healing ulcer cohort was 12 on 
entry to the study, ranging between 10 and 16. Of these 28 ulcers, 9 healed during the 
course of the 24 week study, whilst the rest remained unhealed.  
 
3.2.2 METABOLITE ENRICHMENT AND PURITY 
In the literature an untargeted metabolomic profiling approach has not been 
reported in investigations of wound fluid from chronic leg ulcers. Therefore, it was 
necessary to first develop and optimise several of the steps in the process. The first 
step involved modifying an already established method in our laboratory to separate 
the metabolites from the proteins in the wound fluid (Melissa L. Fernandez et al., 
2012). This method used a different wound fluid collection technique to the direct 
aspiration collection used in the Fernandez et al. (2012) study, where the wound was 
washed with 1 mL of saline and fluid collected using a Pasteur pipette. The large 
collection volume and more dilute sample, compared to that collected from direct 
aspiration, meant this sample could be applied directly to a 3 kDa nanosep cut-off 
spin column to separate metabolites. The direct aspiration method used in the current 
study, however, had an average collection volume of approximately 20 μL. Since 
lower filtration volumes would result in no filtrate passing through the filter a 
dilution step was incorporated prior to centrifugation with the 3 kDa cut-off filter. 
This dilution step was in accordance with the manufacturer’s instructions which 
suggested use of a mid-range volume of 250 μL. The choice of diluent is important, 
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as once the diluted wound fluid sample passes through the cut-off filter the filtrate 
would then need to be concentrated in an MS compatible buffer. Ammonium acetate 
was chosen as it is a volatile buffer that allows sample concentration and is 
compatible with downstream analysis. Furthermore, several previous studies using 
cut-off filters have highlighted the importance of dissociating low molecular weight 
species from high abundant proteins, such as albumin, a well-known carrier and 
transporter protein within the body to which metabolites might be bound (Harper et 
al., 2004; Orvisky et al., 2006; Tirumalai et al., 2003). These studies demonstrated 
that 20-25% acetonitrile (ACN) can be used to disrupt these interactions, allowing an 
increased number of low molecular weight species to pass through the 3 kDa cut-off 
filter. Thus samples were diluted 1:60 (5 μl of wound fluid) in 25 mM ammonium 
acetate buffer containing 20% ACN based on the filtrate and retentate volumes 
observed following centrifugation, approximately 200 μL and 100 μL, respectively.  
 
The second step of the metabolite enrichment method development involved 
optimisation of the centrifugation step. Speeds above 14000 x g were found to 
compromise the cut-off filter membrane (Figure 3.2 A). Thus protein recovery 
experiments were necessary to determine protein loss from the upper retentate 
fraction following centrifugation. The amount of protein in the retentate (above the 
filter) was measured before and after ultracentrifugation. Protein recovery following 
6000 x g resulted in 96.5% protein recovery (3.5% lost on membrane), whilst 
14000 x g resulted in 88.5% protein recovery. When separated by SDS-PAGE it can 
be seen that after the 14000 x g step that proteins with a molecular weight above the 
3 kDa cut-off had passed through the membrane, thereby contaminating the 
metabolite filtrate fraction (Figure 3.2 A). A protein of approximately 60 kDa in 
size, most likely albumin, can be seen in the filtrate, as well as higher molecular 
weight species (Figure 3.2 A). These results were consistent with an earlier study 
(Georgiou et al., 2001) that showed albumin (67 kDa) passed through a 50 kDa filter 
at high centrifugation speeds using similar spin filter technology. The small protein 
loss after the 6000 x g centrifugation step could indicate retention on the filter 
membrane. This was confirmed by the lack of bands following silver staining 
(Figure 3.2 C). Two wound fluid samples were used to assess the enrichment 
method. Samples (5 μL) were diluted 1:60 in the chosen buffer (25 mM ammonium 
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acetate containing 20% ACN) and loaded on cut-off filters pre-equilibrated with the 
same buffer. Following a 15 min centrifugation step at 6000 x g the filtrate and 
retentate were concentrated, separated by SDS-PAGE and visualised with silver 
stain. As expected, the retentate showed the presence of proteins ranging from 
10-250 kDa (Figure 3.2 A). The filtrate collected from the samples showed no 
protein contamination with larger molecular weight proteins (Figure 3.2 B). Thus a 
25 mM ammonium acetate buffer containing 20% ACN was chosen to dilute the 
sample and a centrifugation speed of 6000 x g was chosen for processing to ensure 
that there is no contamination of the metabolite fraction with larger proteins. 
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Figure 3.2 Metabolite enrichment validation and demonstration of filter 
integrity.  Silver stained SDS PAGE analysis of wound fluid using the optimised 
sample preparation method as outlined in section 2.2.3. A| Lane 1 - molecular weight 
marker, Lane 2 - filtrate fraction post 3 kDa cut-off centrifugation at 14000 x g 
demonstrating compromised filter and protein contamination in metabolite fraction. 
B| Lane 1 - molecular weight marker, Lane 2 - blank, Lanes 3 and 4 – protein 
retentate fractions post 3 kDa cut-off centrifugation at 6000 x g. C| Lane 1 -
molecular weight marker, Lane 2 - blank, Lanes 3 and 4 contain filtrate fractions post 
3 kDa cut-off centrifugation at 6000 x g, these have no protein staining in the 
metabolite fraction. 
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3.2.3 DI-ESI-MS AND LC OPTIMISATION 
The first metabolomics approach tested aimed to generate a metabolite 
fingerprint of each wound fluid sample using direct injection MS. The methodology 
of Electro Spray Ionisation, Direct Injection, MS (ESI-DI-MS) was adopted as it had 
been successfully used to identify metabolites in other studies (Bino et al., 2004; 
Castrillo et al., 2003). However, spectral data attained from ESI-DI-MS analysis of 
wound fluid acquired only a limited number (>40) of m/z peaks (data not shown). 
With no chromatographic resolution, only the most abundant analytes in the sample 
are detected. Due to the very low peak counts, this technique was abandoned and a 
LC separation procedure was chosen to improve metabolite resolution and ionisation, 
thereby increasing the amount of analytes detected by MS. 
 
The separation of metabolites is achieved through various column chemistries. The 
most common, reverse phase, was selected for use in this project (Theodoridis et al., 
2008). Three 18-carbon chain (C18) reverse phase columns were chosen with the 
column dimensions, such as length, internal diameter, as well as particle sizes, being 
based on previous studies (Dunn & Ellis, 2005; Lawton et al., 2008; Theodoridis et 
al., 2008). A standard high performance liquid chromatography (HPLC) ACN 
gradient method (0-80% ACN) was created for testing the reverse phase columns and 
the filtrate was injected into each run and the eluted fractions were measured at 
280 nm and 260 nm. As the concentration of ACN increase from 0-80% (from 2-18 
minutes) the analytes bound to the column should be displaced based on their 
hydrophobicity (affinity to the column) as ACN is hydrophobic. The separation 
quality and binding capacity of three columns were then tested with metabolites from 
wound samples; which all three columns had C18 reverse phase chemistry, they have 
marked performance and quality differences. The first column tested was a Grace 
Polar C18; this had very poor binding as evident by the large peaks at the beginning 
of the run, suggesting the majority of sample passed through the column unbound 
(Figure 3.3 A). Very few peaks were seen across the whole run, suggesting that the 
majority of the sample had no binding affinity to the column chemistry. The next 
column tested, a C18 Monolith (Agilent), once again demonstrated poor binding 
performance as the majority of the UV detection occurs at the beginning of the run, 
suggesting the sample had no affinity to the column (Figure 3.3 B). However, the 
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C18 Monolith column has some smaller peaks between 8-12 minutes, suggesting 
slightly better affinity of the metabolites than was found with the Grace Polar C18 
column (Figure 3.3 A). The best binding performance was demonstrated by the C18 
Polaris, which generated not only good separation as demonstrated by the peaks on 
the chromatogram occurring 12 minutes into the gradient, but also had a very small 
unbound sample fraction as indicated by the small peak at the beginning of the run (2 
min) (Figure 3.3 C). The C18 Polaris also provided good peak resolution with each 
peak displaying a sharp and distinct start and finish point (Figure 3.3 C). This 
critical optimisation step not only identified the C18 Polaris as the most effective 
column for the metabolomics experiments, but also allowed ACN gradient 
optimisation that would be used for MS.  
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Figure 3.3 Comparing the performance of three C18 reverse phase columns on 
binding and resolving efficiency of wound metabolites. A| The C18 Grace Polar 
trace shows the majority of metabolites did not bind to the column, B| the C18 
Agilent Monolith trace show a small percentage of metabolites bound to the column, 
and C| with the C18 Polaris column, the majority of the metabolites bound and 
separated with good resolution. Absorbance measured at three wavelengths, 220 nm 
(blue), 260 nm (green trace) and 280 nm (purple trace). 
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3.2.4 LC-MS METABOLITE DETECTION AND THE INVESTIGATION OF PEG 
CONTAMINATION  
Having optimised the sample processing method, as well as the LC method, 
176 wound fluid metabolite samples were processed and analysed using LC-MS. 
Due to instrumentation availability the MS data acquisition of the 176 samples 
occurred in three batches on separate days. Analysis of the metabolite spectra 
revealed the presence of over 800 m/z peaks in all analysed samples; however, 
interfering peaks that affected the quality of the spectra were detected (Figure 3.4). 
Extraction of spectral data from the total ion count revealed that these artefacts were 
associated with a series of high intensity m/z peaks. Closer inspection revealed that 
the peaks were an adduct contaminant series increasing in size by 44 m/z units as 
shown in Figure 3.4 B. It was established through review of the MS literature and 
online troubleshooting that the contaminant was polyethylene glycol (PEG), a 
polymer that is easily ionised by the mass spectrometer and can be introduced into 
the instrument through several sources. The total ion count chromatogram (Figure 
3.4 A) demonstrates the distinct profile of PEG contamination first described by 
Fenn et al. (1989) as following a Guassian shape. The spectral data (Figure 3.4 B) 
extracted from the total ion count chromatogram reveals the 44 m/z adduct series as 
denoted by the ‘+’ symbols beginning at 344 m/z units and increasing in size. 
Spectral data also provides information about the relative quantity of the m/z peaks, 
as denoted by intensity shown by the y-axis (Figure 3.4 B), and this indicated that 
the PEG contamination peaks were highly abundant. It was also noted that the 
contamination was not only present during a small window in the spectral data, but 
occurred across 40% of the MS profile (Figure 3.4 A). 
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Figure 3.4 Identification of a polyethylene glycol (PEG) contamination series in total ion count (TIC) and extracted spectra in the 
metabolite fraction of wound fluid. A| A representative wound fluid metabolite TIC detected by LC-MS. The characteristic Guassian profile 
indicative of PEG contamination is highlighted in the blue region of the TIC. B| Extracted metabolite spectra from the highlighted region in A. 
The star (*) represents an internal calibration standard for LC-MS. The + symbols represent the PEG contamination which increases in a +44 m/z 
series. Also evident is the lack of other spectra around the contamination series; this is a result of ion suppression affected by PEG. 
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3.2.5 PEG REMOVAL 
PEG is a polymer used to stabilise and increase the solubility of compounds in 
a vast range of applications. Previous studies have implicated the actual sample as 
the source of PEG contamination, including it being introduced in the collection 
technique (Forcisi et al., 2013). The storage of samples in certain plastics can also 
result in leaching of the contaminant (Weaver & Riley, 2006). However, these were 
ruled out as both the collection and storage conditions for our samples was 
standardised and PEG contamination was not found in all samples (approximately 
60%). PEG could also be introduced during sample processing, buffer preparation 
and through buffer storage glassware that have been washed in detergents containing 
PEG. However, even though the processing was achieved across several batches the 
contamination was not specific to a particular one, suggesting that PEG was not 
introduced during these steps. The cut-off filtration devices, dilution and 
equilibration buffers were all identical throughout the process, also ruling them out 
as possible sources of PEG. From this it was concluded that the PEG contamination 
was most likely due to wound therapies administered during treatment. PEG is a 
common component in many creams, ointments, drugs, body washes and soaps that 
patients may have used.  
 
Since the exact source of PEG was not identified, an attempt was made to 
remove the PEG from the samples. The majority of the literature on PEG extraction 
from samples is centred on proteomic research where ion suppression can occur in 
regards to peptide detection following trypsin digestion of samples. Removal 
strategies include column-based approaches, such as strong cation-exchange (SCX) 
and titanium dioxide chromatography, dialysis and cut-off centrifugation prior to 
protein digestion (Larger et al., 2005; Worrall et al., 1998; C. Zhao & O’Connor, 
2007). Dialysis tubing was excluded since the smaller pore size that would allow 
removal of PEG would also result in metabolite loss from the sample. A SCX 
column was tested using HPLC and the samples were analysed by MS. Little 
difference was observed in regards to PEG abundance. Solvents, such as chloroform, 
ethanol and toluene, were also tested to determine whether they would trap PEG 
while allowing extraction of the metabolites. The samples were analysed on the 
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Triple TOF, AB Sciex (MA, USA) and found to still have PEG contamination (data 
not shown).  
 
All attempts to remove the PEG from the samples were unsuccessful and it was 
therefore decided to exclude the contaminated samples from further analysis. In 
order to identify PEG contamination, all spectral data was extracted from the raw MS 
files and total ion count chromatograms were created. The chromatograms were 
manually inspected for the distinct Guassian profile, whilst spectral data was 
analysed for the 44 m/z adduct series. Using this method approximately 60% of the 
176 samples were eliminated and the remainder were analysed using metabolomic 
algorithms in order to identify significant peaks.  
 
3.2.6 ANALYSIS OF METABOLITE PROFILING 
Two separate software packages were utilised for metabolite biomarker 
discovery; XCMS online (Scripps, CA, USA) and MarkerView (AB Sciex, MA, 
USA). Both software platforms identify patterns in the multidimensional data sets 
produced by LC-MS. The online XCMS software package allows data to be 
uploaded to the Scripts Institute (Tautenhahn et al., 2012). The data sets were then 
analysed using multivariate and principal component analysis (PCA). MarkerView 
was also used for PCA analysis using similar parameters published in the literature 
(Kim et al., 2009; Tulipani et al., 2012). These two algorithms are extensively used 
with untargeted metabolomics to identify biomarkers by prioritising metabolite 
targets. Multidimensional Scaling (MDS) and PCA both highlight the similarities and 
differences of MS data and allow visualisation to data groupings.  
 
Two datasets, one from wound fluid samples collected from wounds that 
transitioned towards healing during the 24 week study, and the other of wound fluid 
samples from patients whose wounds did not heal, were uploaded to the XCMS 
online servers. Figure 3.5 A shows a PCA plot from the cohort of patients with 
wounds that healed (blue colour), and those with wounds that did not heal during the 
study (red colour). The XCMS PCA algorithm was unable to separate / distinguish 
the two groups based on m/z analytes (unidentified metabolites) present in the 
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samples of the two cohorts. A second plot based on MDS (Figure 3.5 B), was 
generated through XCMS. As with the PCA plot, the blue refers to patient samples 
from those whose wounds healed during the 24 week study, whilst the red refers to 
samples of wound fluids obtained from ulcers that did not heal (Figure 3.5 B). The 
MDS plot was also unable to separate the two patient groups (Figure 3.5 B).  
 
The PCA plots are composed of m/z peaks instead of patient samples as seen in 
the XCMS graphs. In MarkerView each point represented a different m/z peak that 
has been extracted from all the datasets, both healing and non-healing. The points, or 
m/z peaks, are scattered according to which peaks follow similar trends with other 
peaks. This means that two points in close proximity to each other would represent 
two different m/z peaks, but their abundance within the patient samples follows the 
same pattern. The MarkerView PCA plot in Figure 3.6 A illustrates three distinct 
groupings of extracted metabolite peaks. Ideally, differential expression of certain 
metabolites would separate the two groups, healing and non-healing ulcers. The 
circled region labelled B in Figure 3.6 A is illustrated in Figure 3.6 B, which is a 
plot of metabolite peak intensities against each corresponding ulcer wound fluid 
sample. The intensity, or abundance, of the plotted metabolites that are highlighted 
were high in only one group of samples and not present in all others. Region C in 
Figure 3.6 A also contains a large cluster of metabolite peaks circled in blue which 
set it apart from the other two regions (B and D). These metabolites when plotted in 
Figure 3.6 C have high abundance in only a subset of ulcer wound fluid metabolite 
fractions and no detection in the other two regions. Finally, metabolites in Figure 3.6 
D follow the same pattern, with distinct peaks in only select metabolite fractions of 
wound fluid. These groupings had no correlation with the healing outcome of the 
patient, or any other clinical indicator.  
 
On closer examination it was observed that the three groups were separated 
according to the acquisition batch they were analysed in. The acquisition of data was 
completed across three separate dates and the highly grouped samples were most 
likely correlated due to highly abundant contaminants located on that date. This 
suggests that either the LC or the mass spectrometer had high abundant peaks or 
contaminants from samples run on the instrument prior to my batch acquisition 
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which skewed the data. Therefore, our metabolomic study was unfortunately unable 
to yield any biomarkers that correlate with either healing or non-healing wounds due 
to two separate contamination issues. 
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Figure 3.5 Principal Components Analysis (PCA) and Multidimensional Scaling 
(MDS) performed by XCMS online software package on wound fluid 
metabolites in healing (blue) and non-healing ulcers   A| A PCA plot illustrating 
the inability of the two patient cohorts, with healing and non-healing ulcers, to be 
separated. B| Multidimensional Scaling, which is an alternative method to visualise 
the similarities and differences between the datasets. The lack of a distinct separation 
between the healing (blue) and non-healing (red) patient wound fluid samples 
indicates no means of differentiating between the two groups using this method. 
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Figure 3.6 Principal Component Analysis (PCA) of wound fluid metabolome of healing and non-healing ulcers with plotted profiles of 
selected peaks in MarkerView.  A| The PCA plot has been performed unsupervised with Pareto scaling. Analysis demonstrating poor separation 
of the two groups, healing and non-healing leg ulcers. The metabolite peaks have been separated in three groups and these were identified to be 
grouped together due to contamination from the mass spectrometer. B|C|D| The blue circled metabolite peaks were plotted and correspond to 
specific batches that the MS data was acquired on, rather than any clinical indicators. The m/z peaks were in high abundance in each particular 
batch but not detected at all on any other, which was indicative of contamination. 
Chapter 3: Metabolic Profiling of Wound Fluid from Chronic Leg Ulcers 91 
3.2.7 METABOLITE IDENTIFICATION 
Although neither the PCA nor the MDS algorithms were able to separate the 
groups based on healing outcome due to the presence of contaminants, it was decided 
to take the top 20 m/z peaks that were deemed significant and try to identify the 
metabolites. This was performed in an attempt to identify metabolites that were 
related to wound healing or inflammation and to test the feasibility of the metabolite 
biomarker discovery pipeline. The m/z peaks were uploaded to the METLIN and 
HMDB online databases and searched with an accuracy of 10 parts per million 
(ppm). Out of 20 peaks, 12 metabolites were identified, suggesting that the databases 
still required substantially more entries to be more complete (Table 3.1). Further 
analysis of the top 200 significant m/z peaks revealed 117 had no metabolite match. 
Of those metabolites identified (Table 3.1), the majority were found to be plant or 
marine extracts from various species, again suggesting the databases are not at a 
stage where they can be reliably used. The remaining matches were variations of 3-4 
amino acid long peptides.  
 
The identification of metabolites through use of the m/z alone provides only 
very tentative matches (Psychogios et al., 2011) and should be confirmed with 
fragmentation of the m/z ion or using a standard, both of which would require 
analysis with mass spectrometry. The database matches are based on exact weights 
of these molecules or m/z, but it was very apparent that one m/z peak could return 
multiple possible hits (Table 3.1), all within the accuracy tolerance (ppm), making it 
hard for identification without a standard. Additionally, many metabolites are 
stereoisomers of the same metabolite, meaning that they have the same molecular 
formula, therefore same weight, but are different compounds which further 
complicates the data.  
 
Chapter 3: Metabolic Profiling of Wound Fluid from Chronic Leg Ulcers 92 
m/z Hits Name of Metabolite  ∆ppm Metlin ID # Description 
610.3563 1 b-D-Glucopyranosiduronic acid 3 6694 Bile acid-glycine conjugate 
544.9011 0     
295.0683 3 Aplysin 3 71582 Extracted from marine sea slug - Aplysia kurodai 
  Filiformin 3 71583 Extracted from Caribbean Sponge Plakortis sp. 
488.3561 0     
532.3842 0     
366.2013 30 Amino Acids 2  All 30 possible hits are variations of 3 amino acid peptides  
493.3107 12 Amino Acids 5  All 12 possible hits are variations of 4 amino acid peptides  
478.8418 0     
489.3588 19 Bayogenin 2 53775 Compound extract from plants 
  Cimigenol 2 57765 Compound extract from plants 
463.2873 67 Amino Acids  0  12 hits are variations of 4 amino acid peptides  
  Amino Acids 9  52 hits are variations of 4 amino acid peptides  
445.3333 12 Various 4  3 compounds extracted from marine coral 
  Various 4  4 compounds from plant extracts  
490.2202 1 OA-6129 E 3 71650 Carbapenam antibiotic 
394.2026 3 (-)-Tylocrebrine 3 68435 Compound extract from plants 
  Tylophorine 3 38438 Compound extract from plants 
537.3389 12 Amino Acids 1  All 12 possible hits are variations of 4 amino acid peptides  
444.3309 0     
410.2276 0     
430.9121 0     
508.3469 1 Gymnodimine 9 73510 Marine Biotoxin 
488.8695 0     
310.1081 9 Lunamarine 2 68519 Compound extract from plants 
  Cryptodorine 2 89203 Cryptodorine is found in herbs and spices 
Table 3.1 The top 20 significant peaks obtained through PCA analysis of wound fluid metabolites identified through the METLIN 
database.  Each m/z peak was searched and the number of IDs possible for that analyte is recorded in the Hits column. For analytes which have 
multiple hits only the top two have been recorded. The ∆ppm is parts per million and identifies how close the metabolite match is. The METLIN 
ID is the tag which identifies that metabolite on the server. 
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3.3 DISCUSSION 
The metabolomics field has seen a huge increase in publications in the last five 
years and has added to the knowledge of many diseases in regards to identifying 
up- and down-regulation of protein / enzyme activity (Patti et al., 2012; Zhang, Sun, 
& Wang, 2012). Since metabolomics is situated at the end of the “omics” cascade, 
metabolites that are detected during profiling are the direct result, or end product, of 
gene and protein activity. Therefore, metabolomics is seen as the most informative of 
the actual phenotype of all the “omics” fields as it directly responds to environment 
or disease state (Schmidt, 2004). This project identified metabolomic profiling as a 
potential approach to investigate chronic leg ulcer wound fluid samples as a way of 
observing biochemical imbalances in the local wound area that differed between 
healing and non-healing ulcers. The approach has not previously been used in wound 
research and a recent publication highlighted its potential to provide insight into the 
molecules that define a healing wound (Mannello et al., 2014).  
 
In summary, the experiments reported in this chapter report the successful 
optimisation of a separation method for metabolites from the protein portion found in 
wound fluid. The buffers, dilution used and centrifugation speeds were determined 
through a variety of experiments. This separation was confirmed using both silver 
stained SDS-PAGE gels, as well as UV absorbance on HPLC. HPLC was used to 
also determine the best column for metabolite affinity and separation. A liquid 
chromatography component was also optimised on HPLC to identify the best 
gradient for metabolite separation on a C18 column. A direct injection ESI-MS 
approach was performed on 20 wound fluid samples, but the method was abandoned 
due to less than 40 m/z peaks being acquired. The LC-MS approach was instead used 
to allow separation of sample through the use of a reverse phase column (C18 
Polaris) prior to detection, and to improve analyte hits. This untargeted metabolomics 
approach was used on 176 wound fluid samples and yielded over 800 m/z hits. 
Unfortunately, two separate sources of contamination were identified during the 
analysis stage of the metabolomic study. The first, PEG, interfered with ionisation of 
the samples and was found in approximately 60% of the wound fluid samples, with 
the source of the contaminant unknown. The second contamination was attributed to 
various high abundant m/z peaks within the spectral data. The source of the second 
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set of contaminants was also not identified. Algorithm based analysis (XCMS and 
MarkerView) of the MS data was unable to separate the data in regards to healing 
status, or provide any insight into differential abundance of metabolites between 
healing and non-healing leg ulcers. Finally, using databases (METLIN and HMDB) 
to identify metabolites from m/z peaks provided hits with no obvious relevance to 
wound healing.  
 
The metabolomics profiling data was designed to be combined with proteomic 
profiling, which formed part of another project of the WMI-CRC. The data from 
these two ‘omics’ fields would have been combined to apply a systems biology 
approach based on complementary data. Since the samples would be shared between 
the projects, a direct aspiration method of collection was considered ideal as no 
dilution of sample would occur and no sample would be lost during sample recovery 
out of collection materials. The buffer chosen for sample dilution contained both 
ACN and ammonium acetate are volatile and therefore compatible with downstream 
analysis of both metabolomic and proteomic origin. The 20% ACN component was 
added to disrupt the interactions of low molecular weight species from high 
molecular proteins, as had been previously demonstrated in the literature (Harper et 
al., 2004; Orvisky et al., 2006; Tirumalai et al., 2003). A 3 kDa cut-off filtration 
device was then elected for separation of the metabolite filtrate and protein retentate 
following centrifugation. This repeatable step followed literature sample processing 
recommendations which propose keeping handling to a minimum to reduce analyte 
loss (Dettmer et al., 2007). The 3 kDa filtration method had previously been used in 
our lab but required adaption for directly aspirated wound fluid samples as volumes 
collected are lower (Melissa L. Fernandez et al., 2012). A dilution step was 
necessary and the dilution volume was chosen based on the manufacturer’s 
recommendations on appropriate volumes for the filtration device (PALL, Pensacola, 
FL, USA). Using both Broadford protein quantitation and silver stained gels it was 
clear that high centrifugation speeds (14000 x g) resulted in protein loss by 
disrupting the filter and allowing the proteins to enter the metabolite fraction (Figure 
3.2 A). This has previously been reported by others (Georgiou et al., 2001), hence 
resulted in our decision to reduce the centrifugation speed to 6000 x g. With the 
lower speed no protein passed into the filtrate as demonstrated by analysis using 
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silver stained SDS-PAGE gels, while Bradford protein quantitation identified only 
3.5% protein loss; most likely via protein adsorption onto the membrane (Figure 3.2 
B and C). Metabolites were also detected using UV absorbance on HPLC to 
demonstrate presence following the centrifugation. The enrichment method 
successfully separated the metabolites and proteins, whilst allowing incorporation of 
an appropriate buffer that is compatible with downstream metabolomic and 
proteomic analysis of the sample.  
 
The first MS metabolomic profiling method attempted was DI-ESI-MS. This 
resulted in a very low count of approximately 40 m/z peaks, most likely the abundant 
metabolite species present in the samples. Low peak counts occur as a result of ion 
suppression and low ionisation efficiency of the sample due to a lack of separation, 
or the presence of contaminants which prevent the analytes in the sample being 
directed to the detector (Dettmer et al., 2007; Zhang, Sun, Wang, et al., 2012). The 
DI-ESI-MS approach led to poor separation of the metabolites and this resulted in 
only the most abundant metabolites being detected. Additionally, later analysis 
identified PEG as a contamination source in a large subset of samples (60%). PEG 
contamination would also have played a large role in the low m/z peak count as 
detection is dependent on the ability of the metabolites to be ionised (Dunn & Ellis, 
2005). PEG affects ionisation in two different ways, firstly by simply competing for 
charge it reduces the amount of analytes that are ionised. Secondly, the large 
concentrations of the contaminant increase the viscosity of the sample and prevent 
droplet evaporation and therefore entry through the source into the mass 
spectrometer (Weaver & Riley, 2006). 
 
The second profiling approach used was LC-MS and this was chosen to allow 
more metabolites to be detected through prior separation during the LC phase with a 
reverse phase column. Three C18 reverse phase columns were tested using wound 
fluid samples and the optimised 3 kDa separation technique. The Polaris C18 column 
was identified as having the best affinity and separation qualities for metabolite 
detection (Figure 3.3 C). Extraction of spectral LC-MS data, however, identified a 
contamination series in some samples (Figure 3.4). Through review of the literature 
and online troubleshooting we identified the contaminant as PEG through its distinct 
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Guassian distribution, as was illustrated in an early publication about MS 
contaminants (Fenn et al., 1989). We were unsuccessful in identifying the source of 
the PEG but its use in a vast number of products and consumables is well known. 
Examples include excipients in foods, pharmaceuticals such as injectable, topical, 
rectal and nasal formulations, and it is also extensively used in cosmetics and plastics 
manufacture (Harris & Chess, 2003). Any number of these could explain the 
presence of PEG in the wound samples. The major difficulty, as mentioned earlier 
with PEG contamination, is that it is readily ionised in MS (Eckers et al., 2007). 
Furthermore, algorithm-based software packages assign significance based on peak 
intensity, which will be distorted as a result of the PEG contamination.  
 
Several attempts were made to eliminate PEG from the samples, including 
chloroform, ethanol and toluene extraction, as well as alternative chromatography 
using a SCX column, all with no success. Other methods identified in the literature, 
such as dialysis or cut-off filtration, were appropriate for proteomics but not 
metabolomics as it would result in sample loss through the filters applied in the 
approach. One commercial kit was identified, the Oasis MCX kit (Waters, MU, 
USA), however, the MCX is a mixed mode cation-exchange, which is the same 
chemistry used with the SCX column with no success. In regards to the source of the 
PEG contamination, the most likely source was topical applied substances used by 
patients, such as creams, ointments, shower gels and moisturisers (Kadajji & 
Betageri, 2011). Other possible sources include dressings and silver impregnated 
antimicrobial bandages which often incorporate PEG in the formulation 
(Seetharaman et al., 2011). As a result of its wide-spread use and the inability to 
eliminate PEG from the wound samples, any future metabolomic profiling 
approaches will also come across the same challenges.  
 
The second contamination encountered during the data acquisition stage was 
not sample based, but resulted in a huge influx of analytes / m/z peaks being 
introduced into the data, most likely through cross-contaminated LC components or 
source. The LC components include all the tubing, sample injectors, mixers and 
pumps before the sample enters the mass spectrometer; these can be contaminated by 
other users samples. The source serves as a funnel for analytes entering the mass 
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spectrometer and contaminants can build up on the outside perimeter and slowly 
leech into the mass spectrometer. In shared equipment situations, such as that was 
used for this PhD project, both are difficult to negate. Perhaps if all the acquisition 
was all performed in the same batch then the same contaminants can be removed 
pre-analysis with algorithms such as MarkerView. However, since we have not 
identified what these contaminants are it is hard to speculate what effect they could 
have on the sample ionisation and detection. 
 
Apart from the contamination issues, the most challenging and most limiting 
part of metabolomics, as also recognised in the literature, relates to identification 
strategies (Han et al., 2009). Most metabolites detected are still not identifiable 
through the current databases (Patti et al., 2012). This was also apparent in my 
dataset with almost 60% of the m/z peaks not having identifications on any database. 
Additionally, the metabolites that were identified each had multiple potential (some 
over >50) hits, which could not be discriminated unless further analysis is conducted. 
The other weakness is that all the metabolites in the databases are thought to be 
equally valid and fully verified, which is not the case (Psychogios et al., 2011). In 
fact, many of the identifications returned from databases were metabolites from plant 
extracts. Although this was not followed up, it is highly unlikely to be correct and is 
simply an example of the poor state of the databases.   
 
Based on the limitations I encountered, it is clear that using current 
technologies for metabolomic research in wound fluid the studies would need to take 
a targeted approach in which the metabolite is known and is quantified using SRM, 
as has been done previously in our laboratory (Melissa L. Fernandez et al., 2012). In 
this situation the metabolite in the wound fluid was verified through fragmentation 
using a mass spectrometry method known as MS/MS in which the sample and a 
purchased standard of the metabolite are fragmented and patterns are compared and 
matched. This approach can be used if, for example, a metabolite is identified in an 
inflammatory role in another disease state and can then be selected for analysis in 
wound fluid samples. The dangers of untargeted metabolomic approaches is that they 
generate large, complex data sets for each sample analysed and unless manual 
inspection of data is carried out it may lead to contaminants and other errors being 
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missed. All the same, better training and advancement in the identification databases 
could eventually facilitate the detection of diagnostic markers and therapeutic targets 
via a metabolomic approach in various disease states.  
 
Unfortunately my study was unable to identify any metabolites that correlate 
with healing outcome. The PEG contamination, as well as the secondary mass 
spectrometry / LC contaminants and the limited database, have not allowed reliable 
analysis on the data. Nevertheless the optimisation and method development that was 
undertaken has created a metabolomic discovery pipeline which can be used for 
future wound fluid profiling with samples that show no contamination or if a method 
is discovered to remove the contaminant. As PEG contamination is limited to the 
metabolite fraction, the protein fraction could be examined using an alternative 
profiling approach to identify biomarkers that correlate with healing.  
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Chapter 4: Quantitation of Pro and Anti 
Inflammatory Cytokines in wound 
fluid from healing and 
non-healing ulcers 
4.1 INTRODUCTION 
Chronic inflammation is a hallmark of non-healing wounds and the lack of 
inflammatory resolution is described as the most significant factor that contributes to 
the delay in healing (Sabine A Eming et al., 2007). In an acute wound the 
inflammatory phase is marked by the influx of immune cells into the site of injury; 
this lasts for 5-7 days. These inflammatory cells, mainly neutrophils and 
macrophages, release a barrage of pro-inflammatory cytokines in the early stages of 
inflammation, which typically start to decrease in acute wounds 3-5 days following 
injury. This includes the pro-inflammatory cytokines IL-6, TNFα and IL-1α and -1β 
(Werner & Grose, 2003). These cytokines have a number of roles, including 
activating proliferation and migration of keratinocytes and fibroblasts, as well as 
being chemoattractants for further immune cell invasion.  
 
Elevated cytokine levels are found in the local wound environment when 
compared to systemic serum levels (Holzheimer & Steinmetz, 2000). For this reason 
cytokine levels are generally measured in wound fluid to provide information 
regarding the local wound environment. When comparing wound fluid from acute 
and chronic wounds there is a large increase in the levels of pro-inflammatory 
cytokines IL-1β (≈ 100-150 fold increase), TNFα (≈ 100 fold increase) and IL-6 
(4-100 fold increase) (Cowin et al., 2006; Tarnuzzer & Schultz, 1996; Wallace & 
Stacey, 1998; Wiegand et al., 2010). Together these studies indicate a consistently 
higher level of inflammation in chronic wounds compared to acute wounds. Their 
prolonged expression results in increased ROS and proteolytic enzymes that can 
degrade ECM components and damage proteins, which in turn delays healing 
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(Figure 1.1). It has been proposed that in chronic wounds it is this sustained high 
level of pro-inflammatory cytokines that prevents healing (Raffetto, 2013).  
 
Like the pro-inflammatory cytokines, anti-inflammatory cytokines are also 
important regulators of wound healing. Secretion of these cytokines leads to the 
down-regulation of pro-inflammatory cytokines and chemokines (Moore et al., 2001; 
Sato et al., 1999). It is the imbalance between high levels of pro-inflammatory 
compared to anti-inflammatory cytokines in these wounds that is believed to be one 
possible cause of sustained chronicity (Hart, 2002). There is some evidence to 
suggest that anti-inflammatory cytokines, such as IL-10 and IL-1ra, increase during 
healing (Fivenson et al., 1997), but this has not been substantiated as other studies 
found no significant change in concentration during healing progression (Beidler et 
al., 2009; Trengove et al., 2000).  
 
Wound fluid sample volumes and the need to use ELISA kits that target only 
one cytokine meant that in the past typically only a few cytokines were measured per 
study. With advances in technology, more recent studies have been able to measure 
multiple cytokines at the same time in wound fluid from chronic venous leg ulcers. 
Pukstad et al. (2010) were able to measure the level of 40 cytokines in wound fluid 
isolated out of wound dressings from patients undergoing standard moist wound 
care, although it is unclear from the study how many patient samples were analysed 
(Pukstad et al., 2010). IL-1β was the only pro-inflammatory cytokine that 
demonstrated a decrease over time, with no trends observed in the anti-inflammatory 
cytokines in either healing cohort. The lack of changes might have been due to study 
design, where samples were pooled and signal intensity used instead of true cytokine 
quantitation. A second study utilised an antibody based microarray to compare 42 
proteins (cytokines, growth factors, ECM proteins and chemokines) in both sera and 
wound fluid from patients with acute and chronic wounds (Trøstrup et al., 2011). 
From the 42 proteins analysed only two were significant, of which S100A8 / A9 is 
the only protein involved with inflammation. Here, signal levels were compared to a 
pooled sample reference and they were not truly quantitated. The lack of significant 
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differences in the inflammatory cytokines contradicts previous publications and this 
once again may be due to the design of the study. 
 
To date the major body of work in regards to inflammation and chronic 
wounds has been quantifying differences between cytokines in chronic wound fluid 
with those in acute wound fluid. Thus, this aspect of my project was to compare 
cytokine levels in wound fluid from patients with chronic leg ulcers who achieved 
complete wound closure, to those patients whose wounds remained unhealed during 
the 24 week study. All patients received best practise treatment over the study period. 
The cytokines were measured using a multiplexed antibody array as it can provide a 
large amount of quantitative data, whilst requiring little wound fluid sample. The 
Bio-Plex system was chosen as it has been successfully utilised in several recent 
publications to quantitate cytokines in biological fluids, such as plasma and 
cerebrospinal fluid (Cappuzzello et al., 2011; Kanakry et al., 2011; Kwon et al., 
2010). This system utilises fluorescence-based quantitation involving magnetic beads 
and is capable of measuring up to 100 targets simultaneously. The panel selected for 
my project was a 27-plex kit that has recently been used to measure wound fluid 
from acute surgical wounds (Grimstad et al., 2011). The goal was to generate 
detailed longitudinal information on the altered expression of pro- and 
anti- inflammatory cytokines in the wound environment as the ulcers transition from 
a chronic-to-healed state, as well as to measure cytokine levels in chronic wounds 
that do not heal over time.  
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4.2 RESULTS 
4.2.1 PATIENT DEMOGRAPHICS 
Wound fluid was collected from a total of 20 ulcers (18 patients). The median 
age of the patient cohort was 71, with a range between 42 to 84 years of age. The 
majority of the ulcers (13 out of 20) were mixed ulcers and the remainder were 
comprised of venous and arterial origin (6 and 1, respectively). The duration / period 
of the ulcers ranged from 2 weeks to 1040 weeks, whilst the average size of the ulcer 
was 7.7 cm
2
 prior to commencement of the study. Ten of these ulcers failed to heal 
over the 24 week study, whilst the remaining 10 achieved complete wound closure. 
An ulcer was considered healed if it achieved complete closure within the 24 week 
study and remained healed for at least 2 weeks. Wound fluid samples were collected 
at various time points based on when the patient attended the clinic and if the wound 
was exuding fluid (Table 4.1). The healing arm of the study was investigated across 
three time points, whilst the non-healing cohort, having more available samples, was 
assessed across four time points. If multiple samples were available within the 
healing arm then analysis was performed with samples as close as possible to wound 
closure. However, this was not possible for two healing ulcers, 4032 and 4006, as the 
only samples available with sufficient volumes to conduct experiments were 
collected approximately 10 weeks before wound closure.  
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Table 4.1 Patient Demographics of 10 healing and 10 non-healing ulcers. 
 
 Healed Ulcers 
  
Non-Healed Ulcers 
Ulcer 
Type 
Sex 
Age 
Ulcer 
Dur 
Sample 
(week) 
Area 
(cm
2
) 
PUSH 
score 
Ulcer 
Type 
Sex 
Age 
Ulcer 
Dur 
Sample 
(week) 
Area 
(cm
2
) 
PUSH 
score 
4000 
Mixed 
M 
68yr 
36 
weeks 
2 2.5 9 
4001 
Mixed 
M 
68yr 
36 
weeks 
0 2.9 10 
4 2.0 8 6 - 9 
8 0.2 5 8 2 8 
12 0 1 12 1.5 9 
4006 
Mixed 
M 
67yr 
12 
weeks 
6 3.2 10 
4002 
Mixed 
F 
87yr 
116 
weeks 
0 9.5 14 
7 2.6 8 3 10.6 13 
9 1.1 7 7 8.9 14 
21 0 1 10 11.6 14 
4008 
Mixed 
F 
83yr 
26 
weeks 
4 1.3 7 
4009 
Mixed 
M 
81yr 
572 
weeks 
0 3.8 10 
9 1.1 8 6 5.2 11 
10 0.4 6 10 5.3 12 
13 0 2 12 4.9 13 
4019 
Mixed 
M 
59yr 
4 
weeks 
0 1.8 9 
4011 
Mixed 
M 
77yr 
1040 
weeks 
0 35 16 
1 2.9 10 4 38 16 
2 0.5 6 8 25 16 
4 0 0 12 44.2 16 
4032 
Venous 
F 
68yr 
32 
weeks 
4 1.5 7 
4012 
Mixed 
M 
77yr 
1040 
weeks 
0 7.6 13 
5 1.2 7 4 8.9 14 
7 0.7 7 8 10.3 14 
23 0 2 12 21 15 
4034 
Mixed 
M 
84yr 
8 
weeks 
5 6.7 12 
4023 
Mixed 
F 
82yr 
13 
weeks 
0 5 11 
8 3.9 11 2 4.4 11 
17 1.5 9 4 5.1 11 
21 0 0 9 5 11 
4053 
Venous 
F 
55yr 
2 
weeks 
0 0.2 5 
4026 
Arterial 
M 
67yr 
20 
weeks 
8 3.4 10 
2 0.4 7 10 3.3 11 
4 0.2 4 11 2.6 10 
8 0 0 12 2.9 9 
4080 
Venous 
M 
56yr 
9 
weeks 
0 0.9 9 
4038 
Mixed 
F 
76yr 
3 
weeks 
0 5 11 
1 0.9 11 14 13.1 14 
2 0.7 8 16 7.6 11 
5 0 0 18 8.5 12 
4082 
Venous 
M 
42yr 
14 
weeks 
1 6.6 12 
4059 
Venous 
M 
72yr 
40 
weeks 
1 15.9 13 
2 6.3 11 4 11.3 13 
4 5.7 11 9 7.3 11 
9 0 0 12 7.3 11 
4084 
Mixed 
F 
81yr 
6 
weeks 
1 6.8 11 
4072 
Venous 
M 
73yr 
72 
weeks 
0 34.3 16 
4 2.3 10 3 22.5 15 
7 3.3 10 7 15.6 13 
11 0 0 11 8.7 12 
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4.2.2 BIO-PLEX OPTIMISATION  
A small panel of cytokines (IL-1β, TNFα and IL-6) previously detected in 
wound fluid were used to validate the Bio-Plex multiplex assay to identify if it can be 
used to quantitate cytokines in wound fluid and additionally determine the optimal 
sample volume required to achieve this. A test sample was created by pooling 
random wound fluid samples from several healing and non-healing wounds. 
Additionally, two separate individual patient samples were selected to run alongside 
the pooled wound fluid sample to assess individual samples in regards to 
quantitation. The experiment was conducted as per the manufacturer’s instructions 
(described in section 2.3.2). For serum cytokine quantitation the manufacturer 
recommends use of 12.5 μL of serum in 50 μL of sample diluent (supplied). Three 
sample volumes (2.5 μL, 5 μL and 10 μL) were chosen to identify whether 
quantitation was linear following serial dilution of the sample and also to determine 
the minimum volume of wound fluid sample that can be used (Figure 4.1 A).  
 
For all of the cytokines measured (IL-1β, TNFα and IL-6) the levels detected in 
the three volumes were found to be within the standard curve (quantitative range). It 
can be observed that as the sample volume increased the quantitated level of IL-1β 
and TNFα increased also (Figure 4.1 A). The increases seen for both IL-1β and 
TNFα in the individual samples and pooled wound fluid sample were in the linear 
range with r
2
 values of approximately 0.9 or above (Table 4.2). This indicates that 
the sample volumes used are within the working range of the assay. In contrast, IL-6 
detection was not found to be in the linear range. IL-6 levels initially increased in 
concentration over the 2.5 μL and 5 μL range but then decreased with the 10 μL 
sample to a level below that seen in the 5 μL sample (Figure 4.1 A); this could be 
due to what is known as the matrix effect, which occurs when the sample 
constituents interfere with the assay.  
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Table 4.2 Linearity results for wound fluid (WF) pool and two individual WF 
samples from the first and second optimisation experiments.
 IL-1β TNFα IL-6 
First 
Optimisation 
   
Pool 0.9 0.87 - 
WF1 0.9 0.94 - 
WF2 0.99 0.86 - 
Second 
Optimisation    
Pool 0.98 - 0.96 
WF1 0.95 0.97 0.97 
WF2 0.99 0.67* 0.97 
* Indicates poor linearity of the protein measured. 
 
A second optimisation experiment was then conducted using 1 μL, 2 μL, 3 μL 
and 4 μL of pooled wound fluid from a random cohort of healing and non-healing 
wounds, as well as two individual samples, similar to that performed in the first 
optimisation. The lower volumes within the dilution series were assessed to 
determine whether the matrix effect could be removed if samples were further 
diluted. Reducing the volume of sample appears to have eliminated the matrix effect 
seen when measuring IL-6 levels with the multiplex assay (Figure 4.1 B). There was 
an improvement in IL-6 linearity over this sample range with all r-squared values 
above 0.95. When comparing the data for IL-6 between the first and second 
optimisation assays, they both indicated linear increases over the lower volumes, 
2.5 μL and 5 μL (Figure 4.1 A) and 1 μL to 4 μL respectively (Figure 4.1 B).  
 
With TNFα the optimal linear range appears to lie with dilutions below the 
3 μL mark. The linearity is also better within the individual samples (r-squared 0.97 
and 0.67) compared to the wound fluid pool which was not linear at all across the 
1 to 4 μL dilution, although it does increase across the first three dilutions (Figure 
4.1 B). The poor linearity in the wound fluid pool was not seen in the first 
optimisation experiment (Figure 4.1 A), but different pooled samples were included 
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with random samples combined from both healing and non-healing ulcers; this 
makes it hard to speculate why the data varied in the second optimisation 
experiment. IL-1β performed well in both optimisation experiments with all 
r-squared values above 0.9 (Table 4.2). Based on these results the volume chosen for 
all multiplex cytokine analyses described below was 2 μL. This led to responses 
within the detection range, used minimal amount of sample and was within a linear 
range of all cytokines measured (IL-1β, TNFα andIL-6) in regards to quantitation.  
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Figure 4.1 Optimisation of wound fluid (WF) samples using a panel of cytokines with the Bio-Plex assay. A| Wound fluid (2.5, 5 and 
10 μL) from pooled and two individual samples were assayed for IL-1β, IL-6 and TNFα using the Bio-Plex assay. Results suggest that for some 
cytokines the higher volumes are not in the linear range of the assay. B| Reducing the sample volume to 1, 2, 3 and 4 μL improved linearity in the 
same assay. 
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4.2.3 CYTOKINE QUANTITATION AND ANALYSIS 
In this study the ulcer aetiologies selected were based on the prevalence in a 
random sample of patients recruited at the QUT Wound Healing Outreach 
Community Service. Data collected across a three year period (2012-14) identified 
“mixed aetiology” as the most prevalent leg ulcer aetiology (50%) followed by 
venous (40%) and arterial origin (10%) ulcers. We attempted to maintain these 
proportions / percentages for the 20 leg ulcers used in this multiplex study. Thus, our 
samples included 13 mixed, 6 venous and 1 arterial leg ulcers. The 20 ulcers were 
divided into the two cohorts, a healing one that had complete wound closure, and a 
non-healing cohort, with no closure over the 24 week study. As outlined in section 
4.2.2, 2 μL of wound fluid was identified as the optimal volume for Bio-Plex 
cytokine quantitation. Total protein concentrations were determined for all wound 
fluid samples (section 2.1.5) and these were subsequently used to normalise the data 
(pg of cytokine measured / mg of total protein of the wound fluid). The healing 
cohort was graphed relative to wound closure (depicted by the dotted line). The 
non-healing cohort was graphed according to week of treatment.  
 
Similar to the optimisation experiments described above, a new wound fluid 
pool was created with random samples from both healing and non-healing wounds 
and this was subsequently serially diluted (1 μL, 2 μL, 3 μL and 4 μL) to determine 
linearity of each cytokine. This data was used to demonstrate that the measured 
cytokines in the panel were increasing in a linear manner demonstrated by r-squared 
value. Overall, the pro- and anti-inflammatory cytokines measured all demonstrated 
good linearity with one exception, namely IL-13. This data is summarised in Table 
4.3 and good linearity was considered for r-squared values above >0.85; values 
below this infer that there is interference in the assay for that particular cytokine. The 
error bars in the graphs within this chapter indicate standard deviation (SD) of the 
technical replicates for the cytokine assay. Clinical data was collected for every 
patient at each treatment time point, including the size and duration of the ulcer, as 
well as the gender and age of the patient. These wound parameters were included as 
covariates in statistical analysis using a linear mixed model (LMM). The LMM 
analyses longitudinal data between two groups with the ability to account for missing 
values and unbalanced data sets in regards to observations (West, 2009). Therefore, 
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the LMM was to investigate change over time; in the case of this study, the change in 
cytokine concentration over weeks of treatment between the two groups, healing and 
non-healing wounds. The gender of the patient was also analysed to identify if it 
influences cytokine concentrations. Statistical significance was defined as p=<0.05.  
 
4.2.4 MEASUREMENT OF PRO-INFLAMMATORY CYTOKINES  
Pro-inflammatory cytokines are responsible for inducing inflammation through 
recruitment of inflammatory cells and increasing the secretion of other 
pro-inflammatory cytokines, proteases and ROS. The aim of this part of the study 
was to quantitate levels of pro-inflammatory cytokines IL-6, IFNγ, IL-1β, IL-12p70 
and TNFα, which are part of the Bio-Plex 27-plex kit (Bio-Rad).  
 
IL-6 is a pluripotent pro-inflammatory cytokine with various functions in acute 
wound healing, including regulating immune response by inducing expression of 
chemokines and cytokines. It is also important in stimulating keratinocytes and 
fibroblasts (Werner & Grose, 2003). Comparison of the healing and non-healing 
cohorts reveals that the levels of IL-6 were generally higher in non-healing leg ulcers 
compared to the healing ulcers (Figure 4.2 A & B). In general the levels of IL-6 
remain consistent over time in the 10 non-healing chronic wound samples and no 
trends were observed (Figure 4.2 B). In contrast, the level of IL-6 decreased in the 
healing cohort as the wound achieved complete re-epithelialisation in all 10 leg 
ulcers (Figure 4.2 A). Statistical analysis was performed using a linear mixed model 
(LMM) to analyse the two cohorts. This model allows for both fixed and random 
effects to be taken into account. The duration of the wound, age of the patient, as 
well as the wound area, were taken into consideration as covariates in the model as 
they could potentially influence the levels of cytokines. The healing cohort was 
found to have significantly lower levels of IL-6 over time (p=0.006) compared to the 
non-healing cohort, and gender had no significant effect on cytokine levels 
(p=0.154). These results together suggest that as the wound heals the level of IL-6 
reduces, which would fit with a reduction in inflammation. 
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Table 4.3 Summary of linear mixed model analysis of concentration of cytokines 
over time in samples from healing and non-healing leg ulcers. Assessment of 
linearity of pro- and anti-inflammatory cytokines in serial dilution of pooled 
wound fluid is indicated by r-squared.  
Cytokine 
Healing 
outcome 
p-value
 
Gender 
p-value 
Linearity (r
2
) 
IL-6 0.006 0.154 0.98 
IFNγ 0.007 0.777 0.88 
IL-1β 0.133 0.41 0.99 
IL-12p70 0.055 0.367 0.95 
TNFα 0.071 0.289 0.96 
IL-10 0.147 0.497 0.90 
IL-1ra 0.310 0.386 0.98 
IL-13 0.728 0.518 0.69* 
* Indicates poor linearity of the protein measured. 
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Figure 4.2 IL-6 levels decrease over time in wound fluid from patients whose leg 
ulcers heal. IL-6 levels were measured at multiple time points in wound fluid from 
patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of IL-6 were found to be significantly decreasing (p=0.006) in the A| 
healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical replicates)   
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IFNγ is a pro-inflammatory cytokine as it augments the activity of TNFα and induces 
the production of ROS (Dinarello, 2000). During wound healing IFNγ regulates 
collagen production and stimulates keratinocyte proliferation (Kämpfer et al., 2000). 
In the non-healing cohort IFNγ levels remained consistent over treatment time and 
no trends were observed in the samples (Figure 4.3 B). Within the healing ulcer 
cohort the majority of wounds experience a decrease in cytokine over time with the 
exception of ulcer 4032 which exhibited very little change during the treatment 
period. It should be noted, however, that all these patient samples were taken at least 
10 weeks prior to healing. Overall, similar to what was found with IL-6, IFNγ levels 
also significantly decreased over time (p=0.007) in wound fluid from the healing 
cohort when compared to the levels in the non-healing cohort (Figure 4.3 A). The 
LMM also indicated that gender had no significant effect on cytokine concentration 
(p=0.777). The reduction of IFNγ levels in healing ulcers is in line with the IL-6 data 
suggesting a reduction in inflammation as wounds transition towards healing.  
 
IL-1β is described as a pro-inflammatory cytokine that induces the production 
and secretion of other pro-inflammatory cytokines, such as IL-6 (Ferrero‐Miliani et 
al., 2007). Inflammasome activation is required before IL-1β can be cleaved from its 
pro from and secreted into the wound environment (Schroder & Tschopp, 2010). 
IL-1β was expressed at a similar range to the IL-6 (1-100000 pg/mg). Once again the 
overall concentrations of this pro-inflammatory cytokine were higher in samples 
from the non-healing ulcers when compared to the healing cohort (Figure 4.4). In the 
non-healing cohort the concentration of IL-1β for each ulcer did not alter much over 
the time course. On the other hand samples from all 10 healing ulcers had a reduction 
of at least 42% (some as high as 95%) in IL-1β levels at the wound site between the 
first and the last wound fluid sample analysed. It should be noted that two ulcers 
(ulcers 4032 and 4053) in the healing cohort did show an increase in IL-1β at the 
second sample point but then decreased after this. Statistical analysis demonstrated 
that there was no significant difference over time between the healing and 
non-healing cohort, although there was a trend for the cytokine to decrease in the 
healing ulcers (p=0.110). The LMM analysis also demonstrated that gender had no 
significant impact on cytokine concentration (p=0.41).  
  
Chapter 4: Quantitation of Pro and Anti Inflammatory Cytokines in wound fluid from healing and non-healing 
ulcers 113 
 
 
Figure 4.3 IFNγ levels decrease over time in wound fluid from patients whose 
leg ulcers heal.  IFNγ levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of IFNγ were found to be significantly decreasing (p=0.007) in the A| 
healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical replicates)   
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Figure 4.4 IL-1β levels measured over time in wound fluid from healing and 
non-healing ulcers. IL-1β levels were measured at multiple time points in wound 
fluid from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while 
being treated with evidence-based best practice. IL-1β decreased over time when 
comparing A| healing versus the B| non-healing leg ulcers, but the linear mixed 
model demonstrated there was only a trend towards significance (p=0.133). (Error bars 
indicate SD of technical replicates)   
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IL-12 is a pro-inflammatory cytokine that stimulates immune cells such as 
natural killer cells, augments the inflammatory response, and also indirectly reduces 
expression of anti-inflammatory cytokine such as IL-4 (Manetti et al., 1993). It is a 
member of the IL-12 cytokine family, which are composed of two subunits whose 
expression is regulated independently. The antibody used in the Bio-Plex was 
specific for the heterodimeric complex IL-12p70. Individual sample concentrations 
of the cytokine are illustrated in Figure 4.5. The concentrations of IL-12p70 overall 
were generally lower in samples from the healing leg ulcers as visualised in the 
graph. The expression of the cytokine in samples from the non-healing leg ulcers was 
consistent over the sample time points with no trends observed in this cohort. The 
LMM used for statistical analysis demonstrated that gender did not affect IL-12p70 
concentrations (p=0.367). There was a trend towards significance in that there was a 
decrease in IL-12p70 levels over time in the healing cohort compared to the 
non-healing cohort (p=0.055). 
 
TNFα is also a pro-inflammatory cytokine with various functions, including 
activation of immune cells, inducing apoptosis (Cowin et al., 2006), and has been 
shown to work synergistically with IL-1 pro-inflammatory cytokines (Dinarello, 
2000). The expression of TNFα in the wound samples (Figure 4.6) was similar to 
that found for IFNγ and IL-12p70 (1-1000 pg/mg of total protein). TNFα levels in 
the non-healing cohort exhibited greater variation in concentration over the length of 
the study compared to the other pro-inflammatory cytokines discussed above. 
Examination of the levels of TNFα in the healing cohort (Figure 4.6 A) revealed a 
sequential reduction over time in the majority of samples, although ulcer 4034 for 
example increased over time. Perhaps as a result of the large variation in both groups 
the LMM statistical analysis demonstrated no significance between groups but a 
trend was evident (p=0.071). The LMM indicated that gender had no effect on the 
TNFα concentrations (p=0.289). 
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Figure 4.5 IL-12p70 levels decrease over time in wound fluid from patients 
whose leg ulcers heal. IL-12p70 levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. IL-12p70 decreased 
over time when comparing A| healing versus the B| non-healing leg ulcers, but the 
linear mixed model demonstrated there was only a trend towards significance 
(p=0.055). (Error bars indicate SD of technical replicates)   
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Figure 4.6 TNFα levels decrease over time in wound fluid from patients whose 
leg ulcers heal. TNFα levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. TNFα decreased over time when 
comparing A| healing versus the B| non-healing leg ulcers, but the linear mixed 
model demonstrated there was only a trend towards significance (p=0.071). (Error bars 
indicate SD of technical replicates)   
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4.2.5 MEASUREMENT OF ANTI-INFLAMMATORY CYTOKINES 
Anti-inflammatory cytokines, such as IL-4, IL-10 and IL-13, dampen 
inflammatory activity by suppressing the expression of genes of pro-inflammatory 
cytokines (Dinarello, 2000). Other proteins that reduce the inflammatory response 
are IL-1 receptor antagonists (IL-1ra), soluble TNFα receptor 1, decoy IL-1 receptor 
type II and growth factors, such as TGFβ (Holzheimer & Steinmetz, 2000; Koh & 
DiPietro, 2011). Unfortunately, only a few of these anti-inflammatory proteins 
formed part of the 27-plex used in this study. Anti-inflammatory proteins included in 
the panel were IL-1ra, IL-4, IL-10, and IL-13. Quantitating these anti-inflammatory 
proteins in wound fluid samples will nevertheless provide insights into the balance 
between the pro- and anti-inflammatory state of the wound.  
 
Overall, the levels of the anti-inflammatory cytokines in the wound samples 
were generally considerably lower than the amounts measured for the 
pro-inflammatory cytokines. The levels of IL-10 and IL-13 were below 100 pg/mg 
for almost all samples from leg ulcers in both cohorts. In contrast, IL-1ra was 
expressed in much higher concentrations, ranging between 1000-10000 pg/mg, for 
samples from all ulcers. For the majority of samples, the IL-4 concentrations 
measured were below the limit of detection and therefore no data analysis was 
performed on these samples.  
 
IL-10 is considered a key anti-inflammatory cytokine in wound healing as it 
dampens inflammation through several pathways. Firstly, it inhibits the synthesis of 
pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα in macrophages, and 
secondly, it inhibits the synthesis of chemokines, such as MCP-1 and MIP-1α, which 
are important for infiltration of immune cells into the site of injury (Sato et al., 
1999). The levels of IL-10 in both the healing and non-healing cohorts were low but 
detectable (Figure 4.7 A & B), however, but showed no pattern or trend with regards 
to increasing or decreasing in concentration over time. The levels of IL-10 in some 
samples decreased over time in the healing cohort (ulcer 4019, 4082, 4080 and 
4053), while other ulcers remained constant. As expected from examination of the 
  
Chapter 4: Quantitation of Pro and Anti Inflammatory Cytokines in wound fluid from healing and non-healing 
ulcers 119 
graphs there was no significant difference between the two cohorts over time 
(p=0.147) and gender had no effect on the levels (p=0.497). 
 
IL-1ra is anti-inflammatory cytokine which specifically blocks the action of 
pro-inflammatory cytokines IL-1α and IL-1β by competitively inhibiting the IL-1 
receptor (Dinarello, 1997). IL-1ra was the only anti-inflammatory protein that was 
highly expressed in samples collected from the wound site. The overall 
concentrations of IL-1ra for samples from leg ulcers amongst both cohorts were 
10- to 100-fold higher than in any other anti-inflammatory cytokine quantitated. 
Wound samples from the non-healing cohort (Figure 4.8 B) demonstrated some 
fluctuations in levels, but generally concentrations did not change for most ulcers 
over time. Similarly IL-1ra levels in the healing ulcers did not exhibit a particular 
trend (Figure 4.8 A). Only samples from one ulcer (ulcer 4053) decreased with each 
sequential sample, whilst samples from another ulcer increased over time (ulcer 
4008) and the remainder fluctuated. This random fluctuation was reflected in the 
statistical analysis which showed no statistical difference between the two cohorts 
over time (p=0.310) and no effect of gender on the values (p=0.386).  
 
The last anti-inflammatory cytokine measured was IL-13. It is an important 
modulator of monocytes and can down regulate their production of pro-inflammatory 
cytokines, such as TNFα and IL-1, as well as chemokines IL-8 and MIP-1α. Similar 
to IL-10, there were low concentrations of IL-13 in wound fluid from both healing 
and non-healing cohorts, irrespective of the sample time point. The individual 
concentrations in samples from the non-healing leg ulcer cohort (Figure 4.9 B) 
demonstrated consistent expression of IL-13 over time, with samples from ulcer 
4002 being the only exception. The levels of IL-13 in samples from the healing 
cohort (Figure 4.9 A) were similar to the other anti-inflammatory proteins measured 
in that no trends were observed overtime. LMM analysis revealed no significant 
difference (p=0.728) between the two cohorts over time. The gender of the patients 
was not a significant factor influencing IL-13 concentration (p=0.518).  
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Figure 4.7 IL-10 levels did not change over time in wound fluid from healing 
and non-healing ulcers. IL-10 levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. IL-10 decreased over 
time when comparing A| healing versus the B| non-healing leg ulcers, but the linear 
mixed model demonstrated there was only a trend towards significance (p=0.147). 
(Error bars indicate SD of technical replicates)   
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Figure 4.8 IL-1ra levels did not change over time in wound fluid from healing 
and non-healing ulcers. IL-1ra levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. IL-1ra did not change 
over time when comparing A| healing versus the B| non-healing leg ulcers and the 
linear mixed model demonstrated there was no significant difference between the 
two cohorts (p=0.310). (Error bars indicate SD of technical replicates)   
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Figure 4.9 IL-13 levels did not change over time in wound fluid from healing 
and non-healing ulcers. IL-13 levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. IL-13 did not change 
over time when comparing A| healing versus the B| non-healing leg ulcers and the 
linear mixed model demonstrated there was no significant difference between the 
two cohorts (p=0.728). (Error bars indicate SD of technical replicates)   
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4.3 DISCUSSION 
In this study wound fluid was collected from patients whose ulcers healed and 
patients whose ulcers did not heal over 24 weeks, during which they were all treated 
with evidence-based best practice. Wound fluid sampling was conducted over the 
duration of the study and the analysis was performed on samples from weeks where 
sufficient fluid was collected. Three sequential samples were quantitated from each 
wound for the healing cohort and four samples were assessed from each wound for 
the non-healing cohort. Multiplex quantitation of 5 pro-inflammatory cytokines 
(IL-6, IFNγ, IL-1β, IL-12p70 and TNFα) and 4 anti-inflammatory cytokines (IL-10, 
IL-1ra, IL-4 and IL-13) was then performed for both cohorts. The majority of 
cytokines measured were detected, except for IL-4 where most of the determinations 
were below the limit of detection and subsequently no analysis was performed for 
this cytokine. The level of the pro-inflammatory cytokines IL-6 and IFNγ did not 
alter in the non-healing cohort, but did significantly decrease in the healing cohort 
(p=0.006, p=0.007, respectively). Other pro-inflammatory cytokines, namely 
IL-12p70 and TNFα, also decreased over time and were approaching significance 
(p=0.055 and p=0.071), whilst the data for IL-1β was not significant (p=0.133). 
There was, however, a trend of decreasing levels in the healing cohort. The 
anti-inflammatory cytokines, IL-10, IL-1ra and IL-13, were not significantly 
different in the samples over time between the two cohorts (p=0.147, p=0.31 and 
p=0.728, respectively). These results, together, suggest that while an increase in 
anti-inflammatory cytokines was not detected in the wound fluid samples, a decrease 
was observed for key pro-inflammatory cytokine levels, suggesting a reduction in 
inflammation in those wounds that go on to heal.  
 
This study used wound fluid that was directly aspirated from the site of the 
ulcer. To allow the quantitation of several cytokines despite low collection volumes 
of wound fluid the Bio-Rad multiplex system was used. The approach proved 
effective as a 27-plex panel of cytokines successfully detected 20 out of 27 targets in 
the wound fluid. Wound fluid is the ideal candidate for investigating the ulcer 
micro-environment, despite the volume limitations, as previous publications have 
shown that the immune response in wounds is quiet compartmentalised (Holzheimer 
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& Steinmetz, 2000). Patient matched serum and wound fluid measurements show 
that wound fluid cytokines are expressed in higher levels compared to those in serum 
samples. This suggests that samples other than those derived directly from the wound 
site would not be a true representation of the wound environment.  
 
Prior to multiplex technology, earlier studies were only able to quantify a few 
cytokines (2-5) in wound fluid from patient ulcers. This is due to the high cost 
associated with purchasing individual ELISA plates for each cytokine and more 
crucially, limitations due to low wound fluid volumes collected from ulcers (Charles 
et al., 2009; Tarnuzzer & Schultz, 1996; Trengove et al., 2000; Wiegand et al., 
2010). To overcome low sample volumes and provide an alternative sampling 
technique, studies have published quantitative cytokine data by measuring cytokine 
levels in blood collected from superficial veins in lower limbs (Murphy et al., 2002). 
Alternatively, wound debridement material that would contain dead cells, some 
wound fluid and slough from the wound environment has been used to demonstrate 
that several cytokines and chemokines are able to be detected in wound debridement 
material (Kroeze et al., 2012). In these studies the relative levels of cytokines in 
debrided material were compared between cohorts as well as with previous studies 
that measured the same cytokines in wound fluid. The study does not, however, 
demonstrate that the levels are identical or truly representative of the wound as they 
failed to detect IFNγ in the debrided material, whilst our data and published data 
have demonstrated that there is sufficient IFNγ expression at the site for detection 
(Beidler et al., 2009). Two studies that have analysed large panels of cytokines (22 
and 16, respectively) both used tissue biopsies obtained from leg ulcers rather than 
wound fluid (Beidler et al., 2009; Fivenson et al., 1997). Although sampled direct 
from the site of the ulcer, the tissue homogenisation step would liberate cytokines 
from inside the cells which perhaps would not otherwise be secreted into the wound 
area at that time point. The cytokines are not active while they are inside the cells 
and would not be playing a role in inflammation. This might result in overestimation 
of cytokine levels in chronic wounds. Other popular collection techniques, such as 
absorption onto a membrane or wound dressing and collection with swabs, can lead 
to alterations in quantitation due to differential adherence of proteins to the 
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membrane or swab. Thus the wound fluid collection approach that I employed is an 
ideal sampling technique for biochemical analyses such as cytokine quantitation.  
 
The Bio-Rad multiplex first required optimising to ensure that the levels of 
cytokines in the wound fluid were in the standard curve range. Additionally, serial 
dilution of wound fluid was measured to establish that the assay was linear and to 
determine the minimal volume required. The manufacturer’s recommended volume 
for serum analysis is 12.5 μL of sample in 50 μL of sample diluent, however, 
analysis of wound fluid in triplicate would require 37.5 μL of wound fluid and on 
average 20 μL of wound fluid is collected at each time point. The 27-plex multiplex 
array chosen for our investigation has been previously used to quantitate cytokines 
and chemokines in acute wound fluid. Unfortunately, this publication did not specify 
the amount of fluid or total protein used in these experiments (Grimstad et al., 2011). 
Two studies using array technology also did not specify the amount of sample used 
to perform the experiments (Pukstad et al., 2010; Trøstrup et al., 2011). The first 
publication indicated the volume used for the experiment (50 μL) but the sample was 
an elution from wound dressing, therefore, the protein concentration would have 
been more appropriate, especially considering that the wound fluid was diluted 
through the dressing elution process (Pukstad et al., 2010). The second study states 
that a dilution step (1:10) was used following recovery of raw wound fluid from 
polyurethane foam which covered the wound, however, again this report did not 
specify the protein concentration (Trøstrup et al., 2011).  
 
Nevertheless, one publication was identified which specified a concentration 
range (10-40 μg total protein); this therefore provided a starting point for the design 
of the optimisation experiment (Edsberg et al., 2012). The optimisation protocol used 
was designed taking into consideration both the manufacturer’s recommended 
12.5 μL of sample and the 10-40 μg of total protein used by Edsberg et al. (2012). 
Samples in our healing and non-healing cohorts typically were approximately at 
20 mg/mL, suggesting a volume of 1-4 μL was required to replicate the Edsberg et 
al. (2012) study. At higher volumes (5-10 μL) interference, or matrix effect, occurred 
with our wound samples as no increase in cytokine was detected with increased 
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volume. The matrix effect is a key problem when analysing biological material as the 
complex mixture of proteins, carbohydrates, lipids, small molecules and salts can 
affect the measurements (Selby, 1999). The matrix or constituents of the sample, in 
our case wound fluid, can prevent the binding if present at high enough 
concentrations. As a result, smaller volumes were used (1-3 μL); this minimised this 
matrix effect but still enabled cytokine measurement from the midpoint of the 
standard curve. The three cytokines investigated at this stage all had good linearity 
within this dilution range. A volume of 2 μL of wound fluid in 50 μL of diluent was 
therefore chosen as an optimum dilution and was in line with the Edsberg et al. 
(2012) study in regards to total protein loaded on to a multiplex based platform. All 
pro- and anti-inflammatory cytokines measured exhibited good linearity except for 
IL-13. This indicated that there was perhaps a matrix effect or other interfering 
agents binding the IL-13 antibody or preventing the ligand from binding the 
antibody. 
 
A linear mixed model (LMM) was used to analyse the quantitative data 
acquired on the 27 panel Bio-Plex system. This statistical approach is sometimes 
referred to as a mixed-effects model, multilevel model, hierarchical linear model and 
random coefficient model. The advantage of using a LMM is that it can manage 
missing values within datasets but can still perform longitudinal comparisons 
between groups, even if the number of observations per subject is unbalanced. This 
was ideal as our study compared three cytokine concentrations in the healing cohort 
and four in the non-healing cohort. The method reported longitudinal change over 
time between the two groups and a p-value below 0.05 was considered statistically 
significant. From all covariates included in the LMM the only reported p-values were 
for gender. The result indicated that gender was never a significant factor in cytokine 
levels (IL-6 p=0.154, IFNγ p=0.777, IL-12p70 p=0.367, TNFα p=0.289, IL-1β 
p=0.41, IL-10 p=0.497, IL-1ra p=0.386 and IL-13 p=0.518). This is not the first 
study to use a linear mixed model as it has recently been used in study of cytokine 
levels in healing and non-healing pressure ulcers (Edsberg et al., 2012). In contrast to 
our study, the data obtained from the 58 cytokines measured indicated that only 
CXCL9 (monokine induced by gamma interferon), a chemoattractant for T-cells, 
significantly increased as wounds healed. The lack of significance for other 
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cytokines could be attributed to high patient variation, low patient numbers and small 
between-group variations (5 patients and 39 samples). Patient variation has been 
attributed as a key factor for lack of significant findings in a separate cytokine study 
which investigated 7 proteins (IL-1β, TNFα, MMP2, MMP9, bFGF, VEGF and 
TGF β) in venous leg ulcer patients (Manjit S Gohel et al., 2008). The authors found 
no significant difference between levels at recruitment and after five weeks of 
compression treatment. However, this study had only two time points and it might 
have been that five weeks was not sufficient time to identify differences in 
biomarkers. Consequently, Edsberg et al. (2012) performed a second, less robust, 
statistical test (Mann-Whitney) in the same study that did not factor in the time 
component. This method combined the sample data of the two cohorts and found 20 
proteins to be significantly (p=<0.05) different between healing and non-healing 
wound swab samples. Similar to the study reported here, the levels of the 
pro-inflammatory cytokines IFNγ, IL-1β and IL-12p40 (subunit of the IL-12p70 
heterodimer complex) were found to be decreased in the healing ulcers compared to 
the non-healing ulcers. Importantly, the Edsberg et al. (2012) data is consistent with 
my data in that the levels of anti-inflammatory cytokines IL-4, IL-10 and IL-1ra were 
not significantly altered between the different groups.  
 
Early studies of cytokines in wound fluid comparing chronic wound fluid to 
acute wound fluid showed increased levels of IL-1β and TNFα in chronic wounds 
(Tarnuzzer & Schultz, 1996). This led to the theory that chronic wounds were in a 
perpetual exaggerated inflammatory state and this paved the way for more research 
in the area of inflammation and wound healing. In a later study a larger panel of 
cytokines were investigated using ELISA plates analysing tissue / wound biopsies 
across time, as well as plasma levels and wound fluid samples (Fivenson et al., 
1997). IL-6 levels were reported to have a strong tendency to decrease between week 
0 and week 4 after treatment, but this effect was not significant (p=0.062). The only 
significant cytokine difference was with TNFα in wound fluid compared to TNFα in 
tissue samples (p=0.038). The anti-inflammatory cytokines IL-10 and IL-1ra were 
also measured, and in contrast to what I report here, these observed an increase 
during the healing phase following treatment, although this did not reach 
significance. The major difference between the two studies is that Fivenson et al. 
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(1997) collected wound fluid was allowed to accumulate on dressings over a seven 
day period before being extracted. The stability of the wound fluid, in particular the 
cytokines, was not assessed and therefore it is possible that the cytokine levels were 
not well represented due to protein degradation or cleavage by proteases over this 
seven day period.  
 
The focus of later studies was to investigate inflammatory cytokines levels 
over time in order to identify patterns of expression. The first such study examined 
wound fluid samples from chronic venous ulcers using ELISA plates in a 14 patient 
study across a two week period (Trengove et al., 2000). This study differed from the 
majority of cytokine studies in that the patient’s ulcers were skin grafted followed by 
two weeks of bed rest. Healing was measured by a reduction in slough of the graft, 
increased granulation tissue and reepithelialisation although not all patients 
responded to the treatment. Their data, nevertheless, demonstrated that 
pro-inflammatory cytokines (IL-1α, IL-1β, and TNFα) significantly decreased as the 
wound progressed from a non-healing to healing state. Similarly, our data showed a 
decrease in TNFα and IL-1 β over time when comparing the healing and non-cohort 
but was only trending towards significance (p=0.071, p=0.133 respectively). The 
IL-6 decrease seen in patients was trending towards significance (p=0.14) in that 
IL-6 was decreasing in the healing wounds.  
 
A later publication also investigated cytokine concentrations as chronic venous 
ulcers transitioned towards healing using a larger patient cohort (33), but with 
treatment involving compression therapy rather than grafting (Beidler et al., 2009). 
Cytokines were measured in tissue biopsies using a multiplex panel of cytokines (22 
cytokines) and wounds were monitored up to four weeks instead of just two in the 
previous study. Wounds which achieved 40% wound reduction in four weeks were 
considered to be rapid healing, while wounds that did not show a reduction by this 
amount were considered to exhibit delayed healing. This criteria was based on a 
study which demonstrated that a 40% reduction over 3 weeks was a predictor of 
healing, but with only 70% predictive power (T. J. Phillips et al., 2000). Comparison 
of cytokine data in the Beidler et al. (2009) study was made between levels of 
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healthy tissue versus wound tissue before therapy and tissue before versus tissue 
after therapy and rapid versus delayed healing groups. The cytokine levels in tissue 
samples from ulcers following compression therapy were consistent with Trengove 
et al. (2000) and the results from my study. Furthermore, a significant decrease of 
pro-inflammatory cytokines IL-1α, IL-1β, TNFα, IL-6, IFNγ and IL-12p40 were 
found as the wounds healed. Again consistent with our study the anti-inflammatory 
cytokines IL-1ra and IL-10 did not change significantly over time.  
 
An imbalance of pro- and anti-inflammatory cytokines at the wound site has 
been hypothesised to be responsible for delayed wound healing (Hart, 2002; 
Lawrence & Gilroy, 2007; Liu et al., 2011). However, our findings suggest that the 
reduction of pro-inflammatory cytokines may not be due to an increase in 
anti-inflammatory cytokines, as they remain unchanged during treatment and up until 
wound closure. Additionally, the levels of the anti-inflammatory cytokines were 
relatively low overall compared to the highly abundant levels of IL-6, IL-1β and 
TNFα. The complexity of wound healing, however, requires the investigation of 
other factors which influence the wound site, such as growth factors and chemokines, 
as these also have key roles in acute wound healing (Sabine A Eming et al., 2007; 
Werner & Grose, 2003). 
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Chapter 5: Quantitation of Chemokines and 
Growth Factors in wound fluid 
from healing and non-healing 
ulcers 
5.1 INTRODUCTION 
Two key features of chronic wounds are the inability to resolve the 
inflammatory response and the failure of the wound to re-epithelialise. The 
exacerbated inflammatory response is the result of inflammatory cells at the site of 
injury releasing chemokines, which in turn attract more inflammatory cells to the site 
hence perpetuating inflammation. These cells are then activated by local 
pro-inflammatory cytokines that sustain and potentiate the inflammatory response 
(Sabine A Eming et al., 2007). This chemotactic mechanism contributed to the 
hypothesis that white blood cells were being recruited, trapped and activated in 
chronic leg ulcers prolonging inflammation in these wounds (P. C. Smith et al., 
1988). Sustained expression of chemokines have been found to prolong the 
inflammatory response in mouse wound models (Wetzler et al., 2000). Failure to 
re-epithelialise, on the other hand, can in part be attributed to the lack of cell 
proliferation due to the proteolytic degradation of growth factors at the wound site 
(Vincent Falanga & Eaglstein, 1993). Interestingly, it has been reported that acute 
wound fluid increased proliferation of vascular endothelial cells, fibroblasts and 
endothelial cells (Greenburg & Hunt, 1978; Katz et al., 1991), and in contrast, 
proliferation was inhibited when cells were cultured with chronic wound fluid 
(Bucalo et al., 1993; T. Phillips et al., 1998). This may be related to the finding that 
wound fluid collected from chronic ulcers has been found to degrade exogenous 
growth factors (Trengove et al., 1999; D. Yager et al., 1997). More recently, other 
growth factors and enzymes such as hepatocyte growth factor and α1-
Antichymotrypsin also demonstrate reduced function due to proteolytic activity in 
wounds (Buchstein et al., 2009; Hoffmann et al., 2011). These proteolytic enzymes 
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are predominantly secreted by neutrophils and macrophages and so an expansion in 
inflammatory cell numbers is anticipated to increase the levels of proteolysis.  
 
Following wounding, the first cells to arrive at the site of injury are platelets 
which secrete PDGF, EGF, TGF-β, VEGF and FGF (S. Barrientos et al., 2008). 
Neutrophils and monocytes subsequently assume production and secretion of VEGF, 
EGF, FGF, TGF-β, G-CSF and GM-CSF (Enoch & Leaper, 2005). PDGF in the 
wound accelerates the production of the provisional extracellular matrix and 
stimulates collagen production by fibroblast cells (Pierce et al., 1991). Basic FGF is 
required for granulation tissue formation, re-epithelialisation, angiogenesis, tissue 
remodelling and acts as a stimuli for keratinocyte and fibroblast migration and 
proliferation (Belgore et al., 2003; Bikfalvi et al., 1997; Powers et al., 2000; Sogabe 
et al., 2006). In regards to wound healing, VEGF has been demonstrated to be 
critical for granulation tissue formation and wound angiogenesis (Howdieshell et al., 
2001). It is expressed by endothelial cells, keratinocytes, fibroblasts, smooth muscle 
cells, platelets, neutrophils and macrophages (S. Barrientos et al., 2008), and is 
upregulated by PDGF, EGF, IL-1β and TGF-β at the wound site (Frank et al., 1995; 
Nissen et al., 1998). VEGF expression can also be induced by hypoxia, a common 
feature in diabetic wounds, pressure ulcers and venous ulcers (Detmar et al., 1997). 
Proliferation and differentiation of neutrophils is also stimulated by granulocyte-
colony stimulating factor (G-CSF) (Yönem et al., 2001), while monocyte production 
and keratinocyte proliferation are stimulated by GM-CSF (Mann et al., 2001). This 
and other data shows the important roles that growth factors play in 
re-epithelialisation and wound healing. 
 
In addition to their proliferative function, growth factors are also known to 
‘kick start’ the wound healing process by providing chemotactic cues for immune 
cells and fibroblasts (P. Martin, 1997; Mutsaers et al., 1997). PDGF, for example, 
acts as a chemokine to attract neutrophils, macrophages, and fibroblasts to the wound 
site (Heldin & Westermark, 1999). Chemotactic cues in the form of chemokines, 
secreted by various cell types in the wound, also contribute to re-epithelialisation, 
tissue remodelling and angiogenesis (Werner & Grose, 2003). For example, MCP-1 
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is secreted by keratinocytes upon injury and is a chemotactic cue for monocytes, T 
cells and mast cells to migrate to the wound site (DiPietro et al., 1995). Loss of 
MCP-1 in mice leads to delayed wound healing with reduced re-epithelialisation, 
angiogenesis and collagen deposition (Low et al., 2001). In the same study a loss of 
macrophage inflammatory protein (MIP)-1α had no effect on wound healing, 
although the authors concluded that there were compensatory mechanisms for the 
disruption of this chemokine. The other two members within the MIP-1α family, 
MIP-1β and regulated on activation normal T cell expressed and secreted (RANTES) 
act on the same receptors (Borish & Steinke, 2003) and decreasing levels leads to 
reduced monocyte infiltration in wounds (DiPietro et al., 1998). Other chemokines 
implicated in wound healing include IFNγ, interferon-inducible protein 10 (IP-10) 
and IL-8 (Gillitzer & Goebeler, 2001). IP-10 acts directly on endothelial cells and 
down-regulates bFGF and IL-8 (Engelhardt et al., 1998; Medina et al., 2005). 
Overexpression of IP-10 delays wound healing due to a prolonged and disorganised 
granulation phase with impaired blood vessel formation and an amplified 
inflammatory phase (Gillitzer & Goebeler, 2001; Luster et al., 1997). IL-8 is a potent 
chemoattractant of neutrophils, stimulates MMP production in leukocytes 
(Engelhardt et al., 1998; Rennekampff et al., 2000; Werner & Grose, 2003) and 
increases keratinocyte migration and proliferation during wound healing (S. 
Barrientos et al., 2008; Michel et al., 1992; Tuschil et al., 1992). While immune cell 
recruitment is beneficial, increased recruitment can amplify inflammation, delay 
healing and result in tissue damage leading to ulcer formation (Chen & Rogers, 
2007; Hart, 2002). 
 
Given that VEGF, bFGF, GM-CSF, PDGF, IL-8, IP-10, MCP-1, MIP-1α, 
MIP-1β and RANTES all play key roles in wound healing (S. Barrientos et al., 2008; 
Engelhardt et al., 1998), the objective of this part of my PhD study was to examine 
the levels of these growth factors and chemokines in wound fluid from patients with 
healing and non-healing leg ulcers using a multiplex kit.  
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5.2 RESULTS 
5.2.1 GROWTH FACTOR AND CHEMOKINE QUANTITATION  
The growth factor and chemokine quantitation was performed on the same 
27-plex panel discussed in Chapter 4. Patient demographics and sample collection 
details are listed in Table 4.1. The Bio-Plex methodology and analysis parameters 
were identical to that described in Chapter 4. Additionally, as described in Chapter 4 
a wound fluid pool was created containing various random samples from both 
healing and non-healing patients and was used to determine linearity of each 
cytokine and chemokine measured. This was achieved by measuring a dilution series 
of the wound fluid pool on each Bio-Rad plate (1 μL, 2 μL, 3 μL and 4 μL). This data 
was used to demonstrate that the measured chemokines and growth factors in the 
panel were increasing in a linear manner as demonstrated by r-squared value. This 
data is summarised in Table 5.1 and good linearity is considered for values above 
>0.85, inferring that there is no interference in the assay for that particular cytokine. 
VEGF, G-CSF, RANTES, MIP-1β and IP-10 all exhibited good linearity. The error 
bars in the graphs within this chapter indicate standard deviation (SD) of the 
technical replicates for the cytokine assay. An LMM statistical approach was again 
used to analyse the data generated.  
 
5.2.2 MEASUREMENT OF GROWTH FACTORS 
Growth factors were quantitated in wound fluid collected from 10 healing 
ulcers and 10 non-healing ulcers using the same 27-plex antibody array (Bio-Rad). 
The levels of key growth factors (Table 5.1) involved in wound healing were 
measured using this Bio-Plex array. The linearity data (Table 5.1) indicated that 
several growth factors had strong interference from what was most likely 
constituents within the wound fluid. The strongest interference was seen in bFGF, 
GM-CSF and PDGF, with r-squared values of 0.38, 0.39 and 0.63 respectively. The 
remaining growth factors VEGF and G-CSF demonstrated very good r-squared 
values, 0.98 and 0.97, respectively (Table 5.1). 
 
Basic FGF has various functions in wound healing but primarily it is a mitogen 
for fibroblasts and keratinocytes and plays a key role in angiogenesis (Abraham & 
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Klagsbrun, 1988; Risau, 1990). In our study the concentrations of bFGF in fluid from 
non-healing ulcers were found to be inconsistent over time with large fluctuations in 
levels observed in fluid from most leg ulcers (Figure 5.1 B). Of the samples from 10 
healing ulcers, 7 reduced in concentration over time (ulcers 4000, 4034, 4019, 4080, 
4082, 4084 and 4053), whilst the remaining 3 increased over time (Figure 5.1). 
Statistical analysis was performed using the LMM, which identified that gender had 
no effect on the levels of bFGF (p=0.578) but the levels of bFGF significantly 
reduced in wound fluid over time in the healing compared to the non-healing cohort 
(p=0.0001).  
 
As one of the first growth factors released into the wound area PDGF has an 
important role in cell recruitment, specifically for neutrophils, monocytes and 
fibroblasts (Heldin & Westermark, 1999; Werner & Grose, 2003). PDGF has various 
effects on fibroblasts including enhancing their proliferation, stimulating production 
of collagen and in the later stages of wound healing induces the myofibroblast 
phenotype (Clark, 1993; Heldin & Westermark, 1999). In general PDGF in the 
wound fluid samples levels were similar to those observed for bFGF, with little 
change in concentration in samples from the non-healing ulcer cohort (Figure 5.2 B) 
over the duration of treatment. In the healing cohort, samples from 3 ulcers (ulcers 
4000, 4080 and 4006) exhibited a decrease in PDGF levels over time but the extent 
of the reduction was small. The samples from the remaining leg ulcers showed no 
trend over the time course. Gender had no significant effect on PDGF levels 
(p=0.176) and no significant difference between the healing and the non-healing 
ulcer cohorts was seen over the time course (p=0.315).  
 
VEGF is required for angiogenesis and it promotes the migration and 
proliferation of endothelial cells (S. Barrientos et al., 2008; Frank et al., 1995; 
Senger et al., 1996). The overall concentration of VEGF was higher in wound fluid 
than bFGF and PDGF in the non-healing cohort and in general the level of VEGF in 
this cohort was higher than that in the wound fluid collected from the healing leg 
ulcers (Figure 5.3). VEGF levels were variable with the concentration in wound 
fluid from half the non-healing leg ulcers fluctuating over time (ulcer 4011, 4023, 
4059, 4072 and 4001). The samples from the healing leg ulcers exhibited not only a 
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lower concentration overall but samples from six ulcers demonstrated decreases in 
VEGF with each consecutive sample over time (Ulcer 4019, 4008, 4080, 4082 and 
4084). Gender had no significant effect on VEGF concentration (p=0.539) but the 
levels of VEGF in the healing cohort were significantly decreasing over the time 
when compared to the non-healing cohort (p=0.016).  
Table 5.1 Summary of linear mixed model analysis of concentration of growth 
factors and chemokines over time in samples from healing and non-healing leg 
ulcers. Assessment of linearity of growth factor and chemokine in serial dilution 
of pooled wound fluid is indicated by r-squared.  
Chemokine / 
Growth Factor 
Healing outcome 
p-value
 
Gender 
p-value 
Linearity (r
2
) 
bFGF 0.0001 0.578 0.38* 
PDGF 0.315 0.176 0.63* 
VEGF 0.016 0.539 0.98 
G-CSF 0.097 0.284 0.97 
GM-CSF 0.007 0.922 0.39* 
RANTES 0.632 0.918 0.87 
MCP-1 0.058 0.690 0.74 
MIP-1α 0.077 0.978 0.66* 
MIP-1β 0.022 0.178 0.99 
IL-8 0.002 0.433 0.16* 
IP-10 0.367 0.563 0.97 
* Indicates poor linearity of the protein measured.  
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Figure 5.1 bFGF levels decrease over time in wound fluid from patients whose 
leg ulcers healed. bFGF levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of bFGF were found to be significantly decreasing (p=0.0001) in the 
A| healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical 
replicates)   
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Figure 5.2 PDGF levels did not change over time in wound fluid from healing 
and non-healing ulcers PDGF levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. PDGF did not change 
over time when comparing A| healing versus the B| non-healing leg ulcers and the 
linear mixed model demonstrated there was no significant difference between the 
two cohorts (p=0.315). (Error bars indicate SD of technical replicates)   
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Figure 5.3 VEGF levels decrease over time in wound fluid from patients whose 
leg ulcers heal. VEGF levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of VEGF were found to be significantly decreasing (p=0.016) in the 
A| healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical 
replicates)  
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G-CSF is a growth factor that promotes the growth and maturation of myeloid 
cells and in particular is potent at inducing proliferation and differentiation of 
neutrophils (Yönem et al., 2001). The overall concentrations of G-CSF in samples 
from both healing and non-healing ulcers were highest amongst all growth factors 
with the majority of samples falling between 1000-10000 pg/mg total protein 
(Figure 5.4). The non-healing cohort exhibited consistent expression over time in 
samples from three ulcers (ulcers 4026 4012 and 4072), while the remainder 
fluctuated randomly with no trends evident. Six ulcers in the healing cohort had 
reduced levels of G-CSF in samples at each consecutive point over the time course 
(ulcers 4000, 4032, 4019, 4008, 4084 and 4053). The samples from the remaining 
four ulcers either spiked at the second time point (ulcers 4006, 4080 and 4082) or 
decreased initially and increased at the last time point (ulcer 4034). Gender had no 
effect on the G-CSF levels (p=0.284). However, a strong trend for G-CSF to 
decrease over time was observed in the healing compared to the non-healing cohort, 
albeit it was not significant (p=0.097).  
 
GM-CSF stimulates proliferation and activation of macrophages, monocytes 
and neutrophils and can enhance the production of pro-inflammatory cytokines 
(Shiomi & Usui, 2015). The levels of GM-CSF measured in samples from both 
healing and non-healing ulcers were in line with VEGF at approximately 1000 pg/mg 
total protein (Figure 5.5). Samples from all non-healing ulcers demonstrated 
expression of GM-CSF with no increase or decrease over time. In contrast, the 
majority of samples from the healing ulcers showed decreased GM-CSF levels at 
each consecutive time point (ulcers 4000, 4006, 4019, 4008, 4080, 4082 and 4084). 
Samples from ulcer 4032, however, had increased levels of GM-CSF over time, 
whilst samples from ulcer 4053 had slightly increased levels at the second time point 
before decreasing in the final wound fluid sample. Yet again gender had no effect on 
growth factor levels (p=0.922). The decreases in GM-CSF levels in healing versus 
non-healing ulcers samples was found to be significant (p=0.007). 
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Figure 5.4 G-CSF levels measured over time in wound fluid from healing and 
non-healing ulcers. G-CSF levels were measured at multiple time points in wound 
fluid from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while 
being treated with evidence-based best practice. G-CSF decreased over time when 
comparing A| healing versus the B| non-healing leg ulcers but the linear mixed model 
demonstrated there was only a trend towards significance (p=0.097). (Error bars indicate 
SD of technical replicates)   
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Figure 5.5 GM-CSF levels decrease over time in wound fluid from patients 
whose leg ulcers heal.GM-CSF levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. Using a linear mixed 
model the concentrations of GM-CSF were found to be significantly decreasing 
(p=0.007) in the A| healing versus the B| non-healing leg ulcers. (Error bars indicate SD 
of technical replicates)  
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5.2.3 MEASUREMENT OF CHEMOKINES 
Chemokines (MCP-1, MIP-1α, MIP-1β, RANTES, IP-10 and IL-8) were 
quantitated in wound fluid from 10 healing ulcers and 10 non-healing ulcers using 
the 27-plex antibody array (Bio-Rad). Again, serial dilution of the wound fluid pool 
was used to demonstrate assay linearity. The strongest interference was observed 
with IL-8 which exhibited no linearity in the serial dilution control (r
2
= 0.16). This 
was followed by MIP-1α and MCP-1, which had r-squared values of 0.66 and 0.74, 
respectively, although it should be noted that MIP-1α measured levels were all at the 
lower detection limit of the standard curve. The remaining three chemokines, 
RANTES, MIP-1β and IP-10 demonstrated good linearity (r2=0.87, 0.99 and 0.97 
respectively).  
 
RANTES provides chemotactic cues for immune cells such as monocytes and 
neutrophils to migrate to the wound, as well as enhances the expression of 
metalloproteinases in these cells (Gillitzer & Goebeler, 2001). The measured levels 
of RANTES were low in both healing and non-healing cohorts (10-100 pg/mg total 
protein) and lie within the lower third of the standard curve (Figure 5.6). Samples 
from the non-healing cohort demonstrated no trend in regards to changes over time 
as most ulcer concentrations varied. The levels of RANTES in samples from the 
healing cohort also exhibited no trend as the wound progressed towards closure; the 
expression was inconsistent with fluctuation between each time point (Figure 5.6 A). 
Again gender had no effect (p=0.918) and no significant differences in RANTES 
concentrations were seen between samples from the healing and non-healing over the 
time course (p=0.632).  
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Figure 5.6 RANTES levels did not change over time in wound fluid from healing 
and non-healing ulcers.  RANTES levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. RANTES did not 
change over time when comparing A| healing versus the B| non-healing leg ulcers 
and the linear mixed model demonstrated there was no significant difference between 
the two cohorts (p=0.632). (Error bars indicate SD of technical replicates)  
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MCP-1 is the most potent chemoattractant for monocyte infiltration into 
wounds and also activates increased cytokine production (Dipietro et al., 2001). The 
overall concentrations of MCP-1 in samples from both healing and non-healing ulcer 
cohorts was equivalent to RANTES. The majority of time points from healing ulcers 
fell below 100 pg/mg total protein, although several ulcers within the non-healing 
cohort exceeded this concentration (ulcers 4011, 4012 and 4009). The samples from 
non-healing ulcers did not exhibit any trend in MCP-1 levels between sequential 
samples. The levels of MCP-1 increased with each sequential wound fluid sample 
over the time course for two healing ulcers (ulcers 4006 and 4032), whilst the 
remaining ulcers decreased in MCP-1 concentration by the last sample measured 
(ulcers 4000, 4034, 4008, 4084 and 4053). There was a trend towards significance 
(p=0.058) indicating that the concentration of MCP-1 was decreasing in samples 
from the healing compared to the non-healing cohort over time and again gender had 
no effect on this (p=0.69). 
 
There are two major forms of macrophage inflammatory proteins, MIP-1α and 
MIP-1β. MIP-1α is primarily a chemoattractant for monocytes but can also recruit 
neutrophils. This chemokine is also responsible for stimulating MMP production 
(DiPietro et al., 1998; Gillitzer & Goebeler, 2001). The concentrations of MIP-1α in 
samples from both healing and non-healing ulcers were very low and were just above 
the lower limit of detection in regards to the standard curve. In samples from the 
non-healing ulcer cohort MIP-1α expression varied over time and no distinct trend 
was observed. However, the healing ulcers showed a decrease in MIP-1α over time 
and five ulcers reduced at each consecutive point (ulcers 4000, 4006, 4019, 4084 and 
4008). LMM analysis indicated a trend towards significance with a decrease of the 
chemokine over time when comparing samples from the healing and non-healing 
cohorts (p=0.077). The LMM also indicated that gender had no impact on the 
expression levels (p=0.978). 
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Figure 5.7 MCP-1 levels decrease over time in wound fluid from patients whose 
leg ulcers heal. MCP-1 levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. MCP-1 decreased over time when 
comparing A| healing versus the B| non-healing leg ulcers but the linear mixed model 
demonstrated there was only a trend towards significance (p=0.058). (Error bars indicate 
SD of technical replicates)  
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Figure 5.8 MIP-1α levels decrease over time in wound fluid from patients whose 
leg ulcers heal. MIP-1α levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. MIP-1α decreased over time when 
comparing A| healing versus the B| non-healing leg ulcers but the linear mixed model 
demonstrated there was only a trend towards significance (p=0.077). (Error bars indicate 
SD of technical replicates)  
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The second macrophage inflammatory protein quantified, MIP-1β, 
demonstrated approximately 10 fold higher expression overall in samples across both 
cohorts when compared to MIP-1α. Similar to its closely related family member 
MIP-1α, MIP-1β serves as a chemoattractant for monocytes and macrophages but 
also induces chemotaxis of T cells (Kaburagi et al., 2001). The samples from the 
non-healing cohort observed no trends in MIP-1β concentration over time. Within 
samples from the healing cohort five ulcers (ulcers 4000, 4006, 4019, 4080, and 
4084) showed decreased MIP-1β across each successive time point. Three ulcers 
(ulcers 4008 4082 and 4053) displayed a small increase of MIP-1β in their second 
sample, but then decreased considerably at the last point samples were collected prior 
to wound closure. The remaining two ulcers (ulcers 4034 and 4032) demonstrated 
similar expression levels between the first and last sample. Statistical analysis using 
LMM indicated that MIP-1β levels in samples from the healing ulcers significantly 
decreased over time compared to samples from the non-healing ulcers (p=0.022), 
while gender had no effect on these levels (p=0.178).  
 
IL-8 is a strong chemoattractant for neutrophils and also increases keratinocyte 
migration and proliferation (S. Barrientos et al., 2008; Rennekampff et al., 2000; 
Tuschil et al., 1992). Its expression levels are the highest amongst the chemokines 
quantitated in wound fluid samples from healing and non-healing ulcers. The 
non-healing ulcer cohort exhibited no trend in IL-8 levels over time. Within the 
non-healing cohort data from ulcer 4011 was excluded as the values were above the 
highest standard curve value. Some samples also demonstrated large variations 
amongst replicates (ulcers 4082 and 4038). This can be seen in the error bars, which 
in some cases span over 5000 units (pg/mg). The samples from the healing cohort 
demonstrated a significant decrease in IL-8 levels (p=0.002) over time with six ulcers 
reducing in levels at each time point (ulcers 4034, 4019, 4008, 4080, 4082 and 4084). 
Gender again had no effect on IL-8 levels (p=0.433). 
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Figure 5.9 MIP-1β levels decrease over time in wound fluid from patients whose 
leg ulcers heal. MIP-1β levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of MIP-1β were found to be significantly decreasing (p=0.022) in the 
A| healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical 
replicates)  
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Figure 5.10 IL-8 levels decrease over time in wound fluid from patients whose 
leg ulcers heal. IL-8 levels were measured at multiple time points in wound fluid 
from patients whose ulcers A| healed (n=10) and B| failed to heal (n=10), while being 
treated with evidence-based best practice. Using a linear mixed model the 
concentrations of IL-8 were found to be significantly decreasing (p=0.002) in the A| 
healing versus the B| non-healing leg ulcers. (Error bars indicate SD of technical replicates)  
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The levels of the final chemokine quantitated in wound fluid, IP-10, were less 
abundant than IL-8, but were high in relation to other chemokines measured. IP-10 
recruits T cells to the source of inflammation and has been shown to negatively 
impact on angiogenesis through inhibition of endothelial cell chemotaxis (Engelhardt 
et al., 1998). Overall IP-10 levels in samples from the non-healing ulcers were higher 
than samples from healing ulcers. However, the healing cohort did not demonstrate a 
trend over time. Levels in samples from only one ulcer (ulcer 4019) decreased over 
time, several fluctuated but remained at similar levels between the first and last time 
point (ulcers 4000, 4006, 4034, 4032, 4082 and 4053), whilst the remaining three 
ulcers exhibited the same level of the chemokine in wound fluid over time (Ulcer 
4008, 4080 and 4084). No trend was observed in samples between non-healing ulcers 
over their treatment time. Samples from three ulcers had increased levels of IP-10 
(ulcers 4009, 4038 and 4002), whilst samples from two ulcers remained constant 
(ulcers 4001 and 4012) and the remaining five fluctuated. As expected, no effect of 
gender (p=0.563) was seen in IP-10 levels and no significant differences in IP-10 
levels between healing and non-healing cohorts were detected (p=0.367).  
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Figure 5.11 IP-10 levels did not change over time in wound fluid from healing 
and non-healing ulcers. IP-10 levels were measured at multiple time points in 
wound fluid from patients whose ulcers A| healed (n=10) and B| failed to heal 
(n=10), while being treated with evidence-based best practice. IP-10 did not change 
over time when comparing A| healing versus the B| non-healing leg ulcers and the 
linear mixed model demonstrated there was no significant difference between the 
two cohorts (p=0.367). (Error bars indicate SD of technical replicates)  
 I P -1 0  le v e ls  o f  h e a lin g  u lc e r s
W e e k  b e fo r e  c lo s u r e
p
g
/m
g
 o
f
 t
o
t
a
l 
p
r
o
t
e
in
12481 6
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0 W o u n d  C lo s u re
A
U lc e r  4 0 0 0
U lc e r  4 0 0 6
U lc e r  4 0 3 4
U lc e r  4 0 3 2
U lc e r  4 0 1 9
U lc e r  4 0 0 8
U lc e r  4 0 8 0
U lc e r  4 0 8 2
U lc e r  4 0 8 4
U lc e r  4 0 5 3
I P -1 0  le v e ls  o f  n o n -h e a lin g  u lc e r s
W e e k  o f  t r e a tm e n t
p
g
/m
g
 o
f
 t
o
t
a
l 
p
r
o
t
e
in
0 5 1 0 1 5 2 0
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
U lc e r  4 0 0 1
U lc e r  4 0 1 1
U lc e r  4 0 2 3
U lc e r  4 0 3 8
U lc e r  4 0 0 2
U lc e r  4 0 2 6
U lc e r  4 0 1 2
U lc e r  4 0 0 9
U lc e r  4 0 7 2
U lc e r  4 0 5 9
B
  
Chapter 5: Quantitation of Chemokines and Growth Factors in wound fluid from healing and non-healing ulcers153 
5.3 DISCUSSION  
The results presented within this chapter outline the remaining quantitative data 
generated from the 27-plex Bio-Plex assay discussed in the previous chapter. In 
brief, the study collected wound fluid from 10 ulcers that healed and 10 ulcers which 
did not heal over a 24 week period in which both cohorts were treated with evidence 
based best practice. Three samples were quantitated for each wound for the healing 
cohort and four samples for each wound in the non-healing cohort over the period of 
the study. Multiplex quantitation was performed on 5 growth factors (bFGF, PDGF, 
VEGF, G-CSF and GM-CSF) and 7 chemokines (RANTES, MCP-1, MIP-1α, 
MIP-1β, IL-8, IP-10 and eotaxin). Most growth factors measured were detectable in 
wound fluid, although for eotaxin, the majority of samples were below the limit of 
detection and subsequently no analysis was performed on this chemokine. MIP-1α 
was another chemokine with low quantitative values that remained just above the 
limit of detection. These low values may be one of the reasons MIP-1α experienced 
very poor linearity within the assay (r
2
=0.66). Other proteins measured within this 
chapter that also demonstrated poor linearity include bFGF, PDGF, GM-CSF, 
MCP-1 and IL-8 (Table 5.1). The remaining growth factors and chemokines (VEGF, 
G-CSF, RANTES, MIP-1β and IP-10) displayed good linearity within the assay. 
Although analysis was performed on all quantitated growth factors and chemokines, 
results from those with poor linearity should be interpreted carefully. As discussed in 
the previous chapter the most likely reason for the interference within the assay, as 
measured by linearity, is due to matrix effect. This results in interference during 
quantitation by constituents within the sample (Selby, 1999). Analysis of the 
quantitative data using the LMM approach found significant decreases over time 
between the two cohorts, for bFGF (p=0.0001), VEGF (p=0.016) and GM-CSF 
(p=0.007). The remaining two growth factors, PDGF and G-CSF, were not 
statistically different over time between the two groups (Table 5.1). LMM analysis 
of the chemokine data demonstrated that there was a significant decrease in MIP-1β 
and IL-8 over time between the healing and non-healing ulcers (p=0.022 and 
p=0.002, respectively).  
 
Like the growth factors measured some chemokines (RANTES, MIP-1β and 
IP-10), demonstrated strong linearity (with r
2
=0.87, r
2
=0.99 and r
2
=0.97, 
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respectively), whilst some (MIP-1α and IL-8) observed interference (r2 of 0.66 and 
0.16, respectively).  MCP-1 appeared to have good linearity with an r
2
 value of 0.74 
but yielded very poor technical replicates. The poor linearity identified within this 
study is consistent with previously published data using the same kit, particularly 
within the upper rage of the standard curve (De Jager et al., 2003). RANTES, MCP-1 
and MIP-1β levels were detected at the lower end of the standard curve, at around 
100 pg/mg. The chemokine MIP-1α was slightly below this at roughly 10 pg/mg, 
whilst IP-10, was quite highly expressed at 1000 pg/mg on average between the two 
cohorts. 
 
Growth factors are important drivers in wound closure due to their critical roles 
in proliferation and migration of not only epithelial cells, but also immune cells. It 
might be expected that an increase in growth factor levels over time would indicate 
an involvement of growth factors in assisting wound closure. The majority of 
research on growth factors is based on cell culture experiments and limited mouse 
based wound healing models (Werner & Grose, 2003). The growth factors which 
have been identified as the most promising therapeutics through small clinical trials 
are VEGF, bFGF and GM-CSF, although all require larger randomised clinical 
control trials to demonstrate efficacy (Stephan Barrientos et al., 2014). The only 
growth factor which has been through this rigorous process and is now approved by 
the FDA for the use of treating ulcers is PDGF (Mandracchia et al., 2001).  
 
A deficiency in growth factors has long been hypothesised to cause a delay in 
healing, although there have been a limited number of studies which have quantitated 
growth factors in wound fluid samples (Löffler et al., 2013). The data obtained in 
this study demonstrates that PDGF and G-CSF do not change significantly over time 
in wound fluid from ulcers that transition to a healing state, while bFGF, VEGF and 
GM-CSF all decrease significantly in wound fluid collected from healing ulcers. 
Other studies that have quantitated growth factors in fluid of chronic wounds, acute 
wounds and serum samples have produced varied results. G-CSF is highly expressed 
whilst GM-CSF levels were similar when compared to a serum reference 
concentration (Moor et al., 2009). PDGF and bFGF in wound fluid obtained from 
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chronic ulcers showed no significant difference between patient matched healing and 
non-healing samples (Trengove et al., 2000). VEGF has also been studied in wound 
fluid and levels were found to be significantly elevated relative to those in acute 
wounds (Wagner et al., 2003). This correlates to data from venous leg ulcers which 
also demonstrated higher levels of the growth factor when compared to acute wounds 
(Susan L Drinkwater et al., 2003). No published study, however, has quantified 
sequential samples within a healing ulcer cohort.  
 
Some of the large protein array studies discussed in the previous chapter also 
included some growth factors as targets, but as previously discussed they differ a 
great deal with regards to methodology and study design. The first such large array 
study measured bFGF, PDGF and VEGF amongst others growth factors in serum and 
wound fluid of acute and chronic wounds and found no significant difference 
between the patient groups (Trøstrup et al., 2011). A study investigating a large 
panel of proteins in pressure ulcers identified that GM-CSF was the only growth 
factor that was significantly elevated in the non-healing cohort compared to the 
healing cohort (Edsberg et al., 2012). Another large panel study showed no changes 
in the levels of G-CSF, GM-CSF and PDGF between healing and non-healing 
wounds (Pukstad et al., 2010). In contrast, both GM-CSF and G-CSF in venous 
ulcers were found to decrease significantly following four weeks of compression 
therapy (Beidler et al., 2009). This is in line with our findings, which showed that 
GM-CSF and G-CSF reduced in a healing cohort after standard treatment. However, 
the decrease in G-CSF over time was only trending towards significance, which is in 
line with other studies (Beidler et al., 2009). My study did demonstrate that VEGF 
reduced significantly over time, which has not been shown previously. No difference 
in growth factor levels was seen between the two cohorts during the early sample 
time points. This supports the view that the depletion of growth factors in chronic 
wounds is unlikely to be a probable cause of delayed wound healing (Löffler et al., 
2013; Trengove et al., 2000). However, evidence exists that the application of 
exogenous growth factors onto chronic wounds assists wound closure but further 
clinical trials are required (Stephan Barrientos et al., 2014). Data suggests that 
growth factor application may not work on all chronic wounds but they may still be 
useful in accelerating re-epithelialisation of wounds already on a healing trajectory 
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by kick-starting the healing process. In regards to our findings, we hypothesise that 
the decrease over time seen for bFGF, VEGF, G-CSF and GM-CSF may be due to 
the reduced number of immune cells present in the wound bed.  
 
The majority of studies to date have focused on growth factors and pro- and 
anti-inflammatory cytokines and there has been limited research in regards to the 
quantitation and involvement of chemokines in wound healing. We hypothesised that 
as wounds move towards a healing trajectory there would be a decrease of 
chemokines over time in the healing cohort in line with reduced recruitment of 
immune cells. RANTES, MCP-1, MIP-1α, MIP-1β, IP-10 and IL-8 were present on 
the array used in this study. LMM analysis demonstrated that the gender of the 
patient had no effect on the concentrations of all six chemokines measured (Table 
5.1). The levels of RANTES, IP-10 and MIP-1α did not change significantly over 
time when comparing the healing and non-healing ulcer cohorts, while MIP-1β and 
IL-8 both showed a significant decrease in concentration over time when comparing 
the two cohorts. It has previously been found that between healing and non-healing 
cohorts RANTES levels do not significantly change, but there was a trend towards a 
decrease as the wound achieved closure (Fivenson et al., 1997). More recently, a 
review on chemokines identified that our knowledge of RANTES is very limited and 
studies on one of its key functions, angiogenesis, has identified contradictory data 
demonstrating that it can both promote and inhibit new blood vessel formation 
(Bodnar, 2014). One study investigating acute wound healing was unable to detect 
RANTES (Engelhardt et al., 1998). This same study also failed to detect MIP-1α and 
MIP-β in biopsies attained from healthy patients. Perhaps the lack of detection could 
be due to a combination of lower sensitivity of the assay and lower levels of 
expression in acute wounds compared to chronic wounds. A later study demonstrated 
that MIP-1β expression is higher in the interior of the wound compared to the 
periphery of chronic pressure ulcers (Edsberg et al., 2012). However, there was no 
difference in levels when comparing chronic versus healing pressure ulcers.  
 
The results in my study demonstrated a significant decrease in MIP-1α and a 
trend towards significance for MIP-1α when comparing samples from healing and 
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non-healing ulcers. This is in line with another study that showed that both these 
chemokines are elevated in patients with venous ulcers compared to normal skin 
(Fivenson et al., 1997). A more recent study also found that MIP-1α and MIP-1β are 
elevated in biopsies from venous ulcers when compared to healthy tissue (Beidler et 
al., 2009). However, the authors failed to find a significant difference in these two 
chemokines in biopsies from venous ulcers before and after compression therapy. 
The difference between the before and after therapy samples might be due to biopsies 
being used rather than wound fluid as was used in this study. As previously 
described, homogenisation of biopsy samples would result in the quantification of 
material from inside the cells, as well as that present in wound fluid.  
 
My data demonstrated that the levels of MCP-1 were decreasing in wound fluid 
from healing ulcers and were trending towards significance when compared to the 
non-healing ulcers. MCP-1 has been implicated in wound healing as it was observed 
at day one of wounding in acute wounds and correlates with macrophage 
accumulation (Engelhardt et al., 1998). However, this was later disputed using a 
MCP-1 knockout mouse model, which showed similar macrophage numbers in the 
wound compared to the wild type mice (Low et al., 2001). Macrophage number did 
not change as a result of MCP-1 knockdown but did however, result in delayed 
healing through decreased re-epithelialisation, angiogenesis and collagen production 
suggesting it is required for wound healing. While elevated MCP-1 has been found to 
be necessary for healing, alterations in chronic wounds are less clear. It has been 
shown that MCP-1 is increased significantly in venous ulcer tissue when compared 
to healthy tissue control but following compression therapy its level in one study did 
not change significantly, while others have reported a slight trend towards increasing 
during the healing stage (Beidler et al., 2009; Fivenson et al., 1997). Both of these 
results are surprising due to a reduction in inflammation as the wound heals.  
 
IP-10 has been shown to be elevated in venous leg ulcer wound fluid and in 
tissue samples when compared to normal skin biopsies (Fivenson et al., 1997). The 
chemokine has been described as angiostatic and detrimental to blood vessel 
formation and as a result can negatively impact on wound healing (Bodnar et al., 
2009). IP-10 showed strong linearity in our assay and was exhibited at high levels in 
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samples from both cohorts. However, IP-10 remained unchanged over time when 
comparing the two, perhaps indicating no involvement during the transition of a 
chronic wound towards a healing trajectory. The final chemokine, IL-8, 
demonstrated poor linearity and this performance issue has been previously 
identified using the same Bio-Plex kit (De Jager et al., 2003). Although analysis of 
the data is perhaps not ideal given no linear relationship was observed between the 
quantitated levels and linear serial dilution, there seems to be a strong reduction in 
levels in the wound fluid samples evaluated. This is in line with data which has 
shown that chronic pressure ulcers exhibit higher levels when compared to those 
which are healing (Edsberg et al., 2012). This trend has also been observed in venous 
ulcer studies in which levels decreased significantly as the wound moved towards 
closure (Beidler et al., 2009; Fivenson et al., 1997). 
 
To my knowledge this is the first time that growth factors and chemokines 
have been investigated in a longitudinal manner with multiple sequential samples 
following treatment of chronic ulcers of various aetiologies. The majority of the 
research outlined in this discussion involves the comparison of healthy / acute versus 
chronic tissue, or systemic serum levels versus wound fluid levels obtained from the 
site of the ulcer. Apart from the successful quantitation studies outlined in this 
chapter (Beidler et al., 2009; Edsberg et al., 2012; Fivenson et al., 1997), several 
other studies have quantitated chemokines, such as IP-10, MCP-1, MIP-1α and 
MIP-1β within broader cytokine / chemokine panels, however, the data was not 
published in these studies, perhaps due to a lack of significant change or low levels 
(Pukstad et al., 2010). A recent study which quantitated growth factors (bFGF, 
PDGF, and VEGF amongst others) in acute and non-healing ulcers found no 
significant difference between the two cohorts (Trøstrup et al., 2011). These two 
above mentioned studies have been discussed in greater detail in regards to 
experimental design in the previous chapter. Several growth factors and chemokines 
from the 27-Plex panel demonstrated significant change between the two cohorts 
over time, indicating involvement in the healing process. Therefore, these specific 
chemokines and growth factors should be targeted for further investigation and 
possible therapeutic use. The significant reduction of chemokines correlates with the 
reduction of pro-inflammatory cytokine data that was described in the previous 
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chapter. As my data indicates that there is a strong inflammatory response in the 
non-healing ulcer cohort, further investigation is warranted to identify the 
mechanisms underlying inflammation in non-healing wounds.  
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Chapter 6: Evidence of Inflammasome 
activation and triggers of 
inflammation in chronic leg ulcers 
6.1 INTRODUCTION 
There is a significant body of data which has provided evidence that an 
exacerbated immune response delays healing in chronic leg ulcers (Robert F 
Diegelmann & Melissa C Evans, 2004; Sabine A Eming et al., 2007). This results in 
high expression of proteolytic enzymes, ROS and cytokines in the local wound 
environment (summarised in Figure 1.1). Subsequently, more immune cells are 
attracted through chemotaxis to the ulcer site, resulting in a positive feedback loop of 
inflammation. In the previous two chapters evidence was provided indicating that 
there is reduced inflammation at the wound site in healing leg ulcers and significant 
decreases in several pro-inflammatory cytokines, as well as chemokines, over time. 
These data suggest that the transition of chronic leg ulcers to a healing state is not 
due to increased secretion of growth factors or anti-inflammatory cytokines as has 
been suggested in earlier research (Hart, 2002; Lawrence & Gilroy, 2007; Liu et al., 
2011).  
 
The question then remains; what are the underlying causes of inflammation in 
these chronic leg ulcers. Inflammation in the wound is thought to result from 
detection of alarmins by the body’s innate immune system. These triggers of 
inflammation are classified into either PAMPs or DAMPs and are detected by TLRs. 
However, a new inflammatory pathway / mechanism has been discovered which also 
detects these alarmins and induces inflammation; this has been coined the 
inflammasome (Martinon et al., 2002; Tschopp & Schroder, 2010). The 
inflammasome is an important component of innate immunity and has been found to 
have overlapping triggers with TLRs, but serves as a separate regulator of 
inflammation during tissue injury and repair (Pétrilli et al., 2007).  
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Recent investigations have demonstrated the involvement of the inflammasome 
in several diseases, such as rheumatoid arthritis (Geyer & Müller-Ladner, 2010), 
diabetes (Youm et al., 2011) and several auto-inflammatory diseases (Feldmeyer et 
al., 2010). The inflammatory dysregulations evident in these disease states is linked 
to an over active inflammasome. It has been speculated that the inflammasome is 
also activated in chronic leg ulcers and may be a key component in other skin 
diseases (Feldmeyer et al., 2010; Kambe et al., 2011). In chronic leg ulcers the 
activation of the inflammasome is presumed due to the detection of 
pro-inflammatory cytokine IL-1β (Beidler et al., 2009; Trengove et al., 2000). 
However, there is no data confirming the activation of the inflammasome in 
non-healing ulcers. A recent publication has demonstrated that diabetic wounds have 
sustained inflammasome activity and this directly impairs the healing process (R. E. 
Mirza et al., 2014). Therefore, as is described in this chapter, I aimed to identify 
triggers of inflammation in wound fluid obtained from chronic leg ulcers and also to 
investigate whether inflammasome activation occurred in chronic leg ulcers.  
 
6.2 RESULTS 
6.2.1 PATIENT DEMOGRAPHICS  
Wound fluid and microbial swabs were collected from a total of 8 ulcers (8 
patients). The median age of the patient cohort was 73 with a range between 42 to 84 
years of age. Of the 8 chronic leg ulcers selected in this study, 6 were of mixed 
aetiology (venous / arterial), with the remaining two of venous origin. The duration 
of the ulcers prior to the study ranged from 8 to 40 weeks. The average size of the 
ulcers was 6.3 cm
2
 at baseline and treatment was based on best practice guidelines. 
Four of the 8 ulcers failed to heal over the 24 week study, whilst the remaining 4 
achieved complete wound closure. An ulcer was considered healed only if it 
achieved complete re-epithelialisation within 24 weeks and remained healed for two 
weeks following closure. Wound fluid samples and microbial swabs were collected 
at various time points based on attendance at the clinic for treatment. This is 
summarised in Table 6.1. Both the healing and non-healing ulcers were investigated 
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across three time points / samples. For healing ulcers, the week at which the ulcers 
healed is also recorded in the patient demographics table. 
 
Table 6.1 Patient demographics for 4 healing and 4 non-healing ulcers.  
 
 Healed Ulcers Non-Healed Ulcers 
Ulcer 
Type 
Sex 
Age 
Ulcer 
Dur 
Sample 
(week) 
Area 
(cm
2
) 
Ulcer 
Type 
Sex 
Age 
Ulcer 
Dur 
Sample 
(week) 
Area 
(cm
2
) 
4082 
Venous 
M 
42yr 
14 
weeks 
1 6.6 
4113 
Mixed 
M 
81yr 
12 
weeks 
0 3.2 
2 6.3 6 17.6 
4 5.7 11 9.7 
9 0   
4034 
Mixed 
M 
84yr 
8 
weeks 
1 2.6 
4119 
Mixed 
F 
74yr 
12 
weeks 
0 13 
5 6.7 5 15.6 
10 2.1 10 36.2 
21 0   
4084 
Mixed 
F 
81yr 
6 
weeks 
3 4.8 
4059 
Venous 
M 
72yr 
40 
weeks 
1 15.9 
5 2.4 4 11.3 
8 2.2 9 7.3 
11 0   
4122 
Mixed 
M 
59yr 
9 
weeks 
0 1.5 
4001 
Mixed 
M 
68yr 
36 
weeks 
0 2.9 
1 1.5 6 - 
3 0.2 12 1.5 
5 0   
 
 
6.2.2 IL-1β ACTIVITY ASSAY 
In chapter 4, I reported pro-inflammatory cytokine IL-1β levels measured in 
wound fluid from 10 healing and 10 non-healing ulcers over time using the Bio-Plex 
array. In samples from the healing cohort, the concentrations of IL-1β decreased over 
time and were trending towards significance when compared to the non-healing 
cohort (p=0.133). This assay, however, does not distinguish between the “pro” and 
“active” forms of the cytokine. The inflammasome complex includes caspase 1 
which is known to cleave the pro form of IL-1β and IL-18 (see Figure 1.2), resulting 
in its activation. Therefore measuring cleaved active IL-1β in wound fluid will 
indirectly demonstrate the activation of the inflammasome in chronic leg ulcers.  
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A bioassay based on the HEK-Blue IL-1β cell line was used to measure the 
active IL-1β levels in wound fluid. This cell line is derived from the HEK-Blue 
TNF/IL-1β cell, in which the TNF response has been blocked, limiting cell signalling 
to IL-1. Binding of IL-1 to the IL-1 receptor activates the NF-κB signalling pathway 
leading to the production of the secreted embryonic alkaline phosphatase (SEAP) 
reporter gene system. Two microlitres of wound fluid from three wound samples 
obtained from both healing and non-healing patients were quantitated over time 
using the IL-1β activity assay (see 2.4.2 for method). In samples from the healing 
cohort (Figure 6.1 A) the levels of active IL-1β in wound fluid from two ulcers 
reduced with each successive time point (ulcer 4082 and 4084), whilst samples from 
one increased (ulcer 4034) and samples from the remaining ulcer did not change in 
concentration over time (ulcer 4122). Within the non-healing cohort, wound fluid 
from two patient ulcers (ulcer 4001 and 4113) demonstrated very little fluctuation in 
the concentration of active IL-1β over time. In ulcer 4059 the levels of active IL-1β 
in wound fluid did not change between the first and second measured time points, but 
decreased subsequently, whilst wound fluid from ulcer 4119 exhibited an initial 
decrease. The overall concentration of active IL-1β in the two cohorts was relatively 
similar and no trend was observed in either cohort over time. These data were 
confirmed with a LMM analysis which found no significant difference between the 
two groups (p=0.962). However, the data does demonstrate that the inflammasome 
complex is activated in both healing and non-healing ulcers as active IL-1β was 
present in wound fluid from both patient groups.  
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Figure 6.1 Evidence of inflammasome activation through detection of IL-1β in wound fluid from healing and non-healing patients. A| 
The concentration of active IL-1β was measured in wound fluid from four healing patients. B| The concentration of active IL-1β measured in the 
wound fluid from four non-healing patients. LMM analysis found there was no statistical difference between the two groups over time (p=0.962).  
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6.2.3 ASC IS PRESENT IN WOUND FLUID OBTAINED FROM HEALING AND 
NON-HEALING LEG ULCERS 
ASC is an adaptor protein containing two binding domains, PYD and CARD, 
and is critical for the formation of the majority of inflammasomes. ASC particles 
have been found in the serum of patients with auto-immune disorders and 
extracellular ASC particles can activate caspase 1, which can cleave extracellular 
inactive IL-1β (Baroja-Mazo et al., 2014). Thus, extracellular ASC has the potential 
to exacerbate the inflammatory response and the aim was to identify if this was 
occurring in patients suffering from chronic leg ulcers. The 24 wound fluid samples 
described in Table 6.1 are three sequential samples from four patients that healed 
and four which did not heal in our study. These wound fluid samples were equally 
loaded (50 μg) across two SDS-PAGE gels (A and B Figure 6.2).  To prevent any 
bias the gels were not divided by healing outcome but rather were loaded 
alternatively with one healing wound fluid set followed by a non-healing wound 
fluid set. Following a transfer onto PVDF (see section 2.4.3 for more detail) a 
polyclonal antibody against ASC was used to probe these wound fluid samples. The 
presence of ASC was found to be variable and it was not detected in all samples 
(Figure 6.2). There was no overall trend observed amongst the samples form the 
healing cohort (lane 1-3 and 7-9) (Figure 6.2). The levels of ASC did not correlate 
with the IL-1β activity assay in Figure 6.1. Apart from samples from ulcer 4112, the 
amount of ASC appears to be reduced in healing wounds compared to non-healing 
wounds. These results do, however, demonstrate that ASC is present in wound fluid.  
 
 
Figure 6.2 ASC is detected in wound fluid from healing and non-healing leg 
ulcers. A| Wound fluid from healing ulcers 4082 (1-3), ulcer 4084 (7-9) and 
non-healing ulcer 4001 (4-6) and ulcer 4119 (10-12) were separated by SDS-PAGE 
and immunoblotted for ASC. B| Wound fluid from healing ulcers 4034 (1-3) and 
ulcer 4122 (7-9) and non-healing ulcers 4113 (4-6) and ulcer 4059 (10-12) were 
separated by SDS-PAGE and immunoblotted for ASC.  
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6.2.4 HMGB1 LEVELS IN WOUND FLUID FROM HEALING AND NON-HEALING 
LEG ULCERS 
HMGB1 is a nuclear DNA binding protein that participates in DNA 
replication, repair and alters gene expression through transcriptional regulation. In 
addition to its intracellular function, extracellular HMGB1 is recognised as a DAMP 
and a trigger of inflammation. To identify if HMGB1 was a possible trigger of 
inflammation in chronic leg ulcers, an antibody against HMGB1 was used to probe 
for the protein in wound fluid. As in the above Western blot experiment the 24 
wound fluid samples described in Table 6.1 are three sequential samples from four 
patients that healed and four which did not heal in our study. These wound fluid 
samples were equally loaded (50 μg) across two SDS-PAGE gels (A and B Figure 
6.2). To prevent any bias the gels were not divided by healing outcome but rather 
were loaded alternatively with one healing wound fluid set followed by a 
non-healing wound fluid set. Following a transfer onto PVDF (see section 2.4.3 for 
more detail) a polyclonal antibody against HMGB1 was used to probe these wound 
fluid samples. While HMGB1 was detected in most wound fluid samples, no overall 
trend was observed. In wound fluids from two ulcers, one healing and the other 
non-healing, HMGB1 was barely detectable (ulcers 4084 and 4113, lanes A7-9 and 
B4-6), whilst in others consistently higher levels were detected relative to other 
ulcers (ulcer 4119 and 4059) (Figure 6.3). There were only two ulcers which 
exhibited a similar expression level in wound fluid in regards to ASC and HMGB1 
and these are ulcers 4034 and 4119 (healing and non-healing, respectively). There 
was no correlation between IL-1β and HMGB1 levels.  
 
Figure 6.3 HMGB1 in wound fluid from healing and non-healing leg ulcers. A| 
Wound fluid from healing ulcers 4082 (1-3), ulcer 4084 (7-9) and non-healing ulcers 
4001 (4-6) and ulcer 4119 (10-12) were separated by SDS-PAGE and immunblotted 
for HMGB1. B| Wound fluid from healing ulcers 4034 (1-3), ulcer 4122 (7-9) and 
non-healing ulcers 4113 (4-6) and ulcer 4059 (10-12) were separated by SDS-PAGE 
and immunoblotted for HMGB1.  
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6.2.5 MEASURING MICROBIAL LOAD IN SWABS COLLECTED FROM CHRONIC 
LEG ULCERS  
Inflammation in the wound environment can also be triggered by PAMPs from 
microorganisms. PAMPS from bacteria include bacterial cell wall components, 
bacterial DNA and proteins from motility organelles such as flagellin (Akira et al., 
2006). The role of bacterial infections and colonisation have been extensively studied 
in wound repair. In order to quantitate the amount of bacteria present in leg ulcer 
wounds, a RT-PCR method was used. In brief, DNA was extracted from microbial 
swabs collected from chronic leg ulcers, purified and quantitated against a standard 
curve. The total microbial load was defined by the quantitated concentrations of 
microbial DNA from the wound swab samples. A wound with a microbial load 
above 1 μg/mL was considered colonised, and wounds with a microbial load above 
5 μg/mL was deemed infected. RT-PCR analysis demonstrated that the 
concentrations of microbial DNA in non-healing wounds were all well below the 
1 μg/mL cut-off. The highest identified concentration for samples from non-healing 
ulcers was found to be 0.12 μg/mL. Samples from all remaining ulcers yielded values 
below <0.00 (Table 6.2). Samples from healing ulcers on the other hand yielded 
much higher concentrations of microbial DNA overall. The first sample from ulcer 
4122 indicated that the wound was infected (15.00 μg/mL), while the last sample 
indicated that the wound was by then only colonised (2.53 μg/mL). Ulcers 4082 and 
4084 also yielded one sample each that indicated the wound was colonised 
(1.78 μg/mL and 2.25 μg/mL, respectively). Amongst the non-healing ulcers no trend 
was found in regards to microbial load changing over time. Similarly, the microbial 
load within samples from the healing cohort fluctuated and no trend could be 
determined. Overall, however, the samples from the healing cohort contained much 
higher concentrations of microbial DNA.  
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Table 6.2 Relative total microbial load as determined by 16S rRNA quantitation 
against a standard curve. DNA was extracted from microbial swabs collected 
from healing and non-healing ulcers and microbial DNA concentrations 
determined by RT-PCR. 
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4113 0.0000 
4082 1.7804 4113 0.0001 
4082 0.0817 4113 0.0000 
4034 0.0009 4119 0.1203 
4034 0.0084 4119 0.0007 
4034 0.0393 4119 0.0010 
4084 0.0490 4059 0.0005 
4084 0.0067 4059 0.0019 
4084 2.2599 4059 0.0003 
4122 15.0019 4001 0.0003 
4122 0.3761 4001 0.0075 
4122 2.5382 4001 0.0003 
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6.3 DISCUSSION 
The production of active IL-1β requires the assembly of the inflammasome and 
activation of caspase-1 in order to cleave the precursor form of the cytokine 
(Martinon et al., 2002). Numerous studies have quantitated the levels of total 
pro-inflammatory cytokine IL-1β in wound samples using an ELISA based approach 
(Beidler et al., 2009; Edsberg et al., 2012; Trengove et al., 2000). However, the 
above mentioned studies, as well as the Bio-Plex data within chapter 4 of this thesis, 
were unable to differentiate between the active IL-1β and the inactive precursor, 
pro-IL-1β. The Bio-Plex IL-1β data (Figure 4.4) decreased over time when 
comparing the healing and non-healing cohort, and LMM analysis suggests it was 
trending towards significance. The Bio-Plex study indicated that samples from three 
ulcers (ulcer 4082, 4059 and 4001) contained sufficient wound fluid to allow 
quantitation of active IL-1β using the cell based activity assay. The concentration of 
IL-1β were found to be similar between the two assays, however, values were 
consistently higher from the activity assay (Figure 4.5, Figure 6.1). Nevertheless, 
the trends in both data sets were similar and found to decrease over time. 
Importantly, the cell based IL-1β activity bioassay has demonstrated for the first time 
that active IL-1β is present in wound fluid from chronic leg ulcers and that it is not 
the inactive precursor, pro-IL-1β, released from damaged tissue cells in the local 
wound area.  
 
Previous research focussed on diabetic wounds has revealed that sustained 
inflammasome activity impairs healing (R. E. Mirza et al., 2014). Studies in which 
IL-1β is inhibited by blocking antibodies in wounded diabetic mice improved healing 
rates (R. E. Mirza et al., 2013). In separate mouse studies, the loss of NLRP-3 in 
mice leads to impaired healing of acute wounds, suggesting that inflammasome 
activity is necessary in the early phases of wound healing (Weinheimer-Haus et al., 
2015). A number of other studies also support the concept that the early 
inflammatory response is crucial for efficient repair. For example, healing was found 
to be delayed in a murine study where macrophages were depleted in the early stages 
of repair (R. Mirza et al., 2009). Mice that lack TLR9 also exhibit delayed healing 
(Piccinini & Midwood, 2010). It is only in the later stages of repair that persistent 
inflammation is linked to wound chronicity and impaired healing. 
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Activation of the inflammasome complex occurs in the cytosol and requires the 
assembly of a multi-protein complex: a sensor protein (NLRP-3 / LRR), an adaptor 
protein (which in most cases is ASC) and caspase-1 (see figure Figure 1.2) (Tschopp 
& Schroder, 2010). This multi-protein complex polymerises into the multimeric 
(generally hexamer) inflammasome; the active caspase-1 forms the inner catalytic 
domain which is responsible for the cleavage of pro-inflammatory cytokine 
precursors of IL-1β and IL-18. Apart from its critical role in inflammasome 
oligomerisation, ASC has also been found to play a role in pyroptosome assembly, 
which like caspase-1, can trigger a form of programmed cell death coined pyroptosis 
(Fernandes-Alnemri et al., 2007; Sagulenko et al., 2013). Pyroptosis results in a loss 
of cell membrane integrity, thus releasing intracellular proteins, some of which are 
known to propagate inflammation, such as IL-1β and ASC (Baroja-Mazo et al., 
2014). This occurs through two mechanisms; firstly, the inflammasome complex 
maintains activity extracellularly; or, secondly, the ASC is phagocytosed where it 
induces more IL-1β production and lysosomal damage (Franklin et al., 2014). In the 
study reported in this chapter, ASC was detected in wound fluid from chronic leg 
ulcers and was present in both healing and non-healing wounds. This confirms 
activation of the inflammasome in chronic leg ulcers. The detection of ASC in the 
extracellular space suggests pyroptosis might also occur. The ASC might also have 
been released from necrotic cells in the local wound area that contain activated 
inflammasome complexes. However, it is not possible to differentiate the source of 
ASC from the assays employed. Although no correlation between healing outcome 
and ASC levels was found, the results demonstrate that ASC should be considered as 
a candidate for further research.  
 
The activation of caspase-1 through inflammasome assembly results in not 
only pyroptosis, which can release various intracellular proteins, but also protein 
secretion through the ‘secretome’ (Keller et al., 2008; Lamkanfi et al., 2010). The 
secretome describes various proteins which do not have secretion signal peptides and 
the mechanism of secretion is unknown, however, it is known that it is caspase-1 
dependent (Keller et al., 2008). Not surprisingly, these include the inflammasome 
dependent proteins IL-1β, IL-18, ASC. The secretome also includes various DAMPs, 
such as S100 proteins and HMBG1 (Lamkanfi et al., 2010; Vande Walle et al., 
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2011). HMGB1 was detected in 50 μg of total protein from wound fluid from healing 
and non-healing patients. Generally, HMGB1 was found to be elevated in 
non-healing ulcers, but due to the small number of patient samples it is not known 
whether these differences are meaningful (Figure 6.3). Interestingly, HMGB1 has 
emerged as one of the key inducers of inflammation released by necrotic cells 
(Scaffidi et al., 2002). Recent evidence also reveals HMGB1 is endocytosed by 
macrophages and induces pyroptosis (Xu et al., 2014). Thus HMGB1, ASC and 
inflammasome complex formation all serve as propagators of inflammation.  
 
The presence of PAMPs in the wound is another likely trigger for increased 
inflammation. Healthy skin is typically colonised by a very large number of 
commensal microorganisms. Once skin integrity is breached, several species of 
gram-positive and gram-negative bacteria are known to cause infections and even 
sepsis. The species predominantly found in chronic wounds includes Pseudomonas 
sp. The majority of microbes are difficult to culture and it has been suggested that 
only 2% of the microbiota is detected this way (Tuttle et al., 2011). For this reason a 
RT-PCR based method was used for the study reported herein to determine bacterial 
load. Quantitation of microbial load data did not identify any significant differences 
in the total load between healing and non-healing ulcers. These results are consistent 
with previous studies in which no significant difference was found between healing 
and non-healing patients (Trengove et al., 2000). The arbitrary cut-off concentration 
used in this study to define a wound as colonised (1 μg/mL) or infected (>5 μg/mL) 
were determined as a result of a parallel study by Huygens and colleagues (Flavia 
Huygens personal communication 2015). These data are not part of this study. High 
concentrations of microbial DNA might indicate normal microbial flora, or they 
might indicate infectious colonisation. This cannot be determined using the RT-PCR 
approach and is therefore a shortcoming of the technique. Next generation 
sequencing on the other hand represents an ideal method; it is able to resolve species 
while also being a quantitative method. This has been shown valuable in determining 
bacterial species important in acute wound healing (Nicholas et al., 2014).  
 
The Levine swab collection technique used in this study was not ideal. Swabs 
only identify bacteria that are superficial in the wound (Gradon & Adamson, 1995) 
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and disregard those species such as Pseudomonas aeruginosa, which reside deeper 
within the wound tissue (Fazli et al., 2009). Other factors that should be considered 
but which were beyond the limitations of the present study, and which should be 
considered in future studies, are the impact of biofilms on wound healing and how 
this can be monitored using molecular techniques such as RT-PCR and next 
generation sequencing. Although a clear trend of increased microbial load in the 
healing ulcer swabs was evident within the of individual ulcers, the levels within 
some samples may amplify the inflammatory response within an already inflamed 
tissue. Further research is therefore required to investigate how and if bacteria 
contribute to sustained inflammation. Nevertheless, overall the results from this 
study suggest that the inflammasome is activated. Moreover, the presence of ASC in 
wound fluid is likely to perpetuate the inflammatory response in the wound. While 
little correlation was found between the ASC, HMGB1 and microbial load data, each 
has been shown independently to stimulate inflammation. Further, the abundance of 
HMGB1 and ASC were generally elevated in the non-healing cohort, as would be 
expected given that HMBG1 and ASC are strong activators of the inflammasome and 
therefore sustained inflammation. All the same, it is unlikely that HMBG1 and ASC 
are the only pro-inflammatory alarmins in non-healing ulcers; therefore future 
studies should incorporate additional DAMPs that could be measured in wound fluid, 
such as ATP, uric acid, S100 proteins, DNA and RNA.  
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Chapter 7: General Discussion 
Chronic leg ulcers affect 1-3% of adults over the age of 65 (H. Edwards et al., 
2014; Ghatnekar et al., 2015). The treatment and medical care of these chronic 
wounds is a costly burden on society, accounting for 3% of the overall total 
healthcare expenditure in developed countries (Posnett & Franks, 2007). In the 
United States this figure is roughly $25 billion (Chandan K Sen et al., 2009), whilst 
in Australia it equates to approximately $2.61 billion annually (AIHW, 2008). The 
growing aging population that developed countries such as Australia, the United 
States of America and the United Kingdom are experiencing will result in further 
economic strain on their respective healthcare systems. The treatment of chronic leg 
ulcers will also become increasingly challenging as the prevalence of co-morbidities 
such as arterial disease, obesity and diabetes also increase (Cameron et al., 2003; 
Jockenhöfer et al., 2014).  
 
Traditionally chronic leg ulcers are classified into three distinct aetiologies, 
venous (60-70%), arterial (5-20%), and mixed venous / arterial (10-25%) (Manj S 
Gohel & Poskitt, 2010). The increased prevalence of the above mentioned 
co-morbidities has led to a shift towards wounds being more complex in nature and 
as a result, they are harder to treat (Jockenhöfer et al., 2014). Clinical patient data 
collected during the WMI-CRC project (approximately 120 ulcers that provided the 
samples for my project) has revealed that the majority of the wounds are of mixed 
aetiology (49%), whilst venous and arterial ulcers make up the remaining 
presentations (at 40% and 11% respectively). It should be noted that patients with 
diabetic foot ulcers were not recruited for this project and therefore have not been 
considered. These aetiology distributions are similar to recent publications in wound 
research where a larger population study of 31,000 patients with wounds classified 
47% as venous, 18% as mixed and 15% as arterial (Körber et al., 2011). This 
apparent decrease in venous leg ulcers and the increase in mixed leg ulcer prevalence 
suggests that chronic wounds are increasingly multifaceted in regards to underlying 
pathomechanisms and are therefore less likely to respond to standard treatment. This 
is exemplified by publications which demonstrated that the current best practice 
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guidelines for venous leg ulcers, compression therapy, is significantly less effective 
in patients with co-morbidities such as arterial disease (moderate arterial 64-68% and 
severe 23-53%) (Ghauri et al., 1998; Humphreys et al., 2007). This concomitant 
aging of the population and increased incidence of co-morbidities with chronic leg 
ulcers will result in a significant number of patients with increasingly limited 
therapeutic options. Therefore, a wider selection of treatment options will be needed 
into the future to manage the increased occurrence of leg ulcers, as well as their 
complexity.  
 
In spite of this evident increase in leg ulcers, there has been limited progress in 
the assessment of leg ulcers. This is particularly important with the rise in complex 
ulcers which do not respond to standard treatment. Currently assessments are 
performed by clinicians and there are no established biomarkers which can be 
reliably used to help determine whether a wound will heal through best practice 
treatment or not. Current patient clinical parameters such as wound area, and even 
multi-parameter tools such as the PUSH score, are not reliable predictors of poor 
healing outcome. In some cases, large high PUSH score wounds can heal faster than 
small, non-exudating wounds with low PUSH scores. This unmet need for 
biomarkers to differentiate healing and non-healing chronic wounds is increasingly 
highlighted in the literature (Broszczak et al., 2012; Hahm et al., 2011; Löffler et al., 
2013; D. R. Yager et al., 2007).  
 
A biomarker is defined as any substance, protein or metabolite that can be 
objectively measured and evaluated as an indicator of a normal biological process, a 
pathological process, or used to monitor a therapeutic intervention. Although several 
biomarkers have been proposed in regards to chronic wounds, such as matrix 
metalloproteases, chemokines and cytokines, none have been accepted for clinical 
use (Hahm et al., 2011; D. R. Yager et al., 2007). The only diagnostic test available 
in the market, Woundchek
TM
, detects elevated protease activity but it is yet to be 
widely accepted into the clinical setting (Dargaville et al., 2013; Izzo et al., 2014). 
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The identification of potential new biomarkers is largely reliant on ‘omics’ 
approaches using MS techniques capable of detecting low abundant constituents due 
to their high sensitivity (Abu-Asab et al., 2011; Caudle et al., 2010; Wheelock et al., 
2013). Several recent studies used proteomics to identify differentially expressed 
proteins in chronic wounds, however, these have not resulted in the development of 
biomarkers (Edsberg et al., 2012; Sabine A. Eming et al., 2010; M. L. Fernandez et 
al., 2008). A recent review of chronic venous ulcer research has identified an 
absence of metabolomic publications in the area, an approach with the potential to 
elucidate important underlying mechanisms of wound chronicity (Mannello et al., 
2014). In light of this, my PhD research aimed to detect changes in metabolite levels 
in chronic leg ulcers, and in particular was directed at identifying changes as wounds 
transition from a non-healing to healing state. The presence of over expressed 
metabolites in non-healing ulcers that could signify elevated activity of a particular 
metabolomic pathway / enzyme, and offer an indirect measure of healing, were also 
of interest. 
 
The ultimate goal of biomarker discovery projects is to translate research 
outcomes into clinical practice. Therefore, samples used for analysis should ideally 
be representative, easily accessible and acquired non-invasively (Broszczak et al., 
2012). The use of tissue biopsies and microdialyates is therefore deemed by many to 
be too invasive and not practical in a clinical setting. In chronic leg ulcer research 
wound fluid is regarded as being representative of the microenvironment present in 
the chronic wound tissue and therefore represents an ideal candidate for biomarker 
discovery (Löffler et al., 2013; Mani, 1999; Wysocki, 1996; D. R. Yager et al., 
2007). Consequently, direct aspiration was used to collect all wound fluid samples 
used within this project to minimise confounders that might interfere with 
downstream analyses (method described in section 2.1.3). These include, for 
example, collecting wound fluid from materials such as dressings and foams, which 
may result in differential adherence of wound fluid constituents and therefore affect 
subsequent analytical results. Additionally, these techniques often rely on buffers to 
extract wound fluid components, further diluting the sample. This is far from ideal as 
the collection method ideally needs to preserve the original sample characteristics 
and not influence any aspects of analysis.  
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The metabolite biomarker discovery approach as outlined in Chapter 3 required 
the establishment of a LC-MS method to isolate and detect metabolites in wound 
fluid collected from patients suffering from chronic leg ulcers. No single method can 
detect all metabolites in a sample, however, LC-MS was chosen as the preferred 
profiling approach as it provides the widest capacity and superior sensitivity. 
Additionally, LC-MS is also regarded as the most robust approach (Dunn et al., 
2005). We recognise, however, that to attain complete coverage of the wound fluid 
metabolome several other methodologies would be required including; GC-MS and 
NMR. In addition, chromatography chemistries, such as strong cation exchange 
(SCX), anion exchange and hydrophilic chromatography for LC-MS is needed to 
achieve full LC-MS coverage of the metabolome (Psychogios et al., 2011).  
 
The wound fluid processing methodology employed for this study was adapted 
from previous work within our research group in which size exclusion filtration 
(3 kDa) was used to separate the metabolite fraction from the complex wound fluid 
mixture (Melissa L. Fernandez et al., 2012). This method was validated using 
SDS-PAGE (Figure 3.2) and HPLC-UV before subsequently being confirmed by 
LC-MS. As wound fluid metabolomic profiling had never been previously published, 
affinity matrix selection was based on empirical testing of several chemistries (C18, 
HILIC and SCX). Ultimately C18 was chosen due to its robust nature and broad 
binding capacity (Dunn & Ellis, 2005; Lawton et al., 2008; Theodoridis et al., 2008). 
Three C18 matrix formats were trialled as certain designs allow better metabolite 
binding and therefore better separation and detection. The HPLC-UV data indicated 
that the Agilent Polaris column possessed significantly better binding capacity than 
the other two columns trialled and was therefore selected for metabolite profiling 
(Figure 3.3). All three columns evaluated were C18 chemistry, however, it was clear 
that columns by specific manufacturers yielded enhanced performance.  
 
A total of 176 wound fluid samples were profiled, however, subsequent 
analysis using XCMS identified a repeated TIC profile amongst a large number of 
samples (approximately 40%). This was later identified as PEG through a specific 
adduct series in molecular weight (Figure 3.4). Although there are thousands of 
articles within the metabolomics field, it is surprising only one article discussed PEG 
  
Chapter 7: General Discussion 179 
ion suppression (Weaver & Riley, 2006). In fact sample contamination is not 
discussed in any metabolomics review articles even though LC-MS technology is 
prone to contaminant issues. As described in section 3.2.5 several attempts were 
made to remove the PEG from the wound fluid samples, regretfully without success. 
SCX and hydrophilic chromatography (HILIC) were also trialled, however, neither 
chemistry solved the contamination issue. The first matrix, SCX, was able to bind 
metabolites but also exhibited strong affinity for PEG. The second matrix, HILIC, 
had poor affinity for metabolites and suffered from column memory and poor 
reproducibility. Although HILIC columns have been successfully used to analyse 
urine and plant metabolomic samples, in our hands we encountered issues of 
incompatibility, possibly due to the diluent or processing method we adopted 
(Cubbon et al., 2007; Nordström et al., 2008). We also cannot exclude that different 
manufacturers of HILIC columns might yield better results, as was found with the 
C18 chemistry. If we could identify the exact source of PEG contamination then 
specific adjustments could be made to the method to avoid this problem. However, it 
is evident there are multiple possible sources where PEG contamination could occur. 
Moreover, it is also possible that there are other contaminants present in the sample 
which have not yet been identified. We considered excluding PEG from the spectral 
data subsequent to detection, but determined that the ion suppression would produce 
false differential levels of metabolites as has been previously reported (Weaver & 
Riley, 2006).  
 
The selection of bioinformatics tools for metabolomics analysis, such as 
XCMS and PCA and METLIN and HMDB, was based on reports in the published 
literature (Psychogios et al., 2011; Zhang, Sun, & Wang, 2012). The PCA analysis 
relies on the relative quantitation levels of the metabolites and unfortunately due to 
the ion suppression caused by PEG contamination this was unable to be applied to 
the data. Consequently, all sample data that had PEG contamination were removed 
prior to analysis with XCMS and MarkerView, both of which utilise PCA 
algorithms. PCA is an unsupervised method (groups are not known to the algorithm) 
which can identify patterns or trends in data separating it into groups based on 
relative quantitative difference. However, as demonstrated in Figure 3.6 the 
algorithm identified other contaminants which were specific to the acquisition batch. 
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As noted earlier, the 176 samples were acquired across three separate batches and 
each batch exhibited its own high abundant contaminants. However, reacquiring all 
the data in a single batch does not rule out the possibility that the contaminants could 
affect ionisation in a similar manner to PEG as these unique contaminants were not 
identified.  
 
XCMS analysis was performed to identify peaks of interest suitable for 
subsequent identification via databases such as METLIN and HMDB. However, it 
became evident during this analysis that the databases are not comprehensive; 
approximately 60% of the m/z peaks identified in the analysis had no metabolite 
matches in either database. The poor state of the databases is well described in a 
publication which concluded that it is a current major shortfall of untargeted 
metabolomic profiling (Patti et al., 2012). Furthermore, many individual m/z peaks 
were matched to multiple metabolite identities (Table 3.1). In addition, adjusting the 
tolerance / accuracy gates failed to improve metabolite matching. For this reason 
metabolite identification based on just parent ion mass should be interpreted 
cautiously (Psychogios et al., 2011). Analysis of the fragmentation of parent ions 
through MS/MS can provide more conclusive metabolite matches, however, the 
database for MS/MS spectra is currently only a quarter of the size of the main 
database in terms of metabolite matches (METLIN). Disappointingly, a large portion 
of the submitted m/z peaks in Table 3.1 were matched with plant metabolites, 
demonstrating a high misclassification rate associated with these databases. In 
addition, the METLIN and HMDB databases do not allow refined search options to 
limit searches to human only metabolites, thus validating the data from these 
databases requires time consuming manual examination of the results to remove 
irrelevant identifications. The poor state of the databases raises serious doubts about 
published studies in which metabolite identifications have not been validated 
(Psychogios et al., 2011). This differs from the situation for proteomic databases; 
they are much more reliable as they provide protein identifications based on multiple 
peptide hits and calculate theoretical masses of peptides based on the genomic 
sequence. Moreover, there are limited possible combinations as there are only 20 
amino acids, whilst the metabolite atomic arrangement can be very diverse and 
complex (Dunn & Ellis, 2005). Thus, while in silico software packages claim to 
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identify metabolites based on fragmentation, they are a lot less reliable due to the 
above mentioned complexity of metabolites. The fragmentation of metabolites 
through MS/MS is a very time consuming process and it would seem to be of benefit 
only once a target has been identified, rather than for global untargeted profiling 
(Wolf et al., 2010).  
 
Metabolomics is still an emerging field with databases and identification 
pipelines remaining vulnerable to misidentification and more importantly, 
misinterpretation of data (More et al., 2015; Patti et al., 2012). Nonetheless, 
metabolomics has huge potential, especially in the biomarker field, through 
identification of metabolites specific to certain disease states or simply identifying a 
response as a result of disease through a change in abundance. Since metabolites are 
the end products of protein activity, and therefore are most predictive of phenotype 
(Fiehn, 2002), the field will continue to see improvements in both instrumentation 
technology and software/analysis. Additionally, the combination of multiple ‘omic’ 
datasets has shown great promise as they are able to cross-validate complementary 
results (Huang et al., 2014; Wheelock et al., 2013). If the elimination of PEG was 
achievable and improved curation of metabolomic databases occurred, a 
metabolomic profiling approach to diagnosing chronic leg ulcers may be possible in 
the near future. Until that time the best approach to wound fluid analysis would be to 
target specific metabolites which have already been identified in other disease states 
which show similar characteristics. Identifying proteins from previous wound 
research which have metabolite endpoints could also facilitate targeted metabolic 
profiling, however, these proteomic studies have not yet been pursued (Edsberg et 
al., 2012; Sabine A. Eming et al., 2010). 
 
To date our fundamental, albeit relatively rudimentary, knowledge of acute 
wound healing and the wound healing cascade has been used to guide investigations 
into the mechanisms of chronic leg ulceration. This led to growth factors being 
amongst the first types of proteins measured, as a shortage of these proteins was 
believed to decrease proliferation in the wound and therefore delay wound closure 
(Vincent Falanga & Eaglstein, 1993). Research interest only focussed on 
inflammatory cytokines when chronic leg ulcers were described as being “stalled” in 
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the inflammatory phase (Loots et al., 1998). These initial studies were focussed on 
measuring these key proteins by ELISA. The ELISA technology, however, limits the 
number of cytokines / growth factors that can be quantitated in one study due to 
sample volume restrictions (Tarnuzzer & Schultz, 1996; Trengove et al., 2000). 
Nevertheless recent advancements in technology have now allowed the quantitation 
of multiple targets concurrently through multiplexing systems. These were used to 
acquire the data reported in chapters 4 and 5.  
 
The Bio-Plex multiplex system has not previously been used to quantitate 
cytokines in wound fluid. Thus a series of optimisation experiments were required. 
Fortunately, a previous study which used a similar multiplex approach was available 
to guide the assay parameters (Edsberg et al., 2012). Three pro-inflammatory 
cytokines that are abundantly expressed in wound fluid were used for these 
optimisation experiments. The data from these optimisation assays provided 
information on the ideal sample volume (Figure 4.1), and also indicated how linear 
the assay was when performing a serial dilution of wound fluid samples. The volume 
which was selected was suitable for the full 27-Plex kit, however, some cytokines 
were at or below the limit of detection (IL-2, -4, -5, -7, -9, -15 and eotaxin). As the 
matrix effect was identified in the optimisation assays (Figure 4.1) the serial dilution 
of a wound fluid pool was extended to the actual 27-Plex assays. This allowed 
identification of specific cytokine targets that demonstrated poor linearity in the 
multiplex analysis, suggesting some inherent interference was occurring.  
 
Wound fluid is a complex mixture, rendering it difficult to speculate on what 
might affect the quantitation, but it may simply be other proteins and peptides 
interfering with antibody binding. Several publications have compared the Bio-Plex 
kit to different multiplex assays and report it demonstrates good accuracy and 
precision, however, these experiments used serum samples (Elshal & McCoy, 2006; 
Fu et al., 2010). Other authors have suggested that multiplex kits should only be used 
as screens for biomarkers, and that studies with more sensitive targeted assays should 
subsequently be undertaken to ensure accuracy and precision (Siawaya et al., 2008). 
While accepting that multiplex assays are not ideal for accurate quantitation, they do 
enable numerous analyses with low sample volume to be undertaken, thus offer value 
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for studies that are limited by sample availability. In addition, large panel multiplex 
assays can be valuable in that they provide information on the expression of 
cytokines that might not otherwise have been considered as targets or candidates. In 
this study the stability and degradation of protein in wound fluid collected from 
patients was not a concern as it was stored at 4°C before being processed the same 
day as described in section 2.1.4. However, proteolytic degradation can still occur at 
the ulcer site. As described earlier in the thesis (section 1.2.6) some wounds exhibit 
high levels of proteases which can cleave certain proteins. The Bio-Plex assay is 
based on a sandwich ELISA (capture sandwich immunoassay) meaning that the 
target protein is bound firstly to the bead and then again with a primary antibody 
before being quantitated. Therefore, proteins that are degraded due to proteases 
would not have both regions to allow quantitation. Western blot could be used to 
visualise fragmentation, however, this could not be performed within the scope of 
this study as there was insufficient wound fluid to perform the Bio-Plex assay as well 
as Western blot experiments.  
 
The objective of the studies reported in chapters 4 and 5 was to assess cytokine 
and growth factor levels longitudinally in multiple patient samples with the aim of 
identifying individual targets that might be used as biomarkers. In addition, this 
approach might provide information on how they are altered as a wound transitions 
to a healing state. A multiplex style biomarker assay is certainly feasible and the 
FDA already has several approved for diagnostic use to identify allergies, 
autoimmune and infectious diseases (Ellington et al., 2010). The use of cytokines as 
biomarkers is also well established in clinical diagnostics (Hahm et al., 2011; Löffler 
et al., 2013; D. R. Yager et al., 2007). However, in the wound healing field published 
studies have only reported comparisons between two groups across one time point, 
usually involving either chronic versus acute wounds or healing versus non-healing 
ulcers (Beidler et al., 2009; Edsberg et al., 2012; Tarnuzzer & Schultz, 1996; 
Trengove et al., 2000). Although my experimental data demonstrated that IL-6 levels 
are significantly reduced between healing and non-healing ulcers in Chapter 4, it is 
evident that differences between individual patient cytokine concentrations make it 
difficult to design such an all-encompassing assay. For example, while IL-6 
concentrations in the ulcer samples decreased sequentially over time, the first wound 
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fluid sample of ulcer 4032 exhibited a concentration approximately of 600 pg/mg of 
total protein, whilst wound fluid from ulcer 4084 had approximately 20,000 pg/mg of 
total protein – a 30 fold difference. The only feasible way that the quantitation of 
cytokines such as this could be used as biomarkers is to use multiple measurements 
over time and that would involve correlation of these measurements with changes in 
wound area over time (T. J. Phillips et al., 2000). All the same, multiple cytokine 
measurements have potential to provide more predictive power. Two key studies 
reported increased levels of pro-inflammatory cytokines between healing and 
non-healing samples, but were quantitated from tissue biopsies (Beidler et al., 2009; 
Fivenson et al., 1997). Demonstrating that detection of markers of interest can be 
achieved in a non-invasive form through wound fluid is especially beneficial when 
considering biomarker development. As previously mentioned in chapter 4, the use 
of biopsies also has the potential to overestimate cytokine concentrations as the 
tissue homogenisation step might liberate cytokines which may not have otherwise 
been secreted.  
 
One of the more recent hypotheses to explain why chronic leg ulcers remain 
unhealed is that these wounds have an imbalance between pro- and 
anti-inflammatory cytokines (Hart, 2002; Lawrence & Gilroy, 2007; Liu et al., 
2011). Aspects of this hypothesis are not, however, supported by our findings in 
chapter 4. A transition to a healing state would be expected to result in a decrease in 
pro-inflammatory cytokines, with a commensurate increase in anti-inflammatory 
cytokines (summarised in Table 4.3). Of the five pro-inflammatory cytokines 
measured, two were found to be significantly decreased when compared to the 
non-healing cohort (IL-6 p=0.006, IFNγ p=0.007), while the other three were 
trending towards significance (TNFα p=0.071, IL-1β p=0.133, IL-12p70 p=0.055). 
On the other hand, the assay of anti-inflammatory cytokines demonstrated no 
significant change over time (IL-1ra p=0.310, IL-13 p=0.728), or were not detected 
at all (IL-4). The only anti-inflammatory cytokine which was arguably trending 
towards significance, IL-10 (p=0.147), in fact decreased over time, contrary to 
expectations. The quantitation of growth factors in wound fluid from chronic leg 
ulcers was also of great significance to this project as they have been identified early 
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as key components to wound healing (S. Barrientos et al., 2008; Werner & Grose, 
2003).  
 
One of the early hypotheses suggested that a depletion of growth factors at the 
wound site delayed healing (V. Falanga, 1993). As a result, treatment of wounds with 
the application of exogenous growth factors was explored as a treatment option, 
however, thus far without much success (Stephan Barrientos et al., 2014). Only one 
growth factor, PDGF, has received FDA approval, and only for limited indications 
(Mandracchia et al., 2001). However, other cytokines have been identified as 
promising, such as VEGF, bFGF and GM-CSF (Stephan Barrientos et al., 2014). The 
quantitation of these growth factors in wound fluid, as reported in chapter 5, revealed 
that the majority were significantly reduced in the healing ulcer cohort when 
compared to the non-healing cohort (bFGF p=0.0001, VEGF p=0.016, GM-CSF 
p=0.007). The other two growth factors measured did not change significantly over 
time (PDGF and G-CSF, summarised in Table 5.1). This result was surprising and 
challenges the notion that growth factors play a critical role in ‘kick-starting’ the 
healing of chronic leg ulcers, as an increase would be expected to be observed in the 
healing ulcers. However, the reduction observed in some growth factors is perhaps 
the result of a reduced influx of monocytes, the cells that are the main producers of 
these growth factors (S. Barrientos et al., 2008; Werner & Grose, 2003). The 
pro-inflammatory cytokine data certainly demonstrates a reduction in inflammation 
and therefore a reduction in inflammatory cells. The quantitative chemokine data 
outlined in chapter 5 also supports this hypothesis. This is demonstrated by the 
reductions of MCP-1, MIP-1β, MIP-1α and IL-8 in healing ulcers compared to 
non-healing ulcers (p=0.058, p=0.077, p=0.022, p=0.002, respectively). Chemokines 
are known to play an important role in acute wound healing (Engelhardt et al., 1998; 
Martins-Green et al., 2013) and for the first time they are reported here to decrease 
over time in wound fluid from healing leg ulcers.  
 
The population profile of pro-inflammatory cytokines and chemokines 
indicates a dysregulated inflammatory response is evident in non-healing leg ulcers; 
this is not unique to chronic leg ulcers. High expression of pro-inflammatory 
cytokines is shown in non-healing war combat dehiscing wounds (Hawksworth et al., 
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2009), diabetic ulcers (Acosta et al., 2008) and also pressure ulcers (Edsberg et al., 
2012). Indeed, there appears to be a persistent upregulation of pro-inflammatory 
cytokines, which perhaps stalls these wounds in a chronic inflammatory state. One 
positive feedback loop which perpetuates the inflammatory response involves TNFα 
and IL-1β, cytokines which upregulate their own expression, and also activate 
neighbouring cells (S. Barrientos et al., 2008; Mast & Schultz, 1996). Of relevance, 
the pro-inflammatory cytokine IL-6 was assayed to be the most abundant cytokine in 
our study. A recent publication has shown that IL-6 induces production of IL-1β in 
fibroblasts, monocytes and keratinocytes, as well as IFNγ in neutrophils, 
keratinocytes and fibroblasts (Grimstad et al., 2011). In the same study IL-1β was 
found to be a potent inducer of other pro-inflammatory cytokines, such as IFNγ, in 
monocytes, neutrophils, keratinocytes and fibroblasts and coincidently, induced 
expression of IL-6 in monocytes, neutrophils and keratinocytes (Grimstad et al., 
2011). Thus there is strong evidence that IL-6 and IL-1β contribute to the clinical 
interpretation that chronic wounds are “stalled” in an inflammatory state. 
 
IL-1β also induces secretion of chemokine IL-8 and GM-CSF (Grimstad et al., 
2011). In turn, these two chemokines provide strong chemotactic cues for additional 
recruitment of neutrophils and monocytes to the wound area, further perpetuating the 
inflammatory response (Baggiolini & Clark-Lewis, 1992; S. Barrientos et al., 2008; 
Rennekampff et al., 2000). GM-CSF has been demonstrated to exacerbate the 
inflammatory reaction and is pivotal to other inflammatory diseases (Shiomi & Usui, 
2015). GM-CSF can also be independently upregulated by the pro-inflammatory 
cytokine IL-12 (Duhen & Campbell, 2014). IL-12 expression can induce IFNγ 
production, which in turn upregulates IP-10 (Sabine A Eming et al., 2007). Of 
interest, IP-10 has been demonstrated to negatively impact angiogenesis by 
destroying new blood vessels (Bodnar et al., 2009). In our quantitative analysis IP-10 
was noted to be the second most abundant chemokine, however, the levels did 
change over time. Notwithstanding this, IP-10 may have a deleterious impact and 
inhibit angiogenesis in the local wound area.  
 
The relatively high abundance of IL-1β assayed in our Bio-Plex study, 
combined with its ability to induce the production of several other pro-inflammatory 
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cytokines, prompted me to measure its active levels. IL-1β is synthesised as an 
inactive pro-IL-1β molecule. This pro-form must be cleaved before it expresses 
biological activity (Martinon et al., 2002). For this to occur, IL-1β requires the 
assembly of the inflammasome, a multiprotein complex where caspase-1 is activated 
and successively cleaves the pro-IL-1β protein (Martinon et al., 2002).  
 
The discovery of the inflammasome has added another layer of complexity to 
innate immunity. The role of inflammasomes is to detect danger signals similar to 
TLRs (Pétrilli et al., 2007). I therefore examined the activity of IL-1β using the 
HEK-Blue activity assay. The HEK-Blue activity assay indicated that levels of IL-1β 
were not statistically different between the healing and non-healing ulcer cohorts 
using a LMM analysis (Figure 6.1). However, the assay did provide evidence for 
inflammasome activation in chronic leg ulcers; IL-1β cannot be cleaved otherwise. 
To further confirm inflammasome activation antibodies were used to probe for the 
critical inflammasome component ASC. ASC binds the CARD domain that mediates 
caspase-1 docking (Schroder et al., 2010). Western blot analysis of ASC did not 
identify any trend between ASC and wound outcome (Figure 6.2). Given that 
inflammasome assembly and activation is an intercellular process, detection of ASC 
in wound fluid indicates pyroptosis (Schroder et al., 2010). Pyroptosis, or caspase-1 
dependent programmed cell death, is a cell death mechanism dependent on caspase-1 
activation. Pyroptosis results in rapid plasma membrane rupture and release of 
cellular contents (Bergsbaken et al., 2009). This results in what is known as the 
‘caspase-1 secretome’; all proteins released from the cell following the activation of 
capsase-1 (Baroja-Mazo et al., 2014). The ‘secretome’ includes active forms of the 
pro-inflammatory cytokines IL-18 and IL-1β, and also, interestingly, HMGB1 
(Lamkanfi et al., 2010). HMGB1 is the prototypic alarmin, or DAMP, and its release 
via the ‘secretome’ induces a strong innate immune response (Scaffidi et al., 2002). 
We detected HMGB1 in wound fluid using Western Blot assays (Figure 6.3). 
Surprisingly, the levels of HMGB1 did not correlate with ASC, even though one 
would speculate that caspase-1 induced secretion of proteins would result in similar 
levels or trends between the two proteins. It is reported that endocytosis of HMGB1 
by macrophages will cause lysosomal damage and subsequently pyroptosis, 
amplifying inflammatory responses independently of its detection through TLRs (Xu 
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et al., 2014). Similarly, ASC once released extracellularly is recognised as a DAMP 
and when engulfed by macrophages will result in lysosomal damage and therefore 
further IL-1β production (Franklin et al., 2014). Lastly, NLRP3, which forms part of 
the inflammasome complex, can also function extracellularly once released through 
the secretome to activate extracellular capase-1 (Baroja-Mazo et al., 2014). The 
assembly and activation of the inflammasome is followed by the release of its 
components / proteins through the secretome, resulting in the propagation of 
inflammation.  
 
Recent work has determined that ASC in cerebrospinal fluid can be used as a 
biomarker for functional outcome following brain injury (Adamczak et al., 2012). In 
other studies, large amounts of autoantibodies against ASC are present in patients 
with autoimmune disease (Franklin et al., 2014), however, whether these are 
associated with inflammatory pathologies has not yet been investigated. In the 
present study, we are unable to determine a trend in regards to these inflammasome 
proteins and healing outcome, but it needs to be borne in mind that the study was 
limited to eight patients. Perhaps expansion to a larger cohort of patients would 
reveal correlation. Alternatively, the absence of correlation with a larger cohort, 
would suggest that different proteins and pathways underlie the chronic 
inflammation observed in chronic wounds, therefore indicating more individualised 
therapies will be required.  
 
There is high overlap with the DAMPs which trigger inflammation through 
TLR detection also activating the inflammasome, resulting in further inflammation 
(Schroder & Tschopp, 2010). I hypothesise these will increasingly overlap as we 
gain greater knowledge of the respective roles of the inflammasome. Uric acid is an 
example of a DAMP which activates TLR signalling and stimulates inflammasome 
activation (Martinon et al., 2006). Uric acid is evident in wound fluid and high levels 
correlate with wound chronicity, as has been previously reported by our laboratory 
(Melissa L. Fernandez et al., 2012). The overlap is not specific to DAMPs, as 
PAMPs have also been shown to cause inflammasome activation and trigger 
inflammation through TLR detection (Muruve et al., 2008; Sahoo et al., 2011). 
  
Chapter 7: General Discussion 189 
Therefore, quantitating microbial load might reveal that some of the inflammation is 
a result of infection or high microbial levels at the wound site.  
 
As is reported in Table 6.2, we do note a trend of higher total microbial load in 
swab samples from healing ulcers. It is likely this signifies a return to normal flora 
re-colonising the wounded area, rather than pathological colonisation. To confirm 
this interpretation the speciation of the microbial DNA present, rather than the total 
microbial load is required, this was outside the scope of this study. Next generation 
sequencing of microbial DNA collected from swabs, as has been previously used in 
wound analysis (Nicholas et al., 2014), would allow confirmation of species present. 
A further avenue of future research that could be of benefit is identifying and 
quantitating microbes which are capable of activating the inflammasome (Schroder 
& Tschopp, 2010). Given that the data within this thesis has already demonstrated 
inflammasome activation occurs in chronic leg ulcers (chapter 6) it is not 
unreasonable to speculate that perhaps some of this activity results from microbial 
detection by this inflammatory complex.  
 
From all the evidence provided herein, it is clear that chronic leg ulceration is a 
complex and multifaceted inflammatory disorder, hence is similar to other wound 
types, such as diabetic foot ulcers, pressure ulcers and trauma wounds, which also 
exhibit a chronic non-resolving inflammatory response (Acosta et al., 2008; Edsberg 
et al., 2012; Hawksworth et al., 2009). Recent reviews of the clinical management of 
chronic wounds have highlighted inflammation as a key therapeutic target (Behm et 
al., 2012; Turner et al., 2015). Contingent on the outcome of future investigations 
identifying what are the key DAMPs and PAMPs that trigger inflammation, we can 
envision that the treatment of chronic leg ulcers could become individualised. The 
only antibody which has been used to date in chronic leg ulcers to dampen 
inflammation and promote healing is against TNFα; this showed promise with 
improvements in healing rates, however, only 8 patients were involved in the trial 
(Streit et al., 2006). Sustained inflammasome activity has already been demonstrated 
to be a cause of impaired healing in diabetic mice and blocking IL-1β has been 
shown to improve wound closure rates (Bitto et al., 2014; R. E. Mirza et al., 2013; R. 
E. Mirza et al., 2014). In addition, anti-IL-1β treatments are currently used for auto-
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inflammatory diseases, such as those described as cryopyrin-associated periodic 
syndromes (Dinarello et al., 2012) and rheumatoid arthritis (Geyer & Müller-Ladner, 
2010). As IL-1β is a strong inducer of other pro-inflammatory cytokines, and is a 
product of inflammasome activation, it may prove to be a sound therapeutic target in 
chronic leg ulcers. Further, one very recent publication has demonstrated that it is 
also possible to knock out specific inflammasomes, such as NLRP3, using small 
molecule inhibitors (Coll et al., 2015). Taken together, neutralising inflammasome 
activation may be the key to stopping the perpetual inflammatory response which is 
currently observed and characteristic of chronic leg ulcers.  
 
In summary, the data in this thesis confirms that chronic leg ulcers are indeed 
“stuck” in an inflammatory phase. Furthermore, the results indicate that the 
activation of the inflammasome, most likely by alarmins, may be an underlying 
process that prolongs inflammation in chronic wounds. We contend that targeting 
these pathways could ultimately pave the way for the development of therapies for 
patients with chronic wounds.  
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